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Abstract 
Mitochondrial DNA (mtDNA) point mutations clonally expand and result in focal 
respiratory chain deficiency in tissues of patients with mitochondrial disease and to a 
lesser extent in normal human ageing. The consequences of mtDNA point mutations 
upon cellular processes and the mechanisms involved in mitochondrial disease 
heterogeneity and progression as well as age-related tissue dysfunction, however still 
remain unknown. The aim of this thesis was to further our understanding of clonally 
expanded mtDNA point mutations in ageing and the mechanisms associated with 
disease heterogeneity, using mice that harbour mtDNA point mutations.  
Characterisation of mitochondrial dysfunction in the PolgA
+/mut
 mouse colon provided 
evidence for a conserved mechanism for the clonal expansion of somatic mtDNA point 
mutations by random genetic drift, without any selective constraints, resulting in age-
related respiratory chain deficiency in colonic crypts of both PolgA
+/mut
 mice and ageing 
humans. Preliminary data examining the gene expression profile of respiratory chain 
deficient colonic crypts revealed potential alterations in processes concerning: the cell 
cycle and proliferation; DNA maintenance and repair; cell adhesion and tight junction 
formation; the adaptive immune response and energy metabolism. Such changes hold a 
number of potentially interesting associations with the development of colorectal cancer 
and the pathogenesis of inflammatory bowel disease.  
Using histochemical and mtDNA genome analysis, the m.5024C>T tRNA
Ala
 mouse was 
shown to be a fairly good model of a pathogenic mt-tRNA point mutation in disease. 
Results demonstrated that the m.5024C>T mutation was pathogenic; mice displayed 
phenotypic evidence of respiratory chain deficiency; aged mice displayed evidence of 
disease progression; different tissues showed different biochemical thresholds and there 
was a selective loss of the mutation in actively dividing cells.  
These observations have important implications for the role of mtDNA point mutations 
in ageing and potential mechanisms that govern mitochondrial disease presentation, 
progression and transmission.  
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Chapter 1. Introduction 
1.1 Mitochondria 
Mitochondria are dynamic, intracellular organelles found in all nucleated mammalian 
cells that have a variety of roles, of which the production of adenosine triphosphate 
(ATP) by the process of oxidative phosphorylation (OXPHOS) is a dominant function. 
Mitochondria also play a critical role in intermediary metabolism (citric acid cycle, β 
oxidation), iron-sulphur (Fe-S) cluster biogenesis (van der Giezen and Tovar 2005), 
reactive oxygen species (ROS) production (Starkov 2008), regulation of cytosolic 
calcium (Ca
2+
) ion concentration (Pozzan, Magalhães et al. 2000) apoptosis (Newmeyer 
and Ferguson-Miller 2003) and the urea cycle. Mitochondria are commonly believed to 
have evolved from free-living Eubacteria, through the process of endosymbiosis. 
Endosymbiosis was originally believed to comprise two successive events (‘serial 
hypothesis’), involving the initial formation of the cell nucleus from Archaebacterium 
followed by the incorporation of Eubacteria into primitive eukaryotic cells (Margulis 
1971). An alternative theory, known as the ‘hydrogen hypothesis’ however, proposes 
that the eukaryotic nucleus and the mitochondrion were created simultaneously by the 
fusion of hydrogen-requiring Archaebacterium and hydrogen-producing Eubacteria 
(Martin and Müller 1998). In either case, endosymbiosis occurs and the majority of 
genes from the Eubacteria (proto-mitochondrion) were transferred to the cell nucleus, 
creating a long-term, co-dependent relationship between the two (symbiosis). 
1.1.1 Mitochondrial structure  
Electron microscope studies reveal that mitochondria are generally elongated, rod-
shaped structures or oval, circular organelles that measure 1-4μm in length and 0.3-
0.7μm in diameter (Palade 1953). The size and number of mitochondria within tissues 
varies widely according to the cell type and the metabolic activity of the tissue, with 
mitochondria migrating to and clustering at sites of high energy consumption, such a 
neuronal axons and synapses (Morris and Hollenbeck 1993; Li, Okamoto et al. 2004). 
As such mitochondrial biogenesis is closely correlated to the ATP requirements of a 
cell, and this is primarily regulated by peroxisome proliferator-activated receptor γ 
(PPARγ) and co-factor 1α (PGC1-α).  
Given that still electron microscope images were always used to depict mitochondria, 
these organelles were originally believed to be static structures within the cell. 
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However, it is now known that mitochondria are highly dynamic and undergo budding, 
fission and fusion, forming intracellular networks within a cell (Carroll 1989). In 
addition to fission and fusion mitochondrial dynamics also encompasses the process of 
mitophagy, whereby dysfunctional or undesirable mitochondria are selectively targeted 
for degradation via lysosomes (Kim, Rodriguez-Enriquez et al. 2007).  
Mitochondria are double-membraned structures, comprising an outer and inner 
mitochondrial membrane, which form a small intermembrane space and enclose a large, 
internal matrix (Figure 1-1) (Palade 1953). The mitochondrial matrix houses multiple 
copies of the mitochondrial genome, enzymes of intermediary metabolism, transcription 
and translation machinery and it is the site of Fe-S cluster formation. 
The outer mitochondrial membrane is equivalent to a normal cell membrane. It consists 
of a lipid bilayer punctuated by a number of protein channels, known as porin. Porin is a 
voltage dependent anion channel (VDAC), which functions to allow the movement of 
small molecules and ions, <5000 Daltons, between the cell cytoplasm and the 
intermembrane space of the mitochondria (Alberts 2002). 
The inner mitochondrial membrane (IMM) was originally believed to be a continuous, 
closed membrane that folded forming invaginations, known as cristae, into the 
mitochondrial matrix.  It is now known, however, that the IMM actually comprises two 
components: the inner boundary membrane (IBM) and the cristae membrane (CM), 
which are connected through tubular cristae junctions (Freya and Mannellab 2000). The 
IMM is an extremely protein rich lipid bilayer, comprising ~75% proteins (Ardail, 
Privat et al. 1990), and is largely impermeable to small solutes and polar molecules, 
with the exception of O2, CO2, H2O and NH3. The most abundant protein complexes are 
those involved in OXPHOS, which are primarily located in the CM (Vogel, Bornhövd 
et al. 2006). As such the CM is highly specialised to perform OXPHOS, which is 
further facilitated by the large surface area created through folding of the membrane 
into cristae. The CM is further enriched for mitochondrial translation products. The 
IBM forms close interactions with the outer membrane, and as such is enriched in 
proteins concerned with mitochondrial import (Vogel, Bornhövd et al. 2006). The IMM 
lipid components constitute ~25% of the membrane and include phosphotidylcholine,  
phosphatidylethanolamine and cardiolipin (Fleischer 1961), which provide 
electrochemical insulation, essential for OXPHOS.  
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Figure 1-1: Schematic representation of mitochondrial structure.  
(a) Electron micrograph image of a single mitochondria in situ and (B) a simplified representation of the structure of 
mitochondria displaying the key features.  Images courtesy of Dr Amy Reeve and Dr Eve.Simcox.  
1.1.2  OXPHOS and synthesis of ATP 
OXPHOS is the process by which cellular ATP is generated, resulting from the transfer 
of electrons from intermediary products of the citric acid cycle/ tricarboxylic acid 
(TCA) cycle and β oxidation, to oxygen via a series of electron carriers (Hatefi 1985). 
 
The production of ATP is initiated by the process of glycolysis in the cell cytoplasm, 
where glucose is broken down, in the presence of oxygen, into pyruvate, 2 molecules of 
ATP and 2 molecules of NADH. Pyruvate is subsequently transported across the outer 
and inner mitochondrial membranes into the mitochondrial matrix for decarboxylation 
by pyruvate dehydrogenase to produce acetyl Coenzyme A (CoA). One NADH and one 
CO2 molecule are produced during the conversion of pyruvate to acetyl CoA. Acetyl 
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CoA is a key substrate for the TCA cycle, during which it becomes oxidized to CO2 
alongside the reduction of NAD+ and FADH+ to NADH and FADH2. NADH and 
FADH2 function as electron carriers and are fundamental to the OXPHOS pathway.  
 
The OXPHOS system is located in the CM and consists of five transmembrane protein-
lipid enzyme complexes (Complexes I-V) and two electron carriers, coenzyme Q 
(ubiquinone) and cytochrome c (Hatefi 1985) (Figure 1-2). Electrons from NADH and 
FADH2, derived from the TCA cycle and β oxidation, are shuttled along the respiratory 
chain, otherwise known as electron transport chain (ETC), from Complex I to Complex 
IV, and are subsequently transferred to oxygen to be reduced to water. At complexes I, 
III and IV, the transfer of electrons results in the translocation of protons (H
+
 ions) from 
the mitochondrial matrix to the intermembrane space, creating a protonic 
electrochemical gradient. Protons move down this electrochemical gradient, through 
ATP synthase (Complex V), which provides a hydrophilic channel across the IMM. As 
protons flow through ATP synthase, adenosine diphosphate (ADP) is phosphorylated to 
give ATP in an energetically unfavourable reaction (Hatefi 1985). One ATP molecule is 
generated for approximately 3 protons that pass through ATP synthase. 
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Figure 1-2: The OXPHOS system.  
The five transmembrane enzyme complexes of the mitochondrial respiratory chain are located in the CM of the IMM. 
Mitochondrial DNA encodes essential subunits of complexes I, III, IV and V, but complex II is entirely encoded by 
nuclear DNA (Morris 1995). The ratio of mitochondrial: nuclear encoded subunits are shown below each complex. 
Electrons (in red) feed into the electron transport chain at Complex I (via NADH) and Complex II (via FADH2). 
Complex I transfers 2 electrons from NADH to ubiquinone (Q), which is coupled with the translocation of 4 protons 
to the intermembrane space (Hatefi 1985). Complex II catalyzes the oxidation of succinate to fumerate and the 
reduction of ubiquinone to ubiquinol (QH2) using FADH2 (Hägerhäll 1997). Complex III then re-oxidizes ubiquinol 
to ubiquinone and transfers the electrons to cytochrome c (c), which is coupled to the transmembrane translocation of 
2 protons (Hatefi 1985). Cytochrome c is a small heme protein located in the intermembrane space, which serves to 
carry an electron from Complex III to Complex IV. Complex IV is the terminal component of the electron transport 
chain and catalyzes the transfer of electrons to oxygen, reducing it to water. The reduction of oxygen requires the 
transfer of 4 electrons, resulting in the translocation of 4 protons to the intermembrane space (Brändén, Gennis et al. 
2006). Complex V converts ADP and inorganic phosphate (Pi) to ATP as protons move down the electrochemical 
gradient created by complexes I, III and IV. Complex V comprises two components: F1 the ATP synthase and F0 the 
proton translocator. The movement of protons through F0 is proposed to cause rotation of a Y chain in F1 which 
subsequently causes conformational changes in β chains of F1 and the synthesis of ATP (Noji, Yasuda et al. 1997). 
The production of one molecule of ATP is associated with the flow of ~3 protons through ATP synthase (Ferguson 
2010). Image adapted courtesy of Dr Eve Simcox. 
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Regulation of OXPHOS is principally controlled by the relative concentrations of ADP 
and substrates available, as well as the mitochondrial membrane potential (-180mv). As 
such when mitochondrial matrix concentrations of ADP are high, ATP is synthesised 
(Chance 1956) and oxygen is consumed by the ETC to restore the electrochemical 
gradient (state III respiration). Low concentrations of ADP in the matrix are associated 
with low oxygen consumption and the mitochondrial membrane potential is maintained 
as protons are not moving through ATP synthase to generate ATP (state IV respiration) 
(Chance 1956). ATP production is therefore regulated by the balance between state III 
and IV respiration.  
 
Intramitochondrial Ca
2+
 concentration is also believed to regulate ATP synthesis, as 
Ca
2+
 has been found to activate a number of mitochondrial enzymes, including pyruvate 
dehydrogenase, NAD isocitrate dehydrogenase and possibly ATP synthase (Tarasov, 
Griffiths et al. 2012). Activation of these dehydrogenases by increased concentrations of 
Ca
2+
 is proposed to increase the levels of NADH and FADH2 electron carriers available 
to the ETC, thus increasing OXPHOS (Denton 2009). Given that an increase in 
intramitochondrial Ca
2+
 is linked to muscle contraction, the concentration of Ca
2+
 inside 
mitochondria can therefore couple ATP synthesis with the energy demands of the cell 
(Denton 2009). Furthermore Ca
2+
 can also directly bind to ATP synthase (Hubbard and 
McHugh 1996) and binding of a calcium sensing protein (S100A1) has also been shown 
to increase ATP production (Boerries, Most et al. 2007).  
 
1.1.2.1 Respiratory chain supercomplexes 
Complexes of the respiratory chain do not exist as single entities, distributed irregularly 
throughout the IMM but instead have been shown to associate and form 
supercomplexes in both yeast and mammalian mitochondria (Schägger and Pfeiffer 
2000). In mammalian mitochondria complex I associates and forms a supercomplex 
with the majority of complex III and four copies of complex IV (Schägger and Pfeiffer 
2000), giving rise to a network of respiratory chain complexes known as the 
‘respirasome’. Such respirasomes are indeed functional and have been shown to respire, 
given that they can transfer electrons from NADH to oxygen (Acín-Pérez, Fernández-
Silva et al. 2008). In the same study blue native PAGE further demonstrated that 
unsurprisingly supercomplexes do not form if one of the components is not present 
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(Acín-Pérez, Fernández-Silva et al. 2008). Complex I, which forms in multiple stages, is 
fundamental in the construction of respirasomes, providing a framework for the 
collective integration of subunits of complexes III and IV, which assemble 
independently (Moreno-Lastres, Fontanesi et al. 2012; Winge 2012). Respirasome 
activation is achieved upon the final assembly and activation of complex I, when the 
catalytic subunit of NADH dehydrogenase is incorporated (Moreno-Lastres, Fontanesi 
et al. 2012; Winge 2012).  Indeed, the formation of respirasomes is believed to enhance 
efficiency of the ETC and the OXPHOS process, as the association  of respiratory chain 
complexes would enable specific substrates to be directed to specific complexes,  
enhancing catalytic activity (Schägger and Pfeiffer 2000) as well as preventing electron 
leakage, especially from complex III, and the formation of superoxide radicals (Winge 
2012).Given the structural connections and relationships between complexes in 
respirasomes, a single genetic defect could indeed affect the activity of multiple 
respiratory chain complexes, particularly in complexes I, III and IV. Undoubtedly this 
has significant implications for understanding mitochondrial defects in disease 
processes and ageing.  
1.1.3 Other mitochondrial functions 
1.1.3.1 Iron homeostasis and Fe-S cluster biogenesis 
Mitochondria also have a central role in iron homeostasis, with the majority of 
intracellular iron used by mitochondria for the synthesis of haem and Fe-S cluster 
biogenesis (Wang and Pantopoulos 2011). Mitochondrial proteins are essential in the 
formation of Fe-S clusters, providing frameworks for their initial formation (Isu1/2) and 
facilitating development of the clusters (Grx5 and Abcb7) (Wang and Pantopoulos 
2011). Fe-S clusters are fundamental in many cellular processes including OXPHOS, 
the catalysis of enzymatic reactions and the sensing and regulation of mitochondrial 
iron homeostasis. The mitochondrial electron transport chain houses up to 12 different 
Fe-S clusters, which serve as electron carriers by cycling between the Fe
2+
 and Fe
3+
 
form, as well as contributing to complexes I and III (Schultz and Chan 2001).  
1.1.3.2 ROS production 
Mitochondria are known to possess up to 10 different sites of ROS production, 
predominantly located within the mitochondrial ETC. Complexes I and III serve as the 
major sites of ROS production (Turrens and Boveris 1980; Sugioka, Nakano et al. 
1988), where the loss of a single electron reduces molecular oxygen, resulting in the 
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production of a superoxide radical (O2
-
) (Starkov 2008). The deleterious effects of 
mitochondrial derived ROS in oxidative stress and damage are well-documented and are 
believed to have a role in ageing (see section 1.4.2.1). However, ROS  also serve as 
essential signalling molecules in many physiological and cellular pathways including 
cell proliferation, differentiation, autophagy and anti-tumorigenic responses such as 
apoptosis and senescence (Valko, Leibfritz et al. 2007). 
1.1.3.3 Calcium homeostasis 
Given the negative mitochondrial membrane potential (-180mv) created by the ETC, 
mitochondria are ideal organelles for the uptake and sequestration of Ca
2+
 ions and as 
such play a key role in the regulation of intracellular Ca
2+
 concentration, with 
mitochondria capable of absorbing up to 1000nmol Ca
2+
 per mitochondrial protein 
(Kirichok, Krapivinsky et al. 2004). Mitochondrial Ca
2+
 uptake therefore has significant 
implications for multiple cellular processes and pathways in which Ca
2+
 serves as a key 
signalling molecule, including cellular communication (Hofer, Curci et al. 2000), 
apoptosis (Orrenius, Zhivotovsky et al. 2003), ATP production and its regulation 
(Tarasov, Griffiths et al. 2012), metabolism and the TCA cycle (Duchen 2000).  
1.1.3.4 Apoptosis 
Mitochondrial Ca
2+
 overload in a cell is one mechanism by which mitochondria play a 
fundamental role in apoptosis to remove damaged cells and aid normal tissue turnover. 
Mitochondria have also been proposed to contribute to programmed cell death through a 
number of other mechanisms including: the release of cytoxic proteins, such as 
cytochrome c (Liu, Kim et al. 1996) and apoptosis-inducing factor (Susin, Lorenzo et al. 
1999); a rapid reduction in the mitochondrial membrane potential (Goldstein, 
Waterhouse et al. 2000); ROS production (Fleury, Mignotte et al. 2002); opening of the 
permeability transition pore (Zamzami and Kroemer 2001) and mitochondrial network 
fragmentation (Newmeyer and Ferguson-Miller 2003). 
1.2 The mitochondrial genome  
Mitochondria are the only extra nuclear source of DNA within a cell (Nass 1966), 
which is located within the mitochondrial matrix. The mitochondrial genome (mtDNA) 
is a covalently closed, double stranded molecule comprising a heavy strand, which is 
rich in guanine residues, and a light strand, rich in cytosine residues. The human 
mitochondrial genome is a 16 596 base pair (bp) molecule of DNA, encoding 37 genes, 
which include: 13 protein encoding genes for essential subunits of the respiratory chain 
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(Figure 1-2); 2rRNAs (12s and 16s) and 22tRNAs (Figure 1-3) (Anderson, Bankier et 
al. 1981). The remaining proteins of the respiratory chain (~77) are encoded by nuclear 
DNA and are imported into mitochondria from the cytoplasm. As such mitochondria 
rely on both the nuclear and mitochondrial genomes for control.  MtDNA displays an 
organization of extreme economy, as virtually all of the genome has a distinct coding 
function, with tRNA genes scattered in between rRNA and protein encoding genes 
(Figure 1-3)(Anderson, Bankier et al. 1981).  There is an absence of introns and 
termination codons are created via polyadenylation of mRNAs after transcription 
(Anderson, Bankier et al. 1981).The primary non-coding region of the genome is the 
displacement loop (D-loop), a ~1,100 bp region that contains key control elements for 
transcription and replication of mtDNA, including the origin of heavy-strand (OH) 
replication  (Shadel and Clayton 1997). 
 
Figure 1-3: The human mitochondrial genome.  
The human mtDNA genome is covalently closed 16, 596 bp molecule, comprising a heavy strand and a light strand. 
MtDNA encodes 37 genes: 13 essential polypeptides, 2rRNAs and 22tRNAs. The outer heavy strand houses 12 of the 
protein encoding genes, including: 5 subunits of complex I (ND1-5), one subunit of complex III (CytB), 3 subunits of 
complex IV (COX1-3) and 2 subunits of complex V (ATPase 6 &8). The ND6 subunit of complex I is located on the 
inner light strand. The mtDNA genome is an example of extreme economy, with tRNA genes interspersed between 
the protein encoding genes. The only non-coding region is the D-loop, in which the origin of H strand replication 
(OH) is located. The origin of light strand replication (OL) is also displayed. Image (adapted) courtesy of Dr Casey 
Wilson. 
15 
 
Mitochondrial genetics is examined throughout this thesis in the context of mouse 
models. The human and mouse mitochondrial genomes are extremely homologous,  in 
terms of both sequence and the genes encoded for, as well as the organization and 
location of tRNA, rRNA and protein encoding genes in both genomes (Bibb, Van Etten 
et al. 1981).  The mouse mitochondrial genome is a slightly smaller molecule of 16, 259 
bp, which is principally due to a smaller D-loop (879bp) that is 243 nucleotides smaller 
than the human mitochondrial D-loop (Bibb, Van Etten et al. 1981). Indeed it is the D-
loop which is the most dissimilar in sequence between the two genomes. However, 
given that the D-loop contains no open reading frames, this divergence conveys very 
little difference in function (Bibb, Van Etten et al. 1981). The only other features that 
are specific to mouse mtDNA are the initiation and termination codons required for 
translation (see section 1.2.1.1.2).  
Mitochondria contain multiple copies of the mtDNA genome. Given that a somatic 
mammalian cell contains numerous mitochondria, cells within the human body are 
believed to contain thousands of copies of the mtDNA genome  (10
3
-10
4
) (Lightowlers, 
Chinnery et al. 1997). Whilst this is true for many somatic human cells, there are 
however notable exceptions, such as stem cells in which copy number is estimated to be 
~200 mtDNA molecules (Coller, Khrapko et al. 2001). MtDNA is present within cells 
as compacted nucleoprotein complexes, known as nucleoids, which are estimated to 
contain between 2 and 10 molecules of mtDNA (Kukat and Larsson 2013). Nucleoids 
have been identified to contain 21 proteins. Mitochondrial transcription factor A 
(TFAM) is a principal component of nucleoids, which, through its ability to bind, bend 
and wrap mtDNA, is also fundamental in their formation (Kukat and Larsson 2013). 
Other proteins include those with a role in mtDNA replication and transcription, such as 
the mitochondrial TWINKLE helicase, as well as proteins that are generally housed 
within the IMM, such as ANT1 and prohibitin, indicating that mtDNA is associated 
with the inner mitochondrial membrane (Falkenberg, Larsson et al. 2007).   
1.2.1 Mammalian MtDNA transcription and replication 
1.2.1.1 Transcription  
Mammalian mtDNA transcription and replication are principally controlled at the D-
loop, which houses three promoter sites for the initiation of mtDNA transcription:  two 
promoters on the heavy strand (HSP1 and HSP2) and one on the light strand (LSP). A 
full length transcript is produced when transcription is initiated at HSP2, however only 
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2rRNAs and 2 of the mt-tRNAs (tRNA
Phe
 and tRNA
Val
) are transcribed when initiation 
occurs at HSP1 (Rebelo, Dillon et al. 2011). Both rRNA genes, 14 of the tRNA genes 
and all protein encoding genes, except mt-ND6 are transcribed from the heavy strand of 
mtDNA, with the other 8 tRNAs and the mt-ND6 protein encoding gene transcribed 
from the light strand. Transcription of mtDNA occurs in both directions and results in a 
single polycistronic precursor RNA. Polycistronic precursors are subsequently 
processed into the 12S and 16S rRNAs, tRNAs and a number of mRNAs, which are 
then polyadenylated prior to translation (Clayton 1991).  
The machinery necessary for mammalian mtDNA transcription includes the mtRNA 
polymerase (POLRMT), TFAM and mitochondrial transcription factor B1/B2 
(TFB1M/TFB2M) (Falkenberg, Gaspari et al. 2002). Transcription can be initiated by 
either mitochondrial transcription factors in combination with POLRMT and TFAM, 
however TFB2M has been shown to be over 10 times more efficient than TFB1M 
(Falkenberg, Gaspari et al. 2002). TFAM is a fundamental component of the 
transcription machinery, initiating transcription through binding of its carboxyl terminal 
tail to one of the promoter regions, which stimulates a conformational change in 
mtDNA, enabling the binding of POLRMT (Fisher, Topper et al. 1987; Dairaghi, 
Shadel et al. 1995). TFAM also acts as a regulator of the POLRMT/TFB2M and 
POLRMT/ TFB2M complexes (Falkenberg, Gaspari et al. 2002) and expression of 
TFAM is highly correlated with mtDNA copy number (Larsson, Wang et al. 1998). 
Following transcription initiation, elongation occurs by POLRMT, with the aid of 
mitochondrial elongation factor (TEFM). Further details of the mammalian transcription 
machinery and factors required can be found in the following two reviews (Falkenberg, 
Larsson et al. 2007; Rebelo, Dillon et al. 2011). 
1.2.1.1.1 Transcription termination 
Termination of mammalian transcription is instigated by mitochondrial termination 
factors (mTERF), of which four have been identified (Falkenberg, Larsson et al. 2007). 
MTERF1 is the most characterized, having been shown to bind a 28bp region in 
tRNA
Leu (UUR)
 and terminate the transcription of the short transcript initiated at HSP1, 
thus regulating the proportion of mRNA to rRNA (Roberti, Bruni et al. 2006). MTERF1 
is believed to act through bending, unwinding and melting of the DNA duplex, followed 
by base flipping to stabilise binding of the termination factor (Yakubovskaya, Mejia et 
al. 2010). Termination of the long transcript initiated from the HSP2 promoter is less 
well understood, with research having only identified proteins that are able to bind to 
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the H2 termination region. Leucine rich pentatricopeptide-repeat containing protein 
(LRPPRC) is the most characterized of these, having been shown as essential for the 
expression of mtDNA encoded COX subunits and a key regulator of mtDNA 
transcription (Gohil, Nilsson et al. 2010). The other three homologues of mTERF1 are 
less well characterised and their exact functions still remain to be clarified. It has been 
proposed that MTERF2 acts as a positive regulator of transcription, whilst mTERF3 is a 
transcriptional repressor and mTERF4 is proposed to regulate transcription through 
binding to the D-loop (Rebelo, Dillon et al. 2011).  
1.2.1.1.2 Mitochondrial translation  
Mitochondria have their own unique translation system with different wobble rules, 
enabling the decoding of all mRNAs and the synthesis of proteins using only the 
22tRNAs encoded my mtDNA, with no evidence for the importation of nuclear encoded 
tRNAs from the cell cytoplasm (Anderson, Bankier et al. 1981; Bibb, Van Etten et al. 
1981). The mechanism by which mitochondrial translation occurs is largely based on 
our understanding of bacterial translation, with protein synthesis comprising three 
stages: initiation, elongation and termination (Smits, Smeitink et al. 2010) 
Mammalian mitochondrial tRNAs are shorter than bacterial and cytosolic tRNAs, but 
the majority of them display the classic cloverleaf structure, comprising 4 stems and 3 
loops: an acceptor stem, a dihydrouridine stem/loop, a TΨC-stem/loop and an anticodon 
stem/loop. Decoding of all mRNAs by the 22 tRNAs is thought to be achieved by a 
“two out of three” method, whereby the base in the first anticodon position in mRNA 
(corresponding to the third codon position of DNA) conveys little significance (Barrell, 
Anderson et al. 1980). As such there are 8 individual tRNAs that are each capable of 
recognising a U in the first anticodon position of mRNA, which in some cases can be 
distinguished between a purine and a pyrimidine base, enabling the decoding of up to 60 
codons (Barrell, Anderson et al. 1980).  
Translation of mammalian mitochondrial mRNAs occurs on mitoribosomes, consisting 
of a large 39S and a small 28S subunit along with the two mt-rRNAs (12S and 16S), 
which are located within the mitochondrial matrix (Smits, Smeitink et al. 2010). 
Mammalian mitoribosomes are unique and differ from other ribosomes in that they have 
a fairly low rRNA content, but high protein content, with proteins proposed to have 
specific mitochondrial functions (Smits, Smeitink et al. 2010). In addition to tRNAs, 
rRNAs and mitoribosomes mitochondrial translation also requires nuclear encoded 
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initiation, elongation and translation termination factors as well as mitochondrial 
aminoacyl-tRNA synthetases and methionyl-tRNA transformylase, which are needed to 
initiate translation (Smits, Smeitink et al. 2010).  
Translation of nuclear encoded mRNA is most commonly initiated by the presence of 
an AUG codon; however the translation of mitochondrial genes in humans is 
predominantly initiated by the presence of an AUA or AUU codon (Anderson, Bankier 
et al. 1981). In general mitochondrial translation is terminated when mitochondrial 
termination factor 1a (mtRF1a) recognises a UAA and UAG codon within the mRNA 
(Barrell, Anderson et al. 1980; Anderson, Bankier et al. 1981). However, in mammalian 
mitochondria AGA or AGG also occur once at the end of two mitochondrial ORFs, 
effectively acting as hungry codons that promote non-canonical translation termination  
(Temperley, Richter et al. 2010). Irrespective, only a single translation release factor, 
mtRF1a, is required to recognise and terminate translation from all 13 open reading 
frames. Decoding of mRNA in mice is not dissimilar to that in humans, with the only 
unique features being that AUN serves at the translation initiation codon, where any of 
the four nucleotides can occur in the third position, and UAA serves as the termination 
codon for translation (Bibb, Van Etten et al. 1981).  
1.2.1.2 Mitochondrial DNA replication 
1.2.1.2.1 Models of mtDNA replication 
Mammalian mtDNA is constantly turned over and is replicated autonomously, 
independent of nuclear DNA and the cell cycle (Bogenhagen and Clayton 1977). Two 
different models for mammalian  mtDNA replication have been proposed: the 
asynchronous (strand displacement) model (Clayton 1982) and the synchronous model 
(Holt, Lorimer et al. 2000). 
In the asynchronous model, mtDNA replication is highly dependent upon mtDNA 
transcription, as replication initiation at the origin of H strand replication (OH) requires 
RNA primers produced from transcription initiation at the LSP. Synthesis of the leading 
(heavy) strand then advances clockwise, two thirds of the way around the genome until 
it displaces the origin of L strand replication (OL). Exposure of the L strand as a single 
stranded template activates synthesis of the lagging (light) strand in the opposite 
direction (Clayton 1982). MtDNA daughter molecules are then ligated to form closed, 
circular molecules and superhelical turns are introduced to give the final product of 
replication known as C mtDNA (Clayton 1982). It has been proposed that the 
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replication of mtDNA molecules in this manner would take 1 hour (Clayton 1982). 
Indeed this is a slow rate for DNA replication and this is thought to be attributable to the 
low water content in the mitochondrial matrix (Hackenbrock 1968) .  
Study of mtDNA replication intermediates by 2D agarose gel electrophoresis revealed 
that two different types of replication intermediates were produced, which displayed 
different sensitivity to single-strand nuclease digestion (Holt, Lorimer et al. 2000). Such 
a discovery was highly suggestive of a synchronous model of mammalian mtDNA 
replication, whereby synthesis of the leading and lagging strand are coupled and occur 
symmetrically (Holt, Lorimer et al. 2000). In this way mtDNA replication occurs 
bidirectionally and not only initiates at the OH, but can initiate at multiple replication 
forks within a broad zone (OriZ), which encompasses parts of the genome encoding 
cytochrome b and subunits 5 and 6 of NADH dehydrogenase (Bowmaker, Yang et al. 
2003). The same study demonstrated that the OH can actually cause arrest of the 
replication fork and serve as a termination site for mtDNA replication (Bowmaker, 
Yang et al. 2003).  
More recently a different method for mtDNA replication in vertebrates has been 
suggested, known as RITOLS (ribonucleotide incorporation throughout the lagging 
strand) (Yasukawa, Reyes et al. 2006). This model proposes that whilst the leading 
strand is synthesised, RNAs are incorporated into the lagging strand, which are later 
converted to DNA (Yasukawa, Reyes et al. 2006). Thus there is a delay between the 
synthesis of the leading and lagging strand of mtDNA and as such this model is not 
dissimilar to the asynchronous model of replication. 
A firm conclusion regarding the mechanism of mammalian mtDNA replication is yet to 
be made, with experimental evidence from the study of replication intermediates 
supporting the existence of all methods. Indeed it has been suggested that the 
mechanism selected for mtDNA replication is highly dependent upon the cell type, 
mtDNA copy number and the required rate of mtDNA synthesis, with the asynchronous 
model preferred in cells that require rapid replication compared to the synchronous 
model, which may be preferred by cells in a steady state (Holt, Lorimer et al. 2000; 
Yasukawa, Reyes et al. 2006). 
1.2.1.2.2 MtDNA replication machinery 
Even though mtDNA is self-replicating and replication is principally controlled at the 
D-loop, the proteins and machinery required for mtDNA replication are in fact all 
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nuclear encoded. Mammalian mtDNA replication machinery is known as the 
mitochondrial replisome, which comprises three main proteins: the mtDNA polymerase 
gamma (Polγ), the mitochondrial TWINKLE DNA helicase and mitochondrial single-
stranded DNA binding protein (mtSSB) (Falkenberg, Larsson et al. 2007). 
For mtDNA to be replicated the double stranded DNA must be unwound to give the 
two, complementary single strands (ss) of DNA. TWINKLE is the mitochondrial 
replicative helicase enzyme responsible for the ATP dependent unwinding of the DNA 
duplex, in the 5’ to 3’ direction (Korhonen, Gaspari et al. 2003), to give ssDNA (Figure 
1-4). Stabilization of ssDNA is achieved by the mtSSB, a 13-16kDa protein (Kaguni 
2004), which the ssDNA wraps around (Figure 1-4). MtSSB enhances the helicase 
activity of TWINKLE, via protein-protein interactions and in turn triggers the activity 
of Polγ, initiating DNA synthesis (Figure 1-4) (Korhonen, Gaspari et al. 2003). 
Polγ is an RNA dependent DNA polymerase, which consists of a PolγA catalytic 
domain and the PolγB accessory subunit. The catalytic domain has a molecular mass of 
140kDa (Gray and Tai Wai 1992) and has  3’-5’ exonuclease activity and 5’ 
deoxyribose phosphate lyase activity (Pinz and Bogenhagen 1998; Kaguni 2004). PolγB 
is a smaller protein (55kDa) that associates with PolγA to form a heterotimer (PolγAB2) 
in mammalian cells (Figure 1-4) (Yakubovskaya, Chen et al. 2006). The PolγB subunit 
binds to double stranded DNA greater than 45bp in length, and functions to enhance 
DNA and nucleotide binding, thereby increasing the catalytic and processing activity of 
PolγA (Kaguni 2004). Polγ is a high fidelity polymerase enzyme, which efficiently 
selects and incorporates nucleotides into the growing DNA strand whilst eliminating 
errors due to its proofreading activity conveyed by the 3’-5’ exonuclease (Kaguni 
2004). Unlike other DNA polymerases, Polγ therefore has a role in replication, repair 
and recombination (Kaguni 2004). The activity of Polγ is dependent upon POLRMT, 
which provides the RNA primers necessary for mtDNA replication initiation at the OH 
(Shadel and Clayton 1997) and potentially the OL. 
Whilst Polγ, TWINKLE and mtSSB form the core components of mammalian mtDNA 
replication machinery, it has been proposed that other enzymatic activities may be 
required for/or facilitate mtDNA replication.  Ribonuclease H1, has been proposed to 
have a role in the removal of primers from the OH and OL (Cerritelli, Frolova et al. 
2003) and a mitochondrial topoisomerase, encoded by TOP1mt, is necessary to alleviate 
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some of the torsional force created during the replication of closed, circular mtDNA 
molecules  (Zhang, Barceló et al. 2001). 
 
 
Figure 1-4: The machinery involved in mtDNA replication.  
The mitochondrial TWINKLE helicase unwinds double stranded mtDNA in the 5’ to 3’ direction to give two single 
stranded molecules of DNA. mtSSB stabilizes DNA in the single stranded form and activates the Polγ holoenzyme to 
synthesise the complementary strand of mtDNA. Image courtesy of Dr Eve Simcox. 
1.2.2 Mammalian mtDNA repair mechanisms 
Mammalian mtDNA is to some extent protected from damage by mtDNA associated 
proteins, which have been shown to provide protection against mutagenic insults caused 
by x-rays and hydrogen peroxide, equivalent to that provided by histones, (Guliaeva, 
Kuznetsova et al. 2006). Furthermore the packaging of mtDNA into nucleoids, results in 
the covering and protection of large amounts of mtDNA by TFAM. Nonetheless, 
mtDNA, just like nuclear DNA, is exposed to intrinsic and extrinsic harmful agents that 
induce DNA damage. Originally it was believed that mammalian mitochondria, lacked 
any form of repair enzymes or mechanisms to deal with DNA damage, as UV induced 
pyrimidine dimers were not removed from mtDNA (Clayton DA 1974) nor were certain 
types of alkylation damage (Miyaki, Yatagai et al. 1977). However, it is now known 
that mammalian mitochondria do indeed share many of the same repair mechanisms as 
nuclear DNA.  
It is well established that mammalian mitochondria possess the single-patch base 
excision repair (SP-BER) pathway for the removal of modified nucleotides and single 
base lesions caused by oxidative damage, spontaneous hydrolysis and alkylation. SP-
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BER involves DNA glycosylase enzymes to remove the modified base (Bogenhagen 
1999), AP endonucleases to remove the resulting abasic site (Tomkinson, Bonk et al. 
1988) and lyase activity of mtDNA polymerase γ and mtDNA ligase III to seal the DNA 
nick and complete the DNA repair (Bogenhagen 1999). Evidence for the removal of 
photo induced lesions in yeast mitochondria (Prakash 1975) and alkylation damage in 
human mitochondria (Cai, Xu et al. 2005) have also been documented.  
More recently it has also been identified that mtDNA repair pathways actually include 
long patch BER (LP-BER), with flip endonuclease and DNA2 nuclease/ helicase 
activity, for the removal of oxidised lesions involving more than 2 nucleotides (Liu, 
Qian et al. 2008; Zheng, Zhou et al. 2008). Mismatch repair (MMR) has also been 
identified in mammalian mitochondria for the removal of misincorporated bases and 
slippage errors caused by Polγ during mtDNA replication (Mason, Matheson et al. 
2003; de Souza-Pinto, Mason et al. 2009) and there is increasing evidence for the repair 
of double strand breaks in mammalian mitochondria by homologous recombination and 
non-homologous end joining, as detailed in (Liu and Demple 2010). 
Targeted degradation of damaged mtDNA has also been hypothesised as a mechanism 
by which mitochondria can remove high levels of mtDNA damage. This was supported 
with the discovery of a novel endo-exonuclease in the mitochondrial matrix (Davies, 
Hershman et al. 2003) and the more recent discovery that oxidative lesions in mtDNA 
are selectively targeted for degradation to prevent their copying during mtDNA 
replication and mutagenesis (Shokolenko, Venediktova et al. 2009).  
1.2.3 Maternal inheritance and the mtDNA bottleneck 
Inheritance of mtDNA is unique in that it is not subject to Mendelian inheritance but is 
inherited strictly though the maternal lineage. Sperm mitochondria are diluted out by the 
vast number of mitochondria present in the maternal oocyte and following fertilisation 
sperm mitochondria are targeted selectively for degradation by ubiquitination and 
autophagy in the oocyte cytoplasm (Al Rawi, Louvet-Vallée et al. 2011), with any 
remaining paternal mitochondria inactivated by proteolysis during preimplantation 
development (Cummins, Wakayama et al. 1997; Sutovsky, Moreno et al. 2000). Only 
one incidence of paternally inherited mtDNA has ever been reported, where a patient 
presented with a deletion in mt-ND2, that was found to be of paternal origin and absent 
from the maternal haplotype (Schwartz and Vissing 2002). 
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Pathogenic mtDNA mutations are transmitted from mother to child if present in the 
maternal germline (Giles, Blanc et al. 1980), with the risk of transmission governed by 
the heteroplasmy of the mutation (Larsson, Tulinius et al. 1992). Indeed the type of 
mtDNA defect further influences the risk of transmission, with mtDNA deletions rarely 
transmitted from mother to offspring (Larsson, Eiken et al. 1992) whilst the 
transmission of mtDNA point mutations is much more common. The maternal 
transmission of a mtDNA mutation can result in offspring with substantial variability in 
heteroplasmy for the same mutation (Taylor and Turnbull 2005), which is due to a 
phenomenon known as the “genetic bottleneck”. Mammalian oocytes contain ~100, 000 
copies of mtDNA, whereas the primordial germ cell from which they originated 
contains a much lower number of mtDNA genomes, ~200 (Cree, Samuels et al. 2008). 
As such there is the selective replication and amplification of only a small number of 
specific mtDNA molecules during oogenesis. The molecular mechanisms involved in 
the “genetic bottleneck” remain to be elucidated; however the bottleneck is believed to 
exist to act as a constraint on the germline transmission of pathogenic mtDNA 
mutations. Indeed studies performed in mice have demonstrated that pathogenic 
mtDNA mutations are subject to strong purifying selection in the mammalian germline, 
limiting the transmission of severe mutations in protein-encoding genes (Fan, Waymire 
et al. 2008; Stewart, Freyer et al. 2008) . However, despite such selective mechanisms 
pathogenic mtDNA mutations and low level heteroplasmic mutations are still frequently 
inherited through the maternal lineage (He, Wu et al. 2010). 
1.2.4 MtDNA mutagenesis 
As mentioned above mtDNA, is subject to harmful intrinsic and extrinsic noxious 
agents that induce DNA damage and can result in mutations of the mtDNA genome. 
MtDNA mutations can present as point mutations, deletions, insertions and large-scale 
rearrangements. The incidence of damage to the mtDNA genome is substantially higher 
than to the nuclear genome, with the mtDNA mutation rate estimated to be 10-17 fold 
higher than nuclear DNA (Neckelmann, Li et al. 1987; Wallace, Ye et al. 1987). This 
was originally believed to be due to a lack of DNA repair mechanisms (Clayton 1982) 
coupled with a lack of protective histones (Richter C 1988). However, it is now known 
that mitochondria do indeed share many of the same DNA repair mechanisms as the 
nuclear genome (Liu and Demple 2010) and the protective role of histones is actually 
rather dubious, with certain experimental evidence suggesting that histones can 
intensify DNA damage rather than protect against it (Liang and Dedon 2001).  
24 
 
MtDNA point mutations are principally thought to arise from endogenous replication 
errors caused by Polγ through the misincorporation and miscopying of bases (Zheng, 
Khrapko et al. 2006). Indeed mtDNA Polγ is thought to have a greater error rate than 
other DNA polymerase enzymes (Kunkel 1986). Unrepaired oxidized lesions are also a 
cause of mtDNA mutations, with mtDNA being shown to contain a higher incidence of 
the common oxidized lesion, 8-hydroxydeoxyguanosine, occurring every 1 in 8000 
bases, compared to 1 in 130 000 bases in nuclear DNA (Richter C 1988). As such the 
substantial mutation rate of the mtDNA genome is also believed to be attributable to the 
close proximity of the mtDNA genome to the ETC in the IMM and the site of ROS 
production (Richter C 1988). The formation of mtDNA deletions is believed to arise 
from one of two proposed mechanisms: either during slippage replication (Shoffner, 
Lott et al. 1989) or during the repair of DNA damage, caused by double-strand breaks 
(Krishnan, Reeve et al. 2008). 
1.2.5 Heteroplasmy 
Given the high copy number of mtDNA within mitochondria, a mixture of both wild-
type (WT) mtDNA and mutant mtDNA can exist within a cell, giving rise to a state 
known as heteroplasmy (Larsson and Clayton 1995). Heteroplasmy is often expressed 
as the percentage of mtDNA genomes that harbour a mutation within a cell, and is an 
important determining factor in the clinical presentation of mitochondrial DNA disease. 
When all of the mtDNA in a given cell is identical, this is known homoplasmy, such 
that a cell can be homoplasmic WT or homoplasmic mutant.  
1.2.6 The threshold effect 
MtDNA mutations are highly recessive (Sciacco M 1994), which coupled with the high 
copy number of mtDNA in a cell, means that a cell can tolerate a fairly high level of 
mtDNA defects and still maintain normal mitochondrial function. It is well established, 
however that once a mutant mtDNA molecule is present within a cell, it can clonally 
expand and become the dominant genome. It is only when a mutant mtDNA molecule 
clonally expands and reaches a critical threshold level that normal mitochondrial 
function can no longer be maintained, a biochemical defect in the respiratory chain 
occurs and a mutant phenotype is observed (Figure 1-5). The critical threshold level 
differs according to the individual, the cell type (Johns 1995), the metabolic demand of 
the tissue, the mutation type and the amount of residual WT mtDNA. However, in 
general a mutant phenotype is observed when the level of mtDNA deletion exceeds 
~60% in a cell (Sciacco M 1994) and ~85% for mtDNA point mutations, with the 
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critical threshold level for certain tRNA mutations exceeding 90% (Boulet L 1992; 
Chomyn, Martinuzzi et al. 1992).  
 
 
Figure 1-5: Heteroplasmic mtDNA mutations and the threshold effect.  
Heteroplasmic mtDNA mutations can be tolerated by a cell and normal mitochondrial functional maintained, until a 
critical threshold level of mutant mitochondria is reached, which is usually in excess of 60% heteroplasmy. The green 
ovals represent individual mitochondria within a cell, containing WT mtDNA (white circles) and mutant mtDNA (red 
circles). 
The mutant phenotype that ensues when a biochemical defect arises in the respiratory 
chain can routinely be identified in tissues using a histochemical assay for the activity 
of cytochrome c oxidase (COX), complex IV of the respiratory chain, and succinate 
dehydrogenase (SDH), complex II (Old and Johnson 1989). Given that the catalytic 
subunits of complex IV, which are essential for its assembly, are encoded by mtDNA, 
mtDNA defects often result in a loss of COX activity. SDH is entirely nuclear encoded 
and as such is unaffected by mtDNA defects. Using this assay sections are firstly 
incubated with COX medium which comprises 3, 3’-diaminobenzidine (DAB), 
cytochrome c and catalase. DAB acts as an electron donor in the ETC, reducing 
cytochrome c, which in turn is then oxidised by COX. The loss of an electron from 
DAB induces oxidative polymerization and the cyclization of DAB, which results in the 
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formation of a brown, insoluble, indamine polymer in cells that harbour normal COX 
activity (Old and Johnson 1989). Endogenous peroxidase activity, which may interfere 
with the formation of the brown polymer, is inhibited by the inclusion of catalase in the 
reaction medium. The SDH medium used comprises nitro blue tetrazolium (NBT), 
phenazine methosulphate (PMS), sodium azide and sodium succinate. NBT acts as an 
electron acceptor in the ETC, PMS is used an efficient electron carrier, enhancing the 
formation of the final product, sodium azide acts as a terminal respiratory chain 
inhibitor and sodium succinate serves as the substrate in the reaction (Old and Johnson 
1989). The reduction of NBT upon gaining an electron results in the formation of an 
insoluble, microcrystalline, blue formazan. Cells with normal functioning mitochondria 
and preserved COX activity will therefore oxidize DAB and stain brown and cells with 
dysfunctional mitochondria will stain negative for COX activity but positive for SDH 
activity and appear blue upon the reduction of NBT (Muller-Hocker 1989; Old and 
Johnson 1989). As such this histochemical assay can be readily used to identify cells 
harbouring mtDNA defects and is commonly used as a screening tool for mitochondrial 
dysfunction in both disease (Sciacco M 1994; Kaido, Fujimura et al. 1995) and ageing 
(Muller-Hocker 1989; Muller-Hocker 1990; Brierley, Johnson et al. 1998; Cottrell, 
Blakely et al. 2001; Taylor, Barron et al. 2003; Bender, Krishnan et al. 2006). Indeed 
this assay serves as a fundamental screening tool throughout this thesis.  
1.2.7 Clonal expansion  
The ability of a mtDNA mutation to clonally expand and become the dominant genome 
within a cell was first documented in muscle biopsies of patients with mtDNA over 20 
years ago (Mita, Schmidt et al. 1989). However the exact mechanism by which a 
mtDNA mutation clonally expands remains unknown. Several hypotheses have been 
proposed, however these differ in suitability according to the type of mtDNA defect and 
the tissue in which the mutant mtDNA molecule is undergoing clonal expansion. 
1.2.7.1 Structural mechanisms 
The structural mechanisms of clonal expansion suggest that specific structural changes 
invoked by the mtDNA defect convey a replicative advantage to the mutant mtDNA 
genome, thus propagating clonal expansion within the cell. As such it was proposed by 
Wallace in 1992 that a mtDNA genome possessing a large-scale deletion would 
replicate and proliferate faster in the cell, due to the smaller size, than the larger WT 
mtDNA molecule, thus driving clonal expansion (Wallace 1989). Indeed this been 
supported experimentally in two different studies (Diaz, Bayona-Bafaluy et al. 2002; 
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Fukui and Moraes 2009). However, the known rate of mtDNA replication (<90 
minutes) and the interval between replications (~2 weeks), indicates that a faster 
mtDNA replication would bear little benefit to a mutant mtDNA molecule (Shadel and 
Clayton 1997; Korr, Kurz et al. 1998; Kowald and Kirkwood 2000). Furthermore if 
smaller genomes replicated faster, mtDNA deletions should preferentially accumulate in 
replicative tissues with a high turnover rate. However, this is not the case, with clonally 
expanded mtDNA deletions predominantly seen in post-mitotic tissues (Muller-Hocker 
1989; Muller-Hocker 1990; Cottrell, Blakely et al. 2001). Clonally expanded mtDNA 
point mutations prevail in mitotic tissues and indeed the “survival of the smallest” 
concept and the proposed replicative advantage could not explain the clonal expansion 
of these mtDNA genomes, where there is no alteration in size (Taylor, Barron et al. 
2003; McDonald, Preston et al. 2006; Fellous, McDonald et al. 2009). Moreover, given 
that multiple stages of the mtDNA replication process are dependent upon ATP it is 
difficult to understand how a smaller genome, that will undoubtedly have lost genes and 
therefore proteins that are essential for activity of the ETC, could generate enough 
energy to facilitate faster mtDNA replication (Kowald and Kirkwood 2000).  
Alternatively it has been suggested that mtDNA deletions harbour a replicative 
advantage due to the loss or inactivation of cis-acting regulatory elements that usually 
repress proliferation (Shoubridge, Karpati et al. 1990). As such enhanced proliferation 
of deleted mtDNA genomes would ensue leading to their clonal expansion and 
accumulation within the cell. However, the location of such negative regulatory 
elements was not specified in this study and it was found that multiple large deletions 
covering a number of overlapping-regions of the genome accumulate in heart muscle 
fibers (Khrapko, Bodyak et al. 1999). As such the clonal expansion of deletions cannot 
simply be dependent upon the loss/ inactivation of one particular part of the genome. 
1.2.7.2 Functional mechanisms 
The functional mechanisms predict that a mtDNA defect in a tRNA or protein-encoding 
gene causes a functional change, enabling the mutant mtDNA genome to accumulate 
within the cell. In 1990 Shoubridge offered a mechanism for the clonal expansion of 
mtDNA deletions based upon the principle that increased oxidative demand in skeletal 
muscle stimulates mitochondrial biogenesis and proliferation (Williams, Salmons et al. 
1986). As such it was suggested that a cell harbouring mutant mtDNA would stimulate 
increased mtDNA synthesis and mitochondrial proliferation in an attempt to 
compensate for a reduction in OXPHOS and ATP production thus causing expansion of 
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the mutant genome (Shoubridge, Karpati et al. 1990). Indeed this is supported by the 
presence of ragged red fibers (RRF) in skeletal muscle of certain patients with 
mitochondrial DNA disease, demonstrating the subsarcolemmal accumulation of 
mitochondria and a potential hyperproliferative response (Shoffner, Lott et al. 1990). 
This positive feedback mechanism, however would only operate if individual 
mitochondria harbouring mutant mtDNA were stimulated to proliferate (Kowald and 
Kirkwood 2000). Indeed such a mechanism is unlikely given that mitochondria exist in 
a dynamic intracellular network and undergo fission and fusion.  Moreover 
experimental evidence demonstrates that defective mitochondria are selectively 
degraded by autophagy and not preferentially amplified (Twig, Elorza et al. 2008; Kim 
and Lemasters 2011). 
 
Alternatively it has been suggested that a mutation in mtDNA actually results in 
decreased activity of the ETC and decreased ROS production, thereby resulting in less 
oxidative damage to mitochondrial membranes. As such mitochondria harbouring 
mutant mtDNA would be targeted less for degradation by lysosomes, than their WT 
counterparts that would incur more oxidative damage (De Grey 1997). The favoured 
survival of mutant mtDNA would give the mutant genome a selective advantage, thus 
facilitating clonal expansion within the cell. This is otherwise known as the “survival of 
the slowest” mechanism and has been supported by modelling studies (Kowald and 
Kirkwood 2000). However, again this mechanism disregards the dynamic, reticular 
network of mitochondria within a cell, the distribution of mtDNA within this network 
and the compensatory mechanisms that exist for reduced OXPHOS capacity. 
1.2.7.3 Random mechanisms 
Random mechanisms of clonal expansion, unlike the structural and functional 
mechanisms, propose that replication of the mtDNA genome is actually unbiased. 
Computer modelling demonstrated that neutral replication, where some mtDNA 
molecules are randomly replicated and others are randomly lost, coupled with mitotic 
segregation during cell division, is sufficient for a mtDNA mutation to clonally expand 
and reach homoplasmy in a dividing cell after a specific number of divisions (Figure 
1-6) (Coller, Khrapko et al. 2001).This model was found to match experimental data 
and successfully predicted the frequency of homoplasmic mtDNA mutations in normal 
buccal epithelial cells and tumour cells (Coller, Khrapko et al. 2001). However, this 
model assumed that mtDNA replication was coupled with cell division (Coller, 
29 
 
Khrapko et al. 2001) whereas mtDNA is known to replicate autonomously, independent 
of the cell cycle.  
A second computer modelling study, however, further demonstrated that relaxed 
replication of the mtDNA genome coupled with random mtDNA replication, can 
through random intracellular drift, lead to the clonal expansion of mtDNA mutations in 
single post mitotic cells during the human lifespan (Elson, Samuels et al. 2001). This 
model again was found to match experimental data, successfully predicting the 
magnitude of COX deficiency (≤4%) caused by clonally expanded mtDNA mutations in 
human post mitotic tissues (Muller-Hocker 1990; Brierley, Johnson et al. 1998; Cottrell, 
Blakely et al. 2001). The clonal expansion of mtDNA mutations through random 
intracellular drift did indeed take a significant number of years and so it was proposed 
that mtDNA mutations actually occur during childhood or early adulthood and clonally 
expand throughout an individual’s lifetime (Elson, Samuels et al. 2001), which has 
since been reinforced experimentally using mitochondrial mutation assays (Coller, 
Khrapko et al. 2005; Greaves 2014).   
 
Figure 1-6: Clonal expansion of a mutant mtDNA molecule in mitotic tissues by random intracellular drift. 
The mutated mtDNA molecule is shown by the red circle and the WT mtDNA molecules by the white circles. 
Random genetic drift poses that during stem cell division, the relaxed replication of the mtDNA genome coupled with 
the fact that a mutant mtDNA molecule may be randomly lost or randomly replicated, can lead to the clonal 
expansion of the mutant genome when the replicated mutated genomes are both inherited by a daughter cell, as 
shown in the diagram on the left. Alternatively, during stem cell division, a mutant mtDNA molecule may be evenly 
distributed between daughter cells, resulting in an absence of clonal expansion, as indicated by the diagram on the 
right.    
Experiments in certain human cell cybrids have shown that some mtDNA mutations do 
seem to convey a selective advantage and lead to the preferential replication and 
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amplification of the mutant genome (Shay and Ishii 1990; Yoneda, Chomyn et al. 
1992). However, random intracellular drift closely matches the experimental data and 
incidence of clonally expanded mtDNA mutations that we see in human tissues, and so 
whilst there are specific exceptions, it may be a more general mechanism for the clonal 
expansion of mutations in human tissues.  
Understanding the mechanisms by which mtDNA mutations clonally expand is essential 
to facilitate our understanding of the presentation and progression of pathological 
conditions and disease, as well as the ageing process, with clonally expanded mtDNA 
mutations documented in a number of ageing human tissues (see section 1.4.3.1.1). 
1.2.8 Mitotic segregation  
The rate of mtDNA turnover remains poorly understood, however the continuous 
replication of the mtDNA genome means that mtDNA molecules can segregate in both 
mitotic and post-mitotic cells, irrespective of the cell cycle. During mitosis mtDNA 
molecules are randomly segregated between daughter cells, which causes variations in 
the level of mutant mtDNA. Consequently, mtDNA heteroplasmy can vary considerably 
between cell lineages and different tissues (Macmillan, Lach et al. 1993), and it is only 
if the mutation load exceeds the critical threshold level that a mutant phenotype is 
observed, giving rise to the significant heterogeneity seen with mitochondrial DNA 
disease. Indeed tissue segregation of mtDNA molecules can also lead to the loss of a 
mutant mtDNA molecule within a cell population, especially in mitotic tissues with a 
high cellular turnover. This is characteristic of the m.3243A>G mutation in patients 
with mtDNA disease that present with lower heteroplasmy in the blood, buccal and hair 
compared to much higher levels of the mutation in muscle and urine, suggesting a 
selective loss of the mutation in replicative tissues(Chinnery, Zwijnenburg et al. 1999; 
Rahman, Poulton et al. 2001).  
1.3 Mitochondrial disease 
Pathogenic mutations in mtDNA were first identified in 1988 (Holt, Harding et al. 1988; 
Wallace 1988). It is now estimated that 1 in 200 people in the UK harbour a pathogenic 
mtDNA mutation, with ~1 in 10, 000 adults presenting with clinically manifesting 
mitochondrial disease in north east of England (Elliott, Samuels et al. 2008; Schaefer, 
McFarland et al. 2008). Given the presence of mitochondria in all nucleated mammalian 
cells, mitochondrial disease is an extremely heterogeneous group of disorders, that 
affect multiple organ systems and can present at different ages of onset (McFarland, 
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Taylor et al. 2007). The clinical presentation of the disease is governed by the type of 
mutation, heteroplasmy and the threshold level, mitotic segregation, the genetic 
bottleneck and the clonal expansion of the mutation. Neurological and muscle 
phenotypes are common as organ systems that have a high-energy demand are typically 
affected in mitochondrial disease. Mitochondrial diseases are a severely debilitating 
group of disorders, for which there is currently no cure and treatment options purely 
focus on managing disease symptoms. For further details of the different symptoms and 
clinical manifestations of mitochondrial DNA disease in both adults and children please 
refer to the following reviews (Taylor and Turnbull 2005; Tuppen, Blakely et al. 2010).  
Successful diagnosis of mitochondrial disease relies on multiple avenues of 
investigation including histochemical and biochemical analysis as well as whole 
genome sequencing of mtDNA for the detection of mtDNA point mutations or 
deletions. Histological evidence of mitochondrial dysfunction, including the presence of 
ragged red fibres, indicative of subsarcolemmal accumulation of irregular mitochondria, 
and COX deficiency can frequently be detected in muscle biopsies of patients with 
mitochondrial DNA disease (Sciacco M 1994; Kaido, Fujimura et al. 1995). COX 
deficiency can also be detected in certain brain regions of patients with mtDNA disease 
(Kaido, Fujimura et al. 1995). 
Mitochondrial disease is commonly caused by rearrangements in mtDNA or point 
mutations. Given that a substantial number of proteins involved in OXPHOS and all 
proteins required for mtDNA replication are nuclear encoded, nuclear gene mutations 
can also precipitate mitochondrial disease. For example mutations in Polγ and 
TWINKLE have been shown to cause the accumulation of multiple mtDNA deletions 
(Spelbrink, Li et al. 2001; Van Goethem, Dermaut et al. 2001) and mutations in 
complex I subunits encoded by nuclear DNA cause Leigh syndrome (Smeitink and Van 
Den Heuvel 1999). For additional details on mitochondrial respiratory chain disorders 
caused by different nuclear gene defects please see the following reviews (Shoubridge 
2001; DiMauro and Schon 2003). Mitochondrial disease can also be caused by 
problems with fatty acid metabolism, as seen in Medium-chain acyl-Coenzyme A 
Dehydrogenase (MCAD) deficiency, which commonly presents as hypoketotic 
hypoglycaemia and Very-Long-chain acyl-CoA Dehydrogenase (VLCAD) deficiency, 
characterised by cardiomyopathy (Wilcken 2010). 
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MtDNA rearrangement disorders are primarily caused by large-scale deletions in 
mtDNA but can also be caused by duplications. MtDNA deletions typically range from 
~1- 8kb in size and can span several genes (Schon, Rizzuto et al. 1989). They 
commonly occur between the two origins of replication and are flanked by two short 
(13bp) direct repeats (Samuels, Schon et al. 2004; Bua, Johnson et al. 2006). Single 
mtDNA deletions, where the same deletion is present in all cells of an affected tissue, 
commonly cause sporadic mitochondrial disease, such as Kearns-Sayre syndrome 
(Zeviani, Moraes et al. 1988), Chronic Progressive External Opthalmoplegia (Moraes, 
DiMauro et al. 1989) and Pearson syndrome (Rotig, Cormier et al. 1990). The formation 
of mtDNA deletions is covered in section 1.2.4 and further details concerning the 
clinical phenotype and mtDNA genotype of these disorders can be found in the 
following review (Taylor and Turnbull 2005). The presence of multiple mtDNA 
deletions in cells is generally secondary to a nuclear gene defect, such as mutations in 
TWINKLE and mtDNA polymerase  (see above) (Taylor and Turnbull 2005). 
 
Pathogenic point mutations in mtDNA that cause mtDNA disease are typically 
heteroplasmic and are maternally inherited. Point mutations can occur within protein 
encoding genes, directly affecting the function of a respiratory chain complex, as seen 
in Leber’s Hereditary Optic Neuropathy, which is caused by complex I defects (LHON) 
(Johns, Neufeld et al. 1992), rRNA genes or they can occur in tRNA genes, which are 
detrimental to mitochondrial translation. The emphasis of this thesis is not on 
mitochondrial disease in general but rather on a mouse model of a specific mt-tRNA 
point mutation and as such I will only discuss this group of mtDNA point mutations in 
more detail. For further details on the range of clinical mitochondrial DNA diseases 
caused by mtDNA point mutations please see the following review (Taylor and 
Turnbull 2005).    
1.3.1 Mt-tRNA point mutations 
In spite of the fact that tRNA genes only occupy ~10% of the mtDNA genome 
(McFarland, Elson et al. 2004), over half of the disease-causing mtDNA point mutations 
that have been identified occur in mt-tRNA genes and account for the majority of 
pathogenic mtDNA mutations transmitted from mother to child (Schaefer, McFarland et 
al. 2008). Unsurprisingly mt-tRNA mutations precipitate a loss in translational function 
of the tRNA and cells harbouring pathological mt-tRNA commonly show reduced 
activity and function of respiratory chain complexes, reduced oxygen consumption, 
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reduced growth rates and increased levels of lactate, given the cells dependence upon 
glycolysis for energy production (Jacobs 2003).  
Two of the most prominent clinical mitochondrial disorders are caused by mt-tRNA 
mutations:  mitochondrial encephalomyopathy, lactic acidosis and stroke like episodes 
(MELAS), which is caused by the m.3243A> G mutation in mt-tRNA
Leu
 
(UUR)
 (Goto, 
Nonaka et al. 1990) and myoclonic epilepsy with ragged red fibres (MERRF), which is 
caused by the m.8344A>G mutation in mt-tRNA
Lys
 (Shoffner, Lott et al. 1990). The 
m.3243A>G mutation occurs in the dihydrouridine loop of tRNA
Leu (UUR)
, which is 
associated with a decrease in the aminoacylation of the tRNA, causing a defective 
anticodon that leads to impaired translation (Yasukawa, Suzuki et al. 2000) . The 
m.8344A>G mutation occurs in the TΨC loop of tRNALys and is similarly associated 
with an unmodified base in the wobble position of the anticodon, resulting in 
mistranslation (Yasukawa, Suzuki et al. 2000). Whilst the tRNA mutations precipitating 
MELAS and MERRF are fairly common within the population, many other mt-tRNA 
point mutations will only present in one or two families (Majamaa, Moilanen et al. 
1998). 
Certain correlations can be made between disease presentation in patients and the mt-
tRNA gene affected, such that tRNA
Lys 
mutations are often associated with 
cardiomyopathy, as seen in MERRF, tRNA
Ser
 mutations often resulting in sensorineural 
deafness and tRNA
Leu
 mutations are commonly associated with myopathy and muscle 
phenotypes (Jacobs 2003). Specific mt-tRNA mutations, however, still precipitate 
extremely heterogeneous clinical phenotypes in different patients, which is common in 
patients with MELAS. Heteroplasmy, mitotic segregation and the limited number of 
non-specific mitochondrial tRNAs available that cause variation in the proteins 
synthesised, are amongst some of the explanations offered to describe the diverse 
clinical symptoms caused by a specific mt-tRNA mutations (Jacobs 2003). However, 
our understanding of the molecular mechanisms involved in the diversity of 
mitochondrial DNA diseases caused by mt-tRNA mutations still remains fairly poor. 
Dissecting such molecular mechanisms is vital for understanding disease progression, 
maternal transmission, improving disease management and developing new treatments.   
1.4 Ageing 
Ageing is a stochastic process characterised by the accumulation of molecular damage 
within cells, resulting in attenuated tissue function during adulthood, reduced fecundity, 
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enhanced susceptibility to disease and an increased probability of death (Kirkwood 
2008).  Since the late 19
th
 and 20
th
 century, improvements in sanitation, medicine, 
housing and education have resulted in a vast increase in life expectancy, accompanied 
by a reduction in later life mortality (Kirkwood 2008). Consequently, it is becoming 
crucial to understand the mechanisms involved in the ageing process and the driving 
factors of age-related frailty and disease, in order to improve the quality of later life in 
aged individuals. A number of theories, classified as either evolutionary or molecular 
theories of ageing, have been proposed to explain the ageing process and the causal 
factors. However, much of the literature and experimental evidence is still fairly 
dubious, with ageing actually believed to be a multi-factorial process, arising from a 
combination of different mechanisms acting simultaneously. 
1.4.1 Evolutionary theories of ageing 
Given that different species have different lifespans, evolutionary theories of ageing 
assert that lifespan and longevity is controlled by the genome and that the ageing 
process is therefore programmed (Finch and Tanzi 1997). There are three predominant 
evolutionary theories of ageing, which began with August Weismann in 1889, with the 
suggestion that all species possess an ‘ageing gene’ and this acts to programme ageing 
in order to minimise and control population size. Genomic influence on the ageing 
process became well-recognized when Medawar proposed the Mutation Accumulation 
theory, suggesting that ageing is driven by the accumulation of deleterious mutations 
within the genome, that have adverse effects later in life (Medawar 1952). The late-
onset adverse effects of genes is a repeated concept in the Antagonistic Pleotropy theory 
of ageing, which suggests that the selection of favourable genes which convey  a 
reproductive advantage early in life, become detrimental later on (Williams 1957). The 
Disposable Soma theory of ageing is the third evolutionary theory and alternatively 
suggests that ageing arises due to metabolic trade-offs between reproduction, cell 
growth and repair mechanisms in somatic cells (Kirkwood 1977). Given that energy 
will be pooled into reproductive processes to propagate a species, a lack of energy 
resources are available for cell maintenance and repair (Kirkwood 1977). As such 
damage will accumulate within cells and drive the ageing process. However, the 
prospect that genes govern lifespan and that organisms would select for a process that is 
not advantageous for their survival and instead leads to ageing, disease and death, is 
highly unlikely, and is a major argument used against the evolutionary theories of 
ageing (Kirkwood 1995). 
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1.4.2 Molecular theories of ageing 
Molecular theories of ageing propose that ageing is not programmed but rather results 
from the accumulation of unrepaired molecular damage in somatic cells caused by 
biochemical and cellular processes. Given that such processes would occur randomly, 
the molecular theories of ageing are more widely accepted. The molecular theories of 
ageing essentially focus on the accumulation of damage to DNA, telomeres, proteins 
and oxidative damage to macromolecules.  
 
Random mutagenesis of chromosomal DNA coupled with the progressive inefficiency 
of DNA repair mechanisms during the life course of a species (Szilard 1959; Hart 
1974), have been proposed as the principle driving factors of DNA damage 
accumulation within cells, leading to tissue dysfunction with age. The idea that DNA 
damage is fundamental in cellular ageing is further continued by the telomere 
hypothesis of cellular ageing (Harley 1992). Given that the activity of telomerase, the 
enzyme that maintains telomere length, is suppressed in somatic cells, there are only a 
certain number of cell divisions that a cell can undergo before telomere length decreases 
below a specific limit and the cell will enter replicative senescence (Harley 1992). 
Arrested cells therefore begin to accumulate over time, with the lack of functional cells 
leading to tissue failure. Age-related damage to DNA can further arise from time-
dependent, abnormal post-translational cross-linking, which can permanently interfere 
with normal function (Bjorksten and Tenhu 1990). Protein damage can also ensue from 
such chemical cross-linking (Bjorksten and Tenhu 1990), which along with age-related 
disturbances in protein homeostasis and decreased protein turnover within cells (Cuervo 
2000) can cause the accumulation of damaged, aggregated proteins within cells. 
Oxidative damage to DNA, proteins, lipids and macromolecules is a further source of 
damage accumulation and is well-documented in ageing tissues (Balaban, Nemoto et al. 
2005). It was in 1956 that Harman first proposed the free radical theory of ageing to 
explain oxidative damage (Harman 1956), which later became adapted to the 
mitochondrial free radical theory of ageing (Harman 1972). 
 
1.4.2.1 The (mitochondrial) free radical theory of ageing 
According to the free radical theory of ageing, cellular dysfunction arises from 
irreversible oxidative damage to DNA, proteins and cellular membranes caused by 
endogenous ROS, namely the superoxide radical and hydroxyl radical, produced during 
36 
 
OXPHOS (Harman 1956). The discovery of the antioxidant superoxide dismutase, the 
enzyme responsible for metabolising the superoxide radical, in mitochondria (McCord 
1969) and the identification of mitochondria as the dominant site of ROS production in 
a cell (Chance 1979) lead to the adaptation of this theory to the mitochondrial free 
radical theory of ageing (MFTA) (Harman 1972). It is estimated that ~0.2% of the total 
oxygen consumed by mitochondria is responsible for ROS production (St-Pierre, 
Buckingham et al. 2002) and ~90% of total cellular ROS production is attributable to 
the mitochondrial ETC (Balaban, Nemoto et al. 2005). It is proposed that the close 
proximity of mtDNA to the ETC and site of ROS production renders mtDNA 
vulnerable to oxidative damage and mtDNA mutations (Harman 1972). As such the 
MFTA proposes that mtDNA mutations accumulate throughout life and result in 
reduced mitochondrial and respiratory chain function (Miquel, Economos et al. 1980). 
This is proposed to activate a vicious cycle whereby dysfunction of the OXPHOS 
system causes enhanced ROS production and further damage to mtDNA,  leading to the 
progressive accumulation of mtDNA mutations with age and further oxidative damage, 
eventually resulting in cell death (Harman 1972).  
A fundamental association between ROS, mitochondria and lifespan has been 
demonstrated in a number of studies that show a reduced production of the superoxide 
radical in the heart, liver and kidney (Sohal, Svensson et al. 1989) and decreased 
oxidative damage to proteins (Agarwal and Sohal 1996) in longer lived animals. 
Pigeons, which  live 7 years longer than rats, have also been shown to release ~30% less 
hydrogen peroxide from mitochondria than rat mitochondria (Herrero and Barja 1997). 
Furthermore transgenic mouse models demonstrate decreased ROS production and 
oxidative damage when the antioxidant catalase is targeted to mitochondria (Williams, 
Van Remmen et al. 1998; Schriner, Linford et al. 2005) and mice defective in 
manganese superoxide dismutase show increased oxidative damage to DNA and 
proteins (Williams, Van Remmen et al. 1998).  
 
The mitochondrial theory of ageing is very attractive as mitochondria are the only extra 
nuclear source of DNA within a cell; the location of mtDNA renders it vulnerable and 
sensitive to the accumulation of damage (Harman 1972) and mtDNA demonstrates a 
significantly high mutation rate (Neckelmann, Li et al. 1987). Furthermore normal 
functioning of the mitochondrial respiratory chain plays a pivotal role within cellular 
survival and lifespan (Lin, Kaeberlein et al. 2002; Rea, Ventura et al. 2007). Structural 
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changes in mitochondria are also observed with increasing age, including a decline in 
number in post-mitotic tissues such as the heart,(Herbener 1976) and brain (Samorajski, 
Friede et al. 1971) as well as mitochondrial enlargement, cristae abnormalities and 
vacuolization (Wilson and Franks 1975; Wilson and Franks 1975). Seemingly a number 
of changes occur within mitochondria with increasing age, and the pivotal role of the 
ETC for normal cellular function, indicates that such changes in mitochondria and any 
resulting dysfunction are likely to be detrimental to the cell and contribute to the ageing 
process.  
1.4.3 Mitochondrial dysfunction and ageing  
Much of the supporting evidence for the MFTA however is simply correlative, and 
experimental evidence from recent years actually contests the so called ‘vicious cycle’ 
hypothesis. According to the vicious cycle ageing tissues should demonstrate a 
progressive accumulation of mtDNA mutations due to the production of new mtDNA 
mutations induced by the aggressive production of ROS (Harman 1972). However, 
ageing tissues tend to present with respiratory chain deficient cells that harbour a single 
clonally expanded mutant mtDNA molecule, rather than a variety of different mutations 
(Brierley, Johnson et al. 1998) (see section 1.4.3.1) and studies performed in the 
mtDNA mutator mouse, which show a progressive accumulation of mtDNA mutations 
and a premature ageing phenotype, do not show increased ROS production (Kujoth, 
Hiona et al. 2005; Trifunovic, Hansson et al. 2005) (see section 1.5.3), providing 
evidence against the ‘vicious cycle’ hypothesis. As such an alternative explanation for 
the mitochondrial theory of aging has been proposed, suggesting that mtDNA mutations 
actually arise during early life due to oxidative damage or errors that occur during 
mtDNA replication, and it is the clonal expansion of these mutations throughout 
adulthood that results in mitochondrial dysfunction later in life (Elson, Samuels et al. 
2001; Greaves 2014). Tissue dysfunction would subsequently arise from defects in 
energy metabolism, apoptosis and senescence, eventually leading  to age-related frailty 
and disease (Taylor and Turnbull 2005). Age-related respiratory chain dysfunction was 
reported in 1989 with the discovery that COX deficient cardiomyocytes accumulated in 
the hearts of subjects over the age of 60 and were indeed absent from young individuals 
below 20 years of age (Muller-Hocker 1989). COX deficient cells have since been 
documented in numerous ageing human tissues including skeletal muscle (Muller-
Hocker 1990), brain (Cottrell, Blakely et al. 2001), the colon (Taylor, Barron et al. 
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2003), liver (Fellous, Islam et al. 2009), and stomach (McDonald, Greaves et al. 2008), 
indicating a role for mitochondrial respiratory chain deficiency in the ageing process.  
1.4.3.1 MtDNA mutations and ageing 
The central focus of this thesis is to examine the role of mtDNA point mutations in 
ageing mitotic tissues, and so the role of age-related mtDNA deletions will only be 
examined briefly.  
The ‘common deletion’, which spans  4977 nucleotides between the mt-ATPase8 and 
mt-ND5 genes, was the first mtDNA deletion to be discovered in ageing tissues, 
detected in the heart and multiple regions of the brain of elderly individuals (Cortopassi 
and Arnheim 1990). The ‘common deletion’ has subsequently been identified in skeletal 
muscle, the diaphragm, kidney, spleen and liver, with the highest level of the deletion 
detected in post-mitotic tissues, suggesting that mtDNA deletions accumulate in a tissue 
specific manner with age (Cortopassi, Shibata et al. 1992). Skeletal muscle fibers have 
been shown to accumulate multiple deletions in mtDNA with age (Kopsidas, Kovalenko 
et al. 1998) and focal respiratory chain deficiency has been associated with the 
accumulation of clonally expand mtDNA deletions in skeletal muscle fibers and 
neurons of the substantia nigra  (SN) in humans, where single cell analysis has revealed 
the clonal expansion of different mtDNA deletions in different cells of the same tissue 
(Brierley, Johnson et al. 1998; Bender, Krishnan et al. 2006; Kraytsberg, Kudryavtseva 
et al. 2006). Focal COX deficiency has also been identified in skeletal muscle of rhesus 
monkeys and rats, where it was associated with muscle fiber degeneration (Herbst, Pak 
et al. 2007). As such mtDNA deletions are believed to be the root of COX deficiency in 
ageing post-mitotic tissues; however direct experimental evidence demonstrating a 
direct causal role for mtDNA deletions in age-related tissue dysfunction is still lacking.  
 
The involvement of mtDNA point mutations in ageing was initially investigated by 
looking for levels of the m.8344A>G (Munscher, Rieger et al. 1993) and m.3243A>G 
mutations (Zhang, Linnane et al. 1993), that cause MERRF and MELAS respectively. 
Levels of these mutations in ageing tissues were found to be fairly low, reaching only 
~2% in aged subjects (Munscher, Rieger et al. 1993; Zhang, Linnane et al. 1993). The 
use of more sensitive polymerase chain reaction (PCR) techniques, interestingly showed 
that the m.3243A>G mutation was actually present in skeletal muscle, brain, heart, liver 
and kidney of young children as well as adult tissues (Liu, Zhang et al. 1997). However, 
levels of the mutation were 10 fold higher in adult tissues and so this suggested that 
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mtDNA mutagenesis actually occurs during early life, most likely due to the high rates 
of replication during embryogenesis, and mutations subsequently clonally expand 
throughout adulthood. Early studies looking for mtDNA point mutation in ageing 
tissues also found that ~50% of human fibroblasts in elderly subjects harbour a 
m.414T>G mutation in mtDNA, that was indeed found to be absent from younger 
individuals (Michikawa, Mazzucchelli et al. 1999), and aged subjects have also been 
shown to possess ~2-3 point mutations per mitochondrial genome (Simon, Lin et al. 
2004).  
 
Age-related clonally expanded mtDNA point mutations were first documented in 
cardiomyocytes and buccal epithelium of individuals over the age of 75 (Nekhaeva, 
Bodyak et al. 2002). Interestingly, a very different spectrum of mtDNA mutations was 
documented in the two tissues, suggesting a different mechanism for the clonal 
expansion of mtDNA mutations in different tissues, potentially influenced by the 
mitotic activity of the tissue (Nekhaeva, Bodyak et al. 2002). Indeed the presence of 
clonally expanded mtDNA point mutations in COX deficient skeletal muscle fibers has 
not been reported very often (Fayet, Jansson et al. 2002; Durham, Samuels et al. 2006), 
suggesting that the type of mtDNA mutation and the clonal expansion that occurs in 
ageing is tissue specific. A causal role for mtDNA point mutations in the ageing 
process, however, only emerged when Taylor and colleagues discovered an age-related 
accumulation of COX deficient crypts in the ageing human colon, which was associated 
with the clonal expansion of somatic mtDNA point mutations (Taylor, Barron et al. 
2003). Here the use of laser micro-dissection and whole mtDNA genome sequencing of 
individual cells, enabled the co-localization of a mitochondrial dysfunction phenotype 
with a genotypic defect. Furthermore, single cell analysis revealed that different cells of 
the same tissue contained different clonally expanded mtDNA point mutations, in which 
mtDNA deletions were found to be absent (Taylor, Barron et al. 2003). Clonally 
expanded mtDNA point mutations leading to the accumulation of COX deficient cells 
with age, have since been identified in a number of ageing human replicative tissues 
including the stomach, small intestine, liver and prostate, (McDonald, Greaves et al. 
2008; Fellous, Islam et al. 2009; Blackwood, Williamson et al. 2011), indicating a 
potential causal role for clonally expanded mtDNA point mutations in ageing mitotic 
tissues.  
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Clonally expanded mtDNA point mutations are predominantly seen in mitotically active 
tissues that rely on stem cells for self-renewal, whereas mtDNA deletions prevail in 
ageing post-mitotic tissues. This further supports the finding by Nekhaeva and 
colleagues that different tissues exhibit different mechanisms for both the origin of 
mtDNA mutations and their clonal expansion, with the rate of tissue turnover and cell 
division being a key factor. Given that mtDNA point mutations are believed to 
primarily arise from mtDNA replication errors (Zheng, Khrapko et al. 2006), it is 
unsurprising that mtDNA point mutations predominate in dividing cells, for which 
random intracellular drift can explain their clonal expansion with age (Elson, Samuels et 
al. 2001). However, given the absence of cell division and the low rate of mtDNA 
replication in post-mitotic cells (Wang, Nutter et al. 1997), it remains controversial as to 
whether random intracellular drift could account for the clonal expansion of mtDNA 
deletions in post-mitotic tissues, especially the clonally high levels observed in the SN 
(Krishnan, Reeve et al. 2008). 
 
Despite the documentation of clonally expanded somatic mtDNA mutations in a number 
of ageing human tissues, a causal role for mtDNA mutations in the ageing process still 
remains controversial, with many arguing that the overall level of mtDNA defects in 
ageing tissues is too low to cause tissue dysfunction. COX deficient cells in ageing 
human tissues, however frequently present in an intracellular and intercellular mosaic 
pattern. As such, the random distribution of mitochondrial dysfunction could indeed 
cause age-related tissue decline if critical cells, such as stem cells, are lost, by either 
apoptosis or senescence, as a result (Kukat and Trifunovic 2009). Respiratory chain 
deficiency results in clear pathological changes and tissue dysfunction in patients with 
mitochondrial disease and so understanding the consequences of clonally expanded 
mtDNA mutations and COX deficiency at the cellular level in ageing tissues will be 
critical for determining the role of mitochondria in the ageing process.  
1.5 Mouse models of mitochondrial dysfunction  
A number of mouse models, exhibiting mitochondrial dysfunction, have been developed 
that establish a significant causal role for mtDNA defects and respiratory chain 
dysfunction in age-related phenotypes and disease. 
1.5.1 TFAM knockout mice 
Mouse models of mitochondrial dysfunction began with the elimination of TFAM in 
tissue specific knockouts, which results in a drastic reduction in mtDNA copy number 
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and respiratory chain dysfunction.  In pancreatic β-cells, an absence of TFAM in mice 
resulted in mitochondrial respiratory chain dysfunction directly associated with 
attenuated insulin secretion and an age associated loss of β-cells, closely resembling 
age-associated diabetes (Silva, Köhler et al. 2000). Disruption to the mitochondrial 
membrane potential, attributable to the reduced activity of ETC complexes, and 
defective Ca
2+
 homeostasis were also observed in the pancreatic β-cell mutant mice 
(Silva, Köhler et al. 2000).  Tissue specific disruption of TFAM in dopaminergic (DA) 
neurons of mice, resulted in severe respiratory chain deficiency associated with reduced 
locomotion, tremors and limb rigidity, characteristic of a slow progressive movement 
disorder and age-associated Parkinson’s disease (Ekstrand, Terzioglu et al. 2007). Such 
studies suggested that mitochondrial respiratory chain dysfunction has profound effects 
upon tissue function and can induce features characteristic of the ageing process and 
age-related disease. However, respiratory chain deficiency does not always induce age-
related phenotypes, as TFAM depletion and respiratory chain deficiency in mouse 
skeletal muscle unexpectedly does not result in insulin resistance and diabetes 
(Wredenberg, Freyer et al. 2006). Furthermore, the tissue specific depletion of TFAM in 
adipose tissue, does not result in obesity or diabetes but actually enhances mitochondrial 
oxidation (Vernochet, Mourier et al. 2012). As such a causal role between respiratory 
chain dysfunction and age-related phenotypes still remains controversial.  
1.5.2 The MtDNA mutator mouse 
A direct causal relationship between the accumulation of mtDNA mutations and age-
related phenotypes in mammals was established with the development of the mtDNA 
mutator mouse. Homozygous mtDNA mutator mice (PolgA
mut/mut
) have a knock-in 
missense mutation that causes a critical amino acid change from aspartic acid to alanine 
(D257A) in the PolgA catalytic domain of mitochondrial Polγ (Trifunovic, Wredenberg 
et al. 2004; Kujoth, Hiona et al. 2005). This mutation significantly reduces the 
proofreading activity of Polγ and causes the accelerated, random accumulation of 
mtDNA mutations. A 3 to5 fold increase in the level of mtDNA point mutations is 
observed in PolgA
mut/mut
 mice as well as increased levels of mtDNA deletions and severe 
respiratory chain deficiency. From 25 weeks old mice begin to display premature ageing 
phenotypes, which closely resemble signs of normal human ageing and include 
kyphosis, reduced subcutaneous fat, hair loss, weight loss, anaemia, osteoporosis, 
reduced fertility and enlargement of the heart as well as a reduced lifespan, <61 weeks 
old (Trifunovic, Wredenberg et al. 2004; Kujoth, Hiona et al. 2005). Two versions of 
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this mouse exist, which essentially differ in their WT mouse nuclear backgrounds and 
the gene excision system used. The model developed by Trifunovic and colleagues is on 
C57Bl/6N background and utilises an Flp-recombinase system, leaving the POLG gene 
flanked by two loxP sites (Trifunovic, Wredenberg et al. 2004), whereas the model 
developed by Kujoth and colleagues is on C57Bl/6J background and uses  a Cre-
recombinase system leaving behind only loxP site (Kujoth, Hiona et al. 2005).  
 
Despite the significant respiratory chain dysfunction, PolgA
mut/mut
 mice do not 
experience increased ROS production or oxidative damage to macromolecules at the 
tissue level, providing evidence against the ‘vicious cycle’ hypothesis (Kujoth, Hiona et 
al. 2005; Trifunovic, Hansson et al. 2005). Furthermore the random, accumulation of 
mtDNA point mutations was found to be linear and constant across all tissues of the 
PolgA
mut/mut
 mouse, lending further support to the phenomenon that mtDNA 
mutagenesis is initiated early in development and does not involve the progressive 
accumulation of new mutations (Trifunovic, Hansson et al. 2005). Although there is an 
absence of evidence for the ‘vicious cycle’ hypothesis more recent studies have 
provided evidence for a relationship between mtDNA point mutations, ROS and 
oxidative damage in the mtDNA mutator mice. Oxidative damage has recently been 
documented in muscle (Kolesar 2014) and in vivo studies have demonstrated elevated 
levels of hydrogen peroxide in aged PolgA
mut/mut
 mice, where changes in redox 
signalling were proposed to have a pro-apoptotic and pro-inflammatory role (Logan, 
Shabalina et al. 2014). Multiple tissue of PolgA
mut/mut
 mice have been shown to display 
increased levels of caspase-3, suggesting that the progressive accumulation of mtDNA 
mutations could indeed cause enhanced apoptosis, giving rise to tissue dysfunction 
(Kujoth, Hiona et al. 2005). Alternatively, it has been proposed that tissue dysfunction 
may ensue from the induction of replicative senescence/ an energy defect in cells, 
caused directly by the respiratory chain deficiency (Trifunovic, Hansson et al. 2005).  
 
Substantial levels of linear mtDNA molecules, spanning 12kb of the mtDNA genome 
have been detected in multiple tissues of PolgA
mut/mut
 mice (Trifunovic, Wredenberg et 
al. 2004). Linear mtDNA molecules are believed to be a consequence of stalled 
replication; however detection of these molecules at early stages of embryogenesis, a 
lack of accumulation in tissues and an absence of replication and transcription of these 
molecules, argues against a causal role for them in the premature ageing of PolgA
mut/mut
 
mice (Kukat and Trifunovic 2009). 
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The causal role of mtDNA point mutations in the premature ageing of PolgA
mut/mut
 mice, 
was brought into question with the discovery that mice heterozygous for the D257A 
(PolgA
+/mut
) mutation tolerate a 500 fold increase in the frequency of mtDNA point 
mutations compared to WT mice, and yet show no signs of premature ageing or a 
reduced lifespan (Vermulst, Bielas et al. 2007). Meanwhile the frequency of mtDNA 
deletions was shown to be 7 to 11 fold higher in PolgA
mut/mut
 mice compared to WT and 
PolgA
+/mut
 mice (Vermulst, Wanagat et al. 2008). As such it was argued that mtDNA 
deletions, rather than point mutations, drive the premature ageing in PolgA
mut/mut
 mice 
(Vermulst, Wanagat et al. 2008). However, other studies have failed to detect such 
deletions when using the same methods (Edgar, Shabalina et al. 2009), and groups that 
have detected mtDNA deletions only identify fairly low levels, ~1 mtDNA deletion: 
1000 mtDNA point mutations in PolgA
mut/mut
 mice (Kraytsberg, Simon et al. 2009). 
Moreover mtDNA deletions do not progressively accumulate in tissues of PolgA
mut/mut
 
mice but levels remain constant and mitochondrial translation and protein synthesis 
remain unimpaired, which would not be the case with large scale mtDNA deletions that 
generally cause a loss of protein encoding genes and multiple tRNAs (Edgar, Shabalina 
et al. 2009). Additional evidence against a role for mtDNA deletions in causing the 
premature ageing phenotypes of PolgA
mut/mut
 mice comes from other transgenic mouse 
models, such as the ‘deletor mouse’, where a mutation in mtDNA TWINKLE causes the 
progressive accumulation of multiple deletions in mtDNA and respiratory chain 
deficiency, without causing signs of premature ageing or a reduced lifespan 
(Tyynismaa, Mjosund et al. 2005). The genetically engineered ‘mito-mouse’, that 
possess ~30% mtDNA deletions and focal COX deficiency in multiple tissues, also 
display an absence of premature ageing phenotypes (Inoue, Nakada et al. 2000). 
MtDNA point mutations that accumulate in PolgA
mut/mut
 mice, however have been 
shown to result in amino acid substitutions in protein encoding genes, disrupting the 
assembly and stability of respiratory chain complexes (Edgar, Shabalina et al. 2009). 
Indeed a recent study has documented that protein levels of respiratory chain complexes 
are decreased in the PolgA
mut/mut
 mice; however this was not accompanied by a 
reduction in mRNA levels, suggesting that somatic mtDNA mutations actually exhibit 
post-translational effects, leading to the respiratory chain deficiency (Hauser, Dillman et 
al. 2014). As such, it remains that point mutations in mtDNA, which accumulate 
progressively, in a linear fashion over the life course of the  PolgA
mut/mut
 mouse 
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(Trifunovic, Wredenberg et al. 2004), are the primary cause of respiratory chain 
deficiency and tissue dysfunction that drive the premature ageing phenotypes.  
1.5.3 Mouse models of mtDNA disease  
Generating mouse models of mtDNA disease that carry specific mtDNA point 
mutations has proved very challenging, given that we cannot directly manipulate and 
engineer the mouse mtDNA genome in a living animal model. As such attempts to 
produce mouse models have relied on indirect methods to introduce mtDNA mutations 
into mice. Mice that were heterozygous for two different mtDNA haplogroups were the 
first heterozygous mouse models developed (Jenuth, Peterson et al. 1996; Jenuth, 
Peterson et al. 1997). Whilst these mice provided useful insights into mitotic 
segregation and tissue specific differences in the distribution of mtDNA they only 
possessed neutral mtDNA variants and not pathogenic disease causing mtDNA 
mutations.  
1.5.3.1 Mice harbouring mtDNA deletions  
The generation of mice carrying mtDNA deletions resulting in mitochondrial 
dysfunction and phenotypes characteristic of mtDNA disease have been reasonably 
successful. The first of these models was the ‘mito-mouse’, where mtDNA deletions 
were indirectly induced by introducing a respiratory chain deficient cybrid that carried a 
somatic mtDNA deletion, into fertilized mouse eggs (Inoue, Nakada et al. 2000). 
Successful germline transmission of the mtDNA deletion was achieved, producing 
progeny with fairly high levels of the deletion that displayed a mosaic distribution of 
COX deficient fibers in the heart and skeletal muscle as well as signs of 
cardiomyopathy and myopathy (Inoue, Nakada et al. 2000). Mice also presented with 
anemia, renal dysfunction and elevated levels of blood lactate, suggesting that they may 
serve as a model of mtDNA disease. However, certain features of the ‘mito mouse’ 
differed significantly to those seen in mtDNA disease, namely in terms of tissue 
distribution of the deletion, as high levels were detected in mitotic tissues, which is 
rarely reported in humans (Larsson and Clayton 1995; Fayet, Jansson et al. 2002; Yu-
Wai-Man, Lai-Cheong et al. 2010). Furthermore questions remain surrounding the 
transmission of the mtDNA deletion to progeny, which indeed is rarely seen with 
human pathogenic deletions (Larsson 1995). It has however been suggested that this 
was due to transmission of a duplication, which later rearranged to form the deleted 
mtDNA molecule.  
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The alteration of nuclear encoded genes, resulting in the generation of mtDNA deletions 
has also been used to create mouse models, as seen in the ‘deletor mouse’. In this mouse 
a DNA construct carrying a dominant mutation (A360T) in the mouse mtDNA helicase 
TWINKLE, corresponding to the m.359A>T mutation that causes Progressive External 
Opthalmoplegia (PEO) in humans, was injected into mouse fertilised oocytes and used 
to propagate a mouse lineage (Tyynismaa, Mjosund et al. 2005). Resulting mice 
displayed the progressive accumulation of multiple mtDNA deletions in brain and 
skeletal muscle leading to a progressive respiratory chain deficiency with increasing age 
(Tyynismaa, Mjosund et al. 2005). Such features were absent from the ‘deletor mice’ 
until 12 months of age, which is in fact characteristic of chronic late-onset PEO, with 
mouse muscle also displaying several histological features of PEO such as abnormally 
large mitochondria with cristae inclusions (Tyynismaa, Mjosund et al. 2005). Despite 
the morphological homology to PEO, the ‘deletor mice’ did not however show any 
phenotypic evidence of myopathy: displaying normal grip strength, running ability and 
an absence of muscle weakness (Tyynismaa, Mjosund et al. 2005), questioning the 
validity of this mouse as a model of mtDNA disease.  
Mice harbouring multiple mtDNA deletions and large scale rearrangements have also 
been created through the use of a restriction endonuclease targeted to mitochondria in 
mouse skeletal muscle, which resulted in double strand breaks (Srivastava and Moraes 
2005). By 6 months old transgenic mice displayed features of mitochondrial myopathy 
characterised by restricted movement, respiratory chain deficiency and mitochondrial 
morphological abnormalities in skeletal muscle fibers, associated with a significant 
reduction in the levels of mtDNA (Srivastava and Moraes 2005). Such features closely 
resemble those of patients that harbour multiple mtDNA deletions in muscle, suggesting 
that this mouse was a useful model of disease. The accumulation of deletions from 
double strand breaks also provided useful insights into the mechanisms of deletion 
formation.  
1.5.3.2 Mice harbouring mtDNA point mutations 
The generation of mice carrying mtDNA point mutations has however proved more 
challenging. To date mtDNA point mutations have only been introduced into mice and 
stably transmitted through the germline through the use of mouse cell lines that carry 
naturally occurring pathogenic mtDNA point mutations (Kasahara, Ishikawa et al. 2006; 
Fan, Waymire et al. 2008; Yokota, Shitara et al. 2010; Lin, Sharpley et al. 2012).  
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The first of these studies used a respiratory chain deficient mouse cell line carrying a 
homoplasmic mtDNA point mutation in mt-CO1 (T6589C) to transfect embryonic stem 
cells, that were subsequently injected into mouse blastocysts to produce chimeric mice 
(Kasahara, Ishikawa et al. 2006). Chimeric mice were subsequently employed in a 
breeding strategy with WT B6 male mice and this successfully produced 6 generations 
of homoplasmic mutant mice, demonstrating maternal germline transmission of the 
mutation (Kasahara, Ishikawa et al. 2006). Homoplasmic mutant mice displayed COX 
deficiency in the heart and reduced complex IV activity in the liver, skeletal muscle and 
brain (Kasahara, Ishikawa et al. 2006).  Mutant mice also displayed elevated blood 
lactate, a typical feature of pathogenic mt-CO mutations in patients (Rahman, Taanman 
et al. 1999; Varlamov, Kudin et al. 2002) and signs of reduced growth. However, other 
characteristic features of mt-COI mutations, such as epilepsy and muscle fatigue, were 
not observed (Rahman, Taanman et al. 1999; Varlamov, Kudin et al. 2002), thus 
questioning the potential of this mouse as a model of disease caused by mtDNA point 
mutations in structural genes.  
Similarly in a study by Fan and colleagues two respiratory chain deficient mouse cell 
lines carrying the m.6589T>C mutation and a more severe mt-ND6-13885insC 
mutation, were used to transfect embryonic stem cells and generate two different 
chimeric mice that were used to propagate mouse lineages in a similar strategy to that 
above. Again this study showed successful germline transmission of the mt-CO1 
T6589C mutation and a loss of COX activity in multiple tissues. Homoplasmic mice 
also showed histological features of mitochondrial myopathy including abnormal 
mitochondria and ragged red fibers in muscle, as well as predominant evidence of 
cardiomyopathy, including cardiomyocyte hypertrophy and fibrosis, suggesting that this 
mouse may serve as a good model of disease (Fan, Waymire et al. 2008). In contrast, 
the severe mt-ND6 mutation was rapidly and selectively eradicated from the mouse 
maternal germline, within 4 generations, with experiments suggesting that selection 
occurred prior to ovulation, through apoptosis caused by increased oxidative stress (Fan, 
Waymire et al. 2008). Given the different severity of the two mutations, this study 
provided useful insights into the transmission of pathogenic mtDNA point mutations, 
helping to explain why more severe pathogenic point mutations tend to remain 
heteroplasmic in the population and milder mutations can reach homoplasmy (Wallce 
2007). 
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A metastatic cancer cell line has also been used to generate transmitochondrial 
homoplasmic mice, similarly through the transfection of ES cells and generation of 
chimeric mice, to introduce a mutation in mt-ND6-G13997A that causes a complex I 
defect (Yokota, Shitara et al. 2010; Lin, Sharpley et al. 2012). Young mutant mice 
displayed evidence of complex I dysfunction as well as lactic acidosis in the blood; 
however typical features of LHON, which is commonly associated with complex I 
defects (Larsson and Clayton 1995; Wallace 1999), were not observed in these mice, 
which displayed evidence of normal vision and an absence of optic nerve atrophy 
(Yokota, Shitara et al. 2010; Lin, Sharpley et al. 2012). A second study that introduced 
the mt-ND6-G13997A mutation via an alternative cell line, however revealed that aged 
mutant mice (> 14 months old) did display typical signs of LHON, including reduced 
retinal function, loss of certain types of optic nerve fibers and neuronal abnormalities in 
the optic nerve, (Yokota, Shitara et al. 2010; Lin, Sharpley et al. 2012). Furthermore, 
the complex I defect in this mouse was associated with elevated ROS production, 
suggesting that LHON phenotypes may arise through oxidative stress rather than ATP 
deficiency (Yokota, Shitara et al. 2010; Lin, Sharpley et al. 2012). Such studies 
highlighted the importance of studying mutant mice at different ages to determine the 
onset of disease phenotypes, which is indeed a common feature of human mtDNA 
disease where patients present with clinical symptoms at a variety of different ages of 
onset (McFarland, Taylor et al. 2007). 
More recently a transmitochondrial mouse was developed using a polymerase chain 
reaction (PCR) based cloning and sequencing technique to generate a respiratory chain 
deficient cell line carrying a m.7731G>A mutation in tRNA
Lys
, that again was used to 
transfect ES cells and generate chimeric mice (Shimizu, Mito et al. 2014). Germline 
transmission of the mutation was achieved, producing five generations of mito-
mice
Lys7731
, with offspring demonstrating substantial variation in heteroplasmy. 
Heteroplasmy in offspring did not exceed 85%, which was due to lethality of oocytes 
carrying higher levels of the mutation (Shimizu, Mito et al. 2014). Mito- mice
Lys7731 
with high heteroplasmy demonstrated evidence of muscle phenotypes typically 
associated with pathogenic mutations in human mt-tRNA
Lys
 (Houshmand, Lindberg et 
al. 1999; Blakely, Swalwell et al. 2007), including a smaller body size and muscle 
weakness, as well as respiratory chain defects in the muscle and kidney (Shimizu, Mito 
et al. 2014). Mice did not however demonstrate evidence of ragged red fibers or renal 
failure (Shimizu, Mito et al. 2014), which are characteristic metabolic features of human 
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mtDNA disease caused by mutations in tRNA
Lys
 (MERRF) (Wallace 1999). Therefore 
whilst this mouse provided useful insights into the germline transmission and 
pathogenesis of a heteroplasmic mtDNA point mutation, it may serve as a more general 
model of a pathogenic mtDNA point mutation than a model of mtDNA disease and the 
associated clinical phenotypes.  
1.6 The colon  
A central focus of this thesis involves using the colon as a model replicative tissue to 
study the clonal expansion of mtDNA mutations and their consequences in mouse 
models of both ageing and disease. The structure and hierarchial arrangement of the 
colon is therefore examined below along with a brief account of different functions of 
the colon. 
1.6.1 Structure of the colon 
The colon is the terminal component of the gastrointestinal tract, beginning at the 
ileocecal junction at the small intestine and ending at the anus. The colon comprises 
four main parts: the ascending, transverse, descending and sigmoid colon, all made up 
of four discrete layers: the mucosa, the submucosa (a thin layer of smooth muscle), the 
muscularis externa (a double layer of smooth muscle and longitudinal muscle) and the 
submucosa. 
The colonic epithelium is arranged as colonic crypts (tubular glands) that serve to create 
a large surface area for the absorption of water, the primary function of the colon. 
Columnar enterocytes, otherwise known as transporting/absorptive colonocytes and 
mucus-secreting goblet cells are the primary differentiated cell lineages contained 
within colonic crypts, along with a moderate number of hormone secreting cells known 
as enteroendocrine cells (Figure 1-7) (McKay 2005). The colonic epithelium is a high 
turnover, replicative tissue that is constantly developing. Pluripotent stem cells are 
located at the crypt base and as such all cell lineages within the crypts are derived from 
the stem cells (Figure 1-7) (Schmidt, Winton et al. 1988; Potten 1998). Indeed any 
genetic defect present in the stem cells will be inherited by the progeny cells and 
differentiated cells within the crypt and as such the genotype of the whole crypt will be 
equivalent to that of the stem cells. The hierarchial arrangement of the colonic crypt 
therefore enables the study of genetic defects in stem cell populations by studying the 
whole crypt. The exact number of stem cells within colonic crypts remains to be 
elucidated in humans due to a lack of appropriate stem cell markers; however studies in 
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mice suggest there are between 5 and 7 stem cells located at the base of intestinal crypts 
(Kozar, Morrissey et al. 2013), which is also believed to be the case for humans (Taylor, 
Barron et al. 2003). Differentiated cells of the crypt migrate towards the top of the crypt 
and are shed into the gut lumen, with the mean lifespan of an absorptive colonocyte 
estimated to be between 3-5 days (Karam 1999).  
 
Figure 1-7: Structural arrangement of the colonic crypt. 
Colonic stem cells are located at the base of colonic crypts and give rise to daughter/ progenitor cells, which move up 
the crypt dividing until they leave the cell cycle and become committed to one of the differentiated cell types 
(colonocyte/ goblet cell/ eneteroendocrine cell), before being shed into the gut lumen. The colonic epithelium is 
therefore constantly replaced and all cells within colonic crypts can clearly be seen to be derived from the stem cells. 
1.6.2 Functions of the colon 
The primary function of the colon is to serve as a store of faecal material. As such the 
colon is involved in the absorption of water and salts from waste food material, to make 
faeces more solid and compact, facilitating its passage and release through the colon. 
This is further facilitated by the secretion of mucus by goblet cells in the colonic crypts. 
In addition to water absorption, certain electrolytes, vitamins and components of 
undigested food, such as fibre, are broken down in the colon and absorbed, which is 
mediated by the normal gut flora (bacteria). The colon is the largest reserve of normal 
micro flora in the human body, which is estimated to weigh between 1-2kg (Shanahan 
2002). Hundreds of different species have been identified; of which 95% are anaerobic 
bacteria. Gut bacteria are responsible for the production of vitamin K, B12 , riboflavin  
and thiamine as well as bile acid metabolism and the production of ammonia (Baron 
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1996). However, the principle role of the normal gut flora is the development of a 
mucosal barrier between the host and external pathogens. Immune homeostasis in the 
gut relies on a constant dialogue and interdependent relationship between the normal 
gut flora, colonic epithelial cells and mucosal immune cells. Normal gut flora prevents 
colonisation of the colon by external, harmful pathogens and plays a fundamental role 
in stimulating the innate and adaptive immune responses (Berg 1996). The secretion of 
mucins by goblet cells helps form the mucosal barrier and the primary mechanism of 
defence against microbes (Johansson, Phillipson et al. 2008) and normal gut flora 
stimulates the production of antimicrobial proteins (AMPs) by goblet cells and 
coloncytes (Peterson and Artis 2014), forming an essential second line of defence that 
directly targets bacterial structures.  Colonic epithelial cells also contribute to the 
mucosal immune system, as they are involved in: the primary detection of pathogens 
through the expression of surface pattern recognition receptors; the secretion of 
immunoglobulin A (IgA) and the transfer of immune signals to phagocytes and antigen 
presenting cells (Peterson and Artis 2014). Indeed, the colon plays a significant role in 
the mucosal immune response, with its functions very much extending beyond the 
simple storage and release of faecal material.   
1.7 The colon: a model stem cell tissue for studying mtDNA mutations  
Given the hierarchial arrangement of colonic crypts and the fact that all cells within the 
crypt will have the same genotype as the stem cells in the crypt base, the colon is an 
ideal tissue in which to study genetic defects present within stem cells. As such many 
studies examining respiratory chain deficiency and the incidence and spectrum of 
clonally expanded somatic mtDNA point mutations in ageing stem cell populations 
have been performed in the human colon.  
1.7.1 Clonally expanded somatic mtDNA point mutations in the human colon 
In the ageing human colon COX deficient crypts accumulate in an exponential fashion 
with age, with COX deficiency rarely detected below the age of 30 and aged individuals 
display ~15% COX deficient colonic crypts over the age of 70 (Taylor, Barron et al. 
2003). Indeed single cell analysis revealed that COX deficiency in the human colon was 
associated with the clonal expansion of a somatic mtDNA point mutation (Taylor, 
Barron et al. 2003). Over 50% of colonic crypts with respiratory chain deficiency 
display defects in multiple complexes of the respiratory chain, most notably complexes 
I, III and IV, with mtDNA mutations shown  to clonally expand within these crypts 
(Greaves, Barron et al. 2010). Indeed, in some cases crypts displaying defects in 
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multiple complexes of the respiratory chain were found to contain a single clonally 
expanded mtDNA point mutation, demonstrating that a single mtDNA point mutation is 
capable of disturbing the whole respiratory chain (Greaves, Barron et al. 2010). 
Extensive mutational analysis of mtDNA from aged human colonic crypts has revealed 
that 90% of clonally expanded somatic mtDNA mutations are base transitions, of which 
the majority are C-T and G-A mutations, with very few C-A and G-T mutations 
detected (Greaves, Elson et al. 2012). As such it appears that mtDNA replication errors 
mediated by Polγ are the dominant cause of clonally expanded somatic mtDNA 
mutations in the ageing colon, with very little evidence suggesting a causal role for 
oxidative damage, mediated by 8-oxo-deoxyguanine mutagenesis. The point at which 
mtDNA point mutations occur and the mtDNA mutation rate has recently been 
investigated in the human colonic epithelium using three different mtDNA mutation 
assays (Greaves 2014). Interestingly this study revealed that there was no significant 
increase in the number of low level mtDNA point mutations with age (detected by the 
random mutation capture method); however there was a significant increase (~10 fold 
higher) in the frequency of clonally expanded mtDNA point mutations in older 
individuals compared to those in the younger age groups (measured by next generation 
sequencing (NGS)) (Greaves 2014).  Furthermore the same types of mtDNA point 
mutations were detected in young individuals as those previously detected in aged 
subjects (Greaves, Elson et al. 2012; Greaves 2014) and mutational analysis, by NGS of 
buccal and colonic epithelium, matched from the same individuals, revealed the 
presence of the same low level mtDNA point mutations in both tissues (Greaves 2014). 
Given that buccal and colonic epithelium are both derived from the endoderm, 
becoming distinct tissues at 3-4 weeks gestation (Noah, Donahue et al. 2011), this data, 
along with the finding that similar mutation types are present in both young and aged 
subjects, provides further evidence that mtDNA point mutations occur during early 
development/ embryogenesis (Elson, Samuels et al. 2001). Remarkably this study 
revealed that whilst there was no change in the rate of mtDNA mutagenesis with age 
there did appear to be an increase in the incidence of clonal expansions (Greaves 2014). 
Taken together these studies provide further evidence against the ‘vicious cycle’ 
hypothesis and strongly support the early life hypothesis, whereby age-related 
mitochondrial dysfunction is driven principally by mtDNA point mutations that arise 
during early life, most likely due to the high rates of mtDNA replication during 
development, and clonally expand throughout adulthood by random intracellular drift 
(Coller, Khrapko et al. 2001; Elson, Samuels et al. 2001).  
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1.7.2 Random mtDNA mutagenesis and selective constraints 
The clonal expansion of mtDNA point mutations by random genetic drift relies on 
neutral evolution and the unbiased replication and amplification of a mutant mtDNA 
genome. It has been proposed however that mtDNA may be subject to selective 
constraints leading to the preferential amplification of a specific mtDNA genome, such 
that different mtDNA genomes within a cell may directly compete with each other or a 
mutant mtDNA genome may be lost or selected against if it affects cell survival. It is 
known that mtDNA is subject to selective constraints in the mammalian germline via 
the ‘genetic bottleneck, affecting the transmission of certain pathogenic mtDNA 
mutations (see section 1.2.3). Indeed studies in mice have demonstrated strong 
purifying selection on mtDNA in the mammalian germline causing the elimination of 
severe pathogenic mtDNA point mutations. In 2008 Fan and colleagues demonstrated 
that a mild mutation in mt-COI could be successfully transmitted through the mouse 
female germline to multiple generations; however a severe mutation in was rapidly and 
selectively eliminated from the mouse female germline within four successive 
generations (Fan, Waymire et al. 2008). Furthermore studies examining the 
transmission of a random set of mtDNA point mutations  in the PolgA
mut/mut
 mouse 
germline, have revealed strong purifying selection against non-synonymous mutations 
in protein encoding genes, with a mutational bias towards synonymous mutations and 
mutations occurring in mt-tRNA and mt-rRNA genes (Stewart, Freyer et al. 2008). 
Neutral evolution of mtDNA has also been contested by studies showing certain 
selection pressures on mtDNA in humans (Elson, Turnbull et al. 2004).  
Extensive mutational analysis of the spectrum of age-related somatic mtDNA point 
mutations in the ageing colon have been performed to determine whether any selection 
pressures act on clonally expanded somatic mtDNA mutations with age (Greaves, Elson 
et al. 2012). However, it was found that such selective constraints were absent in ageing 
human colonic epithelial tissue, where a random spectrum of clonally expanded somatic 
mtDNA point mutations was shown to accumulate (Greaves, Elson et al. 2012). 
Moreover somatic mtDNA point mutations were frequently non-synonymous or 
frameshift mutations and occurred within protein encoding genes, which were indeed 
shown to be significantly more pathogenic than normal population variants (Greaves, 
Elson et al. 2012). As such there was an absence of evidence for the selective clonal 
expansion of somatic mtDNA point mutations in ageing human somatic tissues. A 
recent study, confirmed an absence of selective constraints on somatic mtDNA point 
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mutations but provided evidence for purifying selection on mtDNA in the human 
germline (Greaves 2014). This was because no significant difference in the ratio of non-
synonymous: synonymous changes was seen between young and aged individuals and 
95% of mutations detected in both the buccal and colonic epithelium (originating from 
the same endoderm) from the same individual were non-pathogenic polymorphic 
variants (Greaves, Elson et al. 2012), suggesting that pathogenic mtDNA point 
mutations were selected against in the human germline. As such it would appear that 
mtDNA is subject to different selection pressures in the germline and in somatic tissues, 
which will undoubtedly have significant implications for the clonal expansion of 
mtDNA point mutations in both ageing and disease.  
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1.8 Aims and objectives 
What can we learn about the clonal expansion of mtDNA point mutations and 
respiratory chain deficiency in the ageing process and mechanisms involved in 
disease, using mouse models?  
To understand the role of mtDNA point mutations and respiratory chain deficiency in 
ageing and the mechanisms involved in mtDNA disease heterogeneity, it is vital to 
establish animal models that can be used to dissect these mechanisms. Transgenic 
mouse models carrying mtDNA point mutations will be used in this thesis to answer the 
following questions: 
 Is the PolgA+/mut mouse a good model of clonally expanded somatic mtDNA 
mutations and respiratory chain deficiency that we see in the ageing human 
colon? 
 What are the functional consequences of age-related respiratory chain deficiency 
upon cellular processes in the colonic stem cell system?  
 Can an in an in vivo mitochondrial dysfunction assay be used in the colonic 
epithelium  as an early experimental screening tool to identify  potentially 
pathogenic mtDNA point mutations in breeding mouse models of mtDNA 
disease? 
 Is a C>T mutation at position m.5024 of the mouse mtDNA genome a candidate 
allele for modelling mitochondrial DNA disease in mice? 
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Chapter 2. Materials and Methods 
2.1 Equipment and consumables 
2.1.1 Equipment  
2511 Dry vacuum pump/compress  Welch 
ABI 3130xl genetic analyzer Applied Biosystems 
ABI Veriti 96 well Thermal Cycler Applied Biosystems 
Agilent 2100 bioanalyzer  Agilent Technologies 
Axioplan 2 Imagining 2 microscope Zeiss 
Axiovision sotware 3.1 Zeiss (imaging associates) 
ChemDoc MP Imaging system BIORAD 
Electrophoresis power supply model 250EX Life Technologies 
Horizontal Agarose Gel Electrophoresis Systems Amersham 
Leica Laser-microdissection system Leica 
Nanodrop ND-1000 Spectrophotometer Labtech International 
ND-1000 Software Labtech International 
OFT 5000 Cryostat Bright 
PALM MicroBeam Zeiss 
PALMRobo software 4.6 Zeiss 
PyroMark assay design software v2.0  Qiagen 
Pyromark Q24 Platform Qiagen 
Pyromark Q24 Workstation Qiagen 
Pyromark’s proprietary Q24 software Qiagen 
Seqscape software v 2.6 Applied Biosystems 
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2.1.2 Consumables 
96 well semi-skirted Plate, with Raised Rim Starlabs 
24 well PCR plate, elevated wells Starlabs 
Agilent RNA 6000 picochip kit Agilent Technologies 
Coverslips (20x20mm and 22x50mm) VWR International 
Microtubes ultra clear, RNase free (1.7ml) Axygen Scientific 
Microscope colourcoat adhesion slides (76x26x1.0-
1.2mm) CellPath 
Polyethylenenaphthalate (PEN) slides  Leica 
PALM Membrane slides (1mm) PALM microlaser technologies 
Rneasy Micro kit (50) Qiagen 
2.2 Solutions and chemicals 
2.2.1 Solutions 
All solutions and buffers were prepared in Nanopure (18 Mega Ohms activity) water 
and subsequently autoclaved. 
DNA Loading Buffer 0.25% (w/v) Bromophenol Blue 
 0.25% (w/v) Xylene Cyanol 
 30% (v/v) Glycerol 
Electrophoresis Buffer (1l) 100ml 10x TAE 
 900ml Nanopure water 
Formal Calcium 3.6% (v/v) Formaldehyde 
 1.1% (w/v) Calcium Chloride 
Formaldehyde solution 100ml Formaldehyde (37-40%) 
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 900ml dH2O 
 4.0g NaH2PO4 
 6.5g Na2HPO4 
Gel Buffer (1l) 100ml 10x TAE 
 900ml Nanopure water 
Genotyping Lysis Buffer 2.5ml 1M Tris 
 5ml 0.5M EDTA 
 1.25ml 10% SDS 
 41.25 ml dH2O 
50μl 0.5M TrisHCL pH 8.5 30.275g Trisma base in 500ml dH2O 
Phosphate Buffer, pH7.4 95ml 0.2M Disodium 
 Hydrogen Phosphate 
 405ml 0.2M Sodium 
 Dihydrogen Phosphate 
 500ml Water 
Phosphate Buffered Saline Prepared from tablets: 1 tablet in  
 100ml dH2O 
Single cell Lysis Buffer (500μl) 250μl 1% Tween 20 
 50μl 0.5M TrisHCL pH 8.5 
 195μl dH2O 
 
5μl  proteinase K 
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2.2.2 Chemicals 
2.2.2.1 Tissue preparation 
Iso-pentane Merck 
Liquid Nitrogen BOC 
OCT cryoembeding matrix Raymond Lamb 
2.2.2.2 Histological and histochemical reagents 
Acetic acid VWR 
Catalase Sigma 
Chromotrope 2R  Sigma-Aldrich 
Cresyl violet acetate Sigma 
Cytochrome c Sigma 
3,3’Diaminobenzidine Tetrahydrochloride Sigma 
DPX™ Merck 
Eosin “yellowish” Merck 
Fast Green FCF Sigma-Aldrich 
Formaldehyde (37-40%) Sigma-Aldrich 
Harris Haematoxylin Sigma-Aldrich 
Mayers Haematoxylin TCS Biosciences Ltd 
Histoclear™ National Diagnostics 
Nitro Blue Tetrazolium Sigma 
Phenazine Methosulphate Sigma 
Phosphate Buffered Saline Tablets Sigma 
Phosphotungstic acid  Sigma-Aldrich  
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Sodium Dodecyl Sulfate (SDS) BDH 
Sodium Azide Sigma 
Sodium Succinate Sigma 
Trisma base Sigma 
 
2.2.2.3 Molecular Biology Reagents 
Agarose MP Roche 
BigDye® Terminator v3.1 cycle sequencing kit Applied Biosystems 
Bromophenol Blue Sigma 
β-mercaptoethanol Sigma 
Deoxynucleotide Triphosphates Rovalab 
DEPC treated water Ambion 
Ethidium Bromide Merck 
Ethylenediaminetetraacetic acid 
disodium salt solution 
Sigma 
Exonuclease-1 Thermo Scientific 
Ex Taq DNA polymerase Takara 
Exo-Sap IT GE Healthcare 
GelRed nucleic acid stain Biotium 
GO Taq Hot Start DNA Polymerase Promega 
Hyperladder IV Bioline 
Hi-Di Formamide Life Technologies 
La Taq DNA polymerase Takara 
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Proteinase K Invitrogen 
PyroMark Annealing buffer Qiagen 
PyroMark Binding buffer Qiagen 
PyroMark Gold Q24 Reagents (5 x 24)  Qiagen 
PyroMark Wash buffer (x10) Qiagen 
Quick-load 1kb DNA ladder BioLabs 
RNase Zap Ambion 
Sodium acetate buffer Sigma 
Streptavidin sepharose
TM
 high performance beads (GE 
Healthcare)  
GE Healthcare 
Tris acetate EDTA (TAE x10) Sigma 
Tris HCl Sigma 
TSAP Promega 
 
  
2.3 Animals 
2.3.1 Heterozygous (PolgA+/mut) mice 
Mitochondrial DNA mutator mice (PolgA
mut/mut
) were generated with a knock-in 
missense mutation (D257A) that changes the amino acid from aspartic acid to alanine in 
the second endonuclease proofreading domain of the PolgA catalytic subunit of the 
mtDNA polymerase gamma (Trifunovic, Wredenberg et al. 2004). Four mice that were 
heterozygous for this mutation (PolgA
+/mut
), aged 59 (n=1) and 81 (n=3) weeks old, 
were sacrificed and colon samples collected, provided by James Stewart and Nils-Göran 
Larsson, Max Planck Institute for Biology of Ageing, Cologne, Germany. 
2.3.2 M.5024C>T tRNAAla mice 
All mouse breeding was performed by James Stewart and Nils-Göran Larsson, Max 
Planck Institute for Biology of Ageing, Cologne, Germany. Female mice, heterozygous 
for the D257A mutation (PolgA
+/mut
) were employed as the founders in a breeding 
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strategy to generate mice that would carry and transmit mtDNA point mutations. 
Female PolgA
+/mut
 mice were used in the breeding strategy as their moderate mtDNA 
mutation rate (Kraytsberg, Simon et al. 2009) produces only 1-3 mutations per mtDNA 
molecule, compared to 16-20 mtDNA mutations produced per molecule by PolgA
mut/mut
 
mothers (Freyer, Cree et al. 2012). A lower number of mutations per mtDNA molecule 
make it easier to associate certain phenotypes with specific mutations, and mtDNA 
mutations of interest can be segregated much more rapidly into specific lineages. 
Female PolgA
+/mut
 mice were backcross mated with pure wild-type (WT) male mice, to 
produce female progeny that expressed wild-type mtDNA polymerase, but transmitted 
mutated mtDNA (PolgA
+/+
 mice) (Figure 2-1). A standard sequencing approach was 
used on mouse lineages to detect and identify candidate mtDNA point mutations for 
modelling disease. Female progeny harbouring an mtDNA mutation of interest were 
subsequently used to propagate the mouse lineages.  
 
Figure 2-1: Germline mtDNA mutagenesis and breeding strategy using PolgA+/mut female mice to segregate 
specific mtDNA mutations into mouse lineages. 
MtDNA mutagenesis was initiated by mating C56Bl/6N female mice with PolgA+/mut males to generate PolgA+/mut 
females. Resulting PolgA+/mut females were backcross mated with C57Bl/6N male mice, to produce female progeny 
that expressed wild-type mtDNA polymerase, but transmitted mutated mtDNA (PolgA+/+ mice). Female progeny 
were subsequently mated with WT (PolgA+/+) male mice to propagate the mouse lineages and segregate specific 
mutations into specific mouse lineages.  
Sequencing revealed a C>T mutation at position m.5024 of the mouse mtDNA genome, 
which was identified as a candidate allele for potentially modelling mitochondrial DNA 
disease in mice and was segregated into an independent mouse lineage using the above 
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strategy, until strong transmission of the allele was achieved (>6
th
 generation) (see 
chapter 5 for further details).  Standard tail biopsies were taken from mice at weaning (3 
weeks old) to measure the m.5024C>T mutation load in each animal, using fluorescent 
restriction fragment length polymorphism (RFLP), completed by James Stewart, Max 
Planck Institute for Biology of Ageing, Cologne, Germany. This mouse lineage is 
currently producing the 14
th
 backcross generation. 
Colon samples were collected from 33 mutant mice across different generations (N1-
N9) aged 10-83 weeks olds, displaying varied m.5024C>T mutation loads (see appendix 
A for details of mice used) and muscle and heart samples were provided for 11 of these 
animals. Colon, muscle and heart samples were also collected from 6 control animals 
with low levels of the m.5024C>T mutation, 4 WT control mice with no detectable 
levels of the m.5024C>T mutation and a colon sample from 1 negative control (TN139) 
with 16 known polymorphic variants in mtDNA (see appendix A for details of mice 
used). All tissue samples were provided by James Stewart and Nils-Göran Larsson, Max 
Planck Institute for Biology of Ageing, Cologne, Germany.  
2.3.3 Breeding of homozygous (PolgAmut/mut) and heterozygous (PolgA+/mut) mice 
PolgA
mut/mut
 male mice (n=4) were originally obtained from a well-established colony 
kindly donated by Tomas Prolla, Departments of Genetics and Medical Genetics, 
University of Wisconsin, Madison, USA. PolgA
mut/mut
 male mice were mated with 
C57Bl/6J female pure, clean wild-type mice (Charles River Laboratories). Resulting 
PolgA
+/mut
 female and PolgA
+/mut
 male mice were mated to propagate our own colony of 
PolgA
mut/mut
 and PolgA
+/mut
 mice (Figure 2-2). All mice were maintained in an ageing 
mouse unit at Newcastle University, UK, where they were kept in individually 
ventilated cages with unrestricted access RM3 expanded chow made by special diet 
services. Mice were kept at a constant temperature of 25
o
C and a 12 hour light/dark 
cycle was provided. Colon samples were collected from female PolgA
mut/mut
 and 
PolgA
+/mut
 at 3 (n=5), 6 (n=5), 9 (n=≥5) and 12 (n=≥5) months of age (see appendix A 
for details of mice used).  
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Figure 2-2: Breeding strategy to establish an ageing colony of PolgAmut/mut, PolgA+/mut and PolgA+/+ mice.  
PolgAmut/mut male mice were mated with C57Bl/6J female WT mice. Resulting PolgA+/mut female and PolgA+/mut male 
mice were mated to propagate our own colony of PolgAmut/mut, PolgA+/mut and Polg+/+ (WT) mice. 
2.4 Tissue preparation 
PolgA
mut/mut
, PolgA
+/mut
 and WT control mice were killed by cervical dislocation. Mouse 
colons were removed immediately and flushed with phosphate buffered saline (PBS), 
pH7.4, to remove any faeces and pellets.  
2.4.1 Frozen Tissue 
Colon tissue was mounted on Whatman filter paper and rapidly frozen in isopentane 
previously cooled to -160
o
C in liquid nitrogen for 15 seconds. Tissue was transferred to 
liquid nitrogen and stored at -80
o
c. For sectioning, colon tissue was mounted upright, 
longitudinally on Whatman filter paper using a small amount of OCT™ medium, 
previously cooled in an OFT 5000 Cryostat (Bright) at -30
o
c for 15 minutes, using 
forceps and a scalpel previously cooled in liquid nitrogen at -160
o
c.  For histological 
staining procedures sections were cut at 10μm using the OFT 5000 Cryostat (Bright) on 
to glass colourcoat adhesion slides (CellPath) and air-dried at room temperature for one 
hour. For laser micro-dissection used for DNA extraction, frozen colon tissue was cut at 
15μm on to polyethylenenaphthalate (PEN) slides (Leica Microsystems) and air-dried at 
room temperature for one hour. Slides were stored in sealed slide mailers at -80
o
c until 
use.  
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2.4.1.1 Frozen tissue used for RNA extraction 
Colon samples were collected from 12 month PolgA
+/mut
 mice from our own breeding 
colony (n=5), frozen in liquid nitrogen and were mounted in OCT medium as described 
above. Using the cryostat serial longitudinal colon sections (10μm) were cut on to PEN 
slides previously exposed to UV light for 30 minutes to remove any RNAses. Tissue 
sections cut on to PEN slides were immediately placed on dry ice and stored at -80
o
c
 
until LCM was completed. At 20μm intervals, 10μm sections were cut on to glass slides 
and air-dried for 1 hour.  
2.5 Histological and Histochemical staining procedures 
2.5.1 Haematoxylin and Eosin staining procedure 
Colon tissue sections (10μm) were air dried for 15 minutes following cutting and fixed 
in formal calcium solution (3.6% (v/v) Formaldehyde, 1.1% (w/v) Calcium Chloride) 
for 15 minutes.  Sections were washed in running tap water for one minute and 
submerged in Mayer’s haematoxylin (TCS biosciences Ltd) for 10 minutes.  Sections 
were subsequently washed in running tap water and then submerged in eosin solution 
(1% (w/v) Eosin ‘yellowish’, 0.4% (w/v) Erythrosin B, 0.2% (w/v) Phloxin B) for 30 
seconds.  Sections were washed in running tap water and dehydrated through a graded 
ethanol series (70%, 95% and 2x 100%) and two concentrations of Histoclear™ 
(National Diagnostics, Atlanta, USA) and mounted in DPX using a glass coverslip. 
2.5.2 Dual cytochrome c oxidase (COX)/ succinate dehydrogenase (SDH) 
histochemistry 
Colon (10μm), heart (8μm) and muscle (10μm) tissue sections were cut using the 
cryostat on to glass slides and dried at room temperature for one hour. COX medium 
was prepared by adding 200µl of cytochrome c stock solution (500M cytochrome c in 
0.2M phosphate buffer, pH 7.0) to 800l of 3,3’diaminobenzidine tetrahydrochloride 
(DAB) stock solution (5mM DAB in 0.2M phosphate buffer, pH 7.0) with 20g.ml-1 
catalase. 50l of COX solution was applied to each tissue section and incubated at 37oc.  
Sections were washed in phosphate buffered saline (PBS) (3 x 5 minutes). SDH 
medium was prepared by adding 800l NitroBlue tetrazolium (NBT) stock solution 
(1.5mM NBT in 0.2M phosphate buffer pH 7.0) to 100l sodium succinate stock 
solution (1.3M sodium succinate in 0.2M phosphate buffer pH 7.0), 100l phenazine 
methosulphate (PMS) stock solution (2mM PMS in 0.2M phosphate buffer pH 7.0) and 
10l sodium azide stock solution (100mM sodium azide in 0.2M phosphate buffer pH 
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7.0).  50l of SDH medium was applied to tissue sections and incubated at 37oc. Tissue 
sections were washed in PBS (3 x 5 minutes) and dehydrated through graded ethanol 
(70%, 95% and 2x 100%) and two concentrations of Histoclear™ (National 
Diagnostics, Atlanta, USA) and mounted in DPX. Incubation times for the COX and 
SDH medium on the different mouse tissue types are detailed in the table below.  
Tissue COX medium SDH medium 
Colon 25 minutes 35 minutes 
Heart 40 minutes 10 minutes 
Skeletal muscle 35 minutes 30 minutes 
 
The percentage of COX deficient colonic crypts and skeletal muscle fibers were 
identified in transverse and longitudinal tissue sections at multiple different levels and 
approximately 500 cells were examined per sample using Axiovision software 3.1on an 
Axioplan 2 Imaging 2 microscope (Zeiss). Given the small size and overlapping nature 
of colonic smooth muscle fibers and heart muscle fibers a colour detection algorithm 
was designed and constructed within MATLAB (version 8.0 MathWorks, 
Massachusetts, United States) to accurately detect and quantify the percentage of COX 
deficiency present within the tissue sections, courtesy of Craig Stamp. The Hue 
Saturation Value (HSV) colour space model was employed for automated detection of 
COX deficient (blue) fibers and COX positive (brown) fibers. Given that individual 
samples displayed slight variability in the intensity of blue and brown staining, variable 
colour space Hue tolerances of 0.025, 0.05 and 0.10 were employed for each image, and 
I subjectively chose the appropriate tolerance to ensure that all colour variations in COX 
deficiency and COX activity were correctly identified and quantified. A minimum of 15 
images across various sections were analysed for each tissue type using the HSV colour 
space model and an average percentage of COX deficiency calculated for each tissue. 
For laser micro-dissection colon tissue sections (15µm) mounted on PEN slides (Leica 
Microsystems) were exposed to dual colour histochemistry, as described above, and 
sections were air-dried for 90 minutes after dehydration through graded ethanol.   
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2.5.3 Cresol violet acetate alcoholic staining procedure  
Slides were removed from the -80
o
c freezer and were placed directly on to dry ice. 
Without allowing the tissue sections to defrost slides were fixed directly with ice cold 
75% EtOH for 3 minutes to reduce RNAses activity by dehydration. Sections were 
incubated in a solution of 1% cresol violet acetate (w/v) made in 50% EtOH for 1 
minute, followed by rinsing in ice cold 75% EtOH and 95% EtOH for 30 seconds each. 
Finally sections were dehydrated in 100% EtOH for 1 minute, air dried for 5-10 minutes 
and used immediately for laser capture micro-dissection. All solutions were made with 
DEPC treated water and fresh solutions were used for each staining procedure. Fixing 
and staining using alcoholic solutions dehydrates the tissue sections and prevents 
RNAses activity, preserving RNA integrity for up to 90 minutes for micro-dissection 
(Clément-Ziza, Munnich et al. 2008). 
2.6 Molecular Biology Techniques 
2.6.1 Isolation of total DNA from mouse tissue 
2.6.1.1 Mouse ear notches 
For genotyping of PolgA
mut/mut
, PolgA
+/mut
 and PolgA
/wt
 mice, pups were weaned at 3 
weeks old and ear-notches were taken. Ear-notches were lyses overnight at 55
o
c in 
48.7μl lyses buffer (1m Tris, 0.5m EDTA, 10% SDS and dH2O) and 1.3μl proteinase K.  
2.6.1.2 Homogenate tissue 
Frozen colon, heart and skeletal muscle tissue was mounted as above and 20μm tissue 
sections were cut using the OFT 5000 Cryostat (Bright) into sterile 1.5ml eppendorf 
tubes (Bio gene). Samples were centrifuged at 14 000rpm for 15 minutes and DNA was 
extracted using the DNeasy Blood and Tissue kit (Qiegen) according to the 
manufacturer’s protocol. 
2.6.1.3 Laser micro-dissected colonic crypts and colon smooth muscle fibers  
Single COX positive and COX deficient colonic crypts were cut using Zeiss PALM 
micro-dissection system into sterile 0.5ml PCR tubes into 15µl of cell lysis buffer 
(50mM Tris-HCl pH8.5, 1% Tween-20, 20mg/ml proteinase K and dH2O). Given the 
small size of the fibers, ≥25 colonic smooth muscle fibers were collected into lysis 
buffer per individual tube, to give enough DNA for pyrosequencing. Samples were 
centrifuged at 14 000rpm for 15 minutes and lysed at 55
o
c for 2 hours and then 95
o
c for 
10 minutes to denature the proteinase K.  
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2.6.2 Isolation of total RNA from colonic crypts 
Dual colour COX/SDH histochemistry was performed on 10μm colon sections on glass 
slides cut at 20μm intervals, as described above. This enabled identification of COX 
deficient and COX positive crypts during laser micro-dissection on colon sections 
(10µM) mounted on PEN slides that had been exposed to the cresyl violet acetate 
alcoholic staining procedure. A total of 250 COX positive and 250 COX deficient 
colonic crypts were cut for each 12 month old PolgA
+/mut
 mouse using the Zeiss PALM 
micro-dissection system into sterile 0.5ml PCR tubes containing 65µl buffer RLT 
(Qiagen RNeasy Micro Kit) with β-mercaptoethanol (Sigma-Aldrich). Colonic crypts 
were lifted using a cut energy of 48, focus of 75 and LPC energy of 63, focus of 71. 
RNA integrity is only preserved for up to 90 minutes during micro-dissection following 
the cresyl violet acetate alcoholic staining procedure (Clément-Ziza, Munnich et al. 
2008) and so the above method was repeated until a total of 250 COX positive and 250 
COX deficient crypts were collected from each mouse. Samples were vortexed upside 
down for 30 seconds and centrifuged at 14 000rpm for 5 minutes and stored at -80
o
c. 
Lysates were subsequently pooled together to give samples of 250 COX positive and 
250 COX deficient colonic crypts for each 12-month-old animal. The sample volume 
was adjusted to 350µl with buffer RLT containing β-mercaptoethanol, vortexed for 30 
seconds and centrifuged at 14 000rpm for 1 minute. Samples were then incubated at 
room temperature for 30 minutes to ensure thorough lysis and a good RNA yield. RNA 
was extracted using the RNeasy Micro Kit (Qiagen) according to the manufacturer’s 
protocol, including on-column DNase digestion. 
2.6.3 Polymerase Chain Reaction (PCR) for PolgAmut/mut genotyping  
The DNA lysate from mouse ear notches was taken to a 1:10 dilution and PCR reactions 
were implemented in 25µl volumes using a mastermix comprising 1x LA PCR buffer 
(Mg2+) (Takara Bio Inc), 0.25mM dNTPs, 10.0µM primers, 5 U LA Taq DNA 
Polymerase (Takara Bio Inc) and 2µl of tissue lysate (1:10 dilution). See Appendix B 
for primer positions and sequences. 
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The PCR programme was as follows: 
Cycles Process Temperature Time 
1 Initial Denaturation 94
o
c 1 minute 
35 Denaturation 
Primer annealing 
Extension 
94
o
c 
64
o
c 
68
o
c 
20 seconds 
20 seconds 
45 seconds 
1 Final Extension 72
o
c 5 minutes 
 
The size of the PCR products was used to determine the correct genotype of the mice 
(Figure 2-3). 
 
Figure 2-3: Example gel electrophoresis image gel following Polg PCR for genotyping.  
Gel electrophoresis image showing the different sized DNA products produced in the presence or absence of the 
D257A mutation. Mice homozygous for the D257A mutation (PolgAmut/mut) produce a 468bp DNA product, WT 
(PolgA+/+) mice produce a 296bp DNA product and mice heterozygous for the D257A mutation (PolgA+/mut) produce 
both the 468bp and 296bp fragments. 
2.6.4 PCR amplification of the entire mitochondrial genome  
The single cell lysate (see above) was employed as the DNA template to establish the 
complete mtDNA sequence from the single micro-dissected colonic crypts. The 
mitochondrial genome was amplified in a single PCR reaction using 30 pairs of forward 
and reverse primers to generate overlapping fragments of 1-1.2kb covering the entire 
mouse mtDNA genome (see appendix B for primer positions and sequences). The 
primer pairs were tagged with M13 sequence (Forward - 5’-tgtaaaacgacggccagt-3’, 
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Reverse - 5’-caggaaacagctatgacc) to enable sequencing of the PCR products with a 
universal M13 primer, designed to anneal at 58
o
c. The DNA lysate was taken to a 1:10 
dilution and PCR reactions were implemented in 37.5µl volumes using a mastermix 
comprising 1x LA PCR buffer (Mg2+) (Takara Bio Inc), 0.2mM dNTPs, 0.9µM 
primers, 5 U LA Taq DNA Polymerase (Takara Bio Inc) and 3.75µl of single cell lysate 
(1:10 dilution). The PCR programme was as follows: 
Cycles Process Temperature Time 
1 Initial Denaturation 94
o
c 1 minute 
35 Denaturation 
Primer annealing 
Extension 
94
o
c 
58
o
c 
72
o
c 
20 seconds 
20 seconds 
2 minutes 
1 Final Extension 72
o
c 2 minutes 
 
2.6.5 PCR amplification of the m.5024 region of the mouse mtDNA genome for 
sequencing  
The cell lysate (see above) was used as the DNA template to establish the mtDNA 
genome sequence spanning ~1.3 kb around the m.5024 region from the single micro-
dissected crypts and colon smooth muscle fibers using a two-stage PCR amplification 
protocol. The primary PCR reaction involved amplification of the mitochondrial 
genome with forward and reverse primers to generate a ~4.5kb fragment spanning the 
m.5024 region of the mouse mtDNA genome. PCR reactions were performed in 37.5µl 
volumes using a mastermix comprising 1x LA PCR buffer (Mg
2+
) (Takara Bio Inc), 
0.2mM dNTPs, 0.6M primers, 5 U LA Taq DNA Polymerase (Takara Bio Inc) and 3l 
single cell lysate.  PCR reaction conditions were as follows: 
Cycles Process Temperature Time 
1 Initial Denaturation 94
o
c 1 minute 
35 Denaturation 
Primer annealing 
Extension 
94
o
c 
58
o
c 
72
o
c 
20 seconds 
20 seconds 
8 minutes 
1 Final Extension 72
o
c 2 minutes 
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The secondary PCR reaction used the DNA product from the first round PCR reaction 
as a template to amplify a ~1.3kb region encompassing the m.5024 region of the mouse 
mtDNA genome (see appendix B for primer positions and sequences). The PCR 
reactions employed 1l of the primary PCR product as the DNA template with 24μl of 
mastermix using the same mastermix components as described above. The PCR 
reaction conditions were as follows:  
Cycles Process Temperature Time 
1 Initial Denaturation 94
o
c 1 minute 
35 Denaturation 
Primer annealing 
Extension 
94
o
c 
58
o
c 
72
o
c 
20 seconds 
20 seconds 
2 minutes 
1 Final Extension 72
o
c 2 minutes 
 
2.6.6 PCR amplification of the m.5024 region of the mouse mtDNA genome for 
pyrosequencing 
The single cell lysate (see above) was used as the DNA template to establish the 
m.5024C>T mutation load from the single micro-dissected colonic crypts and colon 
smooth muscle fibers from mice harboring the m.5024C>T tRNA
Ala
 mutation. 
PyroMark assay design software v2.0 (Qiagen, Hilden, Germany) was used to design 
the trio of pyrosequencing (PSQ) primers in the reverse direction, comprising a forward 
biotinylated primer, reverse primer (see appendix B for primer positions and sequences) 
and pyrosequencing primer. A single PCR reaction was employed to amplify a 178bp 
PCR fragment spanning the m.5024 mutation site, using the forward biotinylated and 
reverse primers. The PCR reaction was implemented in 25µl volumes using a 
mastermix consisting of 5µl, 5 x reaction buffer (promega, UK), 3µl MgCl2, 0.2mM 
dNTPs, 1.25ng primers (100µM), 5U Go Taq DNA polymerase (promega, UK) and 1µl 
DNA lysate for colonic crypts and 3µl for colonic smooth muscle fibers. The PCR 
programme was as follows, using 35 cycles for colonic crypts and 40 cycles for colonic 
smooth muscle fibers: 
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Cycles Process Temperature Time 
1 Initial Denaturation 95
o
c 10 minute 
35/40 Denaturation 
Primer annealing 
Extension 
95
o
c 
62
o
c 
72
o
c 
30 seconds 
30 seconds 
30 seconds 
1 Final Extension 72
o
c 10 minutes 
 
2.6.7 Long-range PCR of single colonic crypts 
The single crypt lysate (see above) was used as the DNA template for long-range PCR 
to establish whether large-scale circular mtDNA deletions were present in individual 
colonic crypts. This was completed using a two-stage PCR amplification protocol, 
performed by Dr Laura Greaves, Mitochondrial Research Group, Newcastle University. 
The initial PCR was performed using primers L272 and H16 283 to create a ~16kb 
product (see appendix B for primer positions and sequences). The PCR reaction was 
implemented in 25µl volumes using a mastermix comprising 1X LA PCR buffer (Mg
2+
) 
(Takara Bio Inc.), 0.2mM dNTPs, 10mM primers, 5 U LA Taq DNA Polymerase 
(Takara Bio Inc) and 2l single cell lysate. The PCR cycle conditions were as follows:  
Cycles Process Temperature Time 
1 Initial Denaturation 94
o
c 10 minute 
30 Denaturation 
Primer annealing 
94
o
c 
68
o
c 
20 seconds 
16 minutes 
1 Final Extension 72
o
c 5 minutes 
 
The secondary PCR reaction used 2l of the first round product as the DNA template to 
give an expected product size of ~14.5kb, using primers L1275 and H15833 (see 
appendix B for primer positions and sequences). The secondary PCR reaction employed 
the same mastermix constituents as above with the same PCR cycle conditions, but for 
20 cycles instead of 30.  
2.6.8 Agarose Gel electrophoresis 
5l of each PCR product was mixed with 1l of loading dye (0.25% (w/v) bromophenol 
blue, 0.25% (w/v) xylene cyanol, 30% (v/v) glycerol) and then loaded on to a 1.0% 
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(W/V) agarose gel for mtDNA PCR sequencing and pyrosequencing products, 1.5% 
(W/V) agarose gel for genotyping PCR products and a 0.8%(W/V) agarsose gel for long 
range PCR products. Gels contained GelRed for DNA visualisation and were loaded 
with either Quick-load 1kb DNA ladder (BioLabs) or 100bp Hyperladder IV (Bioline) 
depending on the size of the PCR product generated. Gels were electrophoresed at 75 
volts for 45 minutes in 1x TAE (0.8mM Tris acetate, 0.02mM EDTA, 0.4g/ml 
Ethidium Bromide) and the PCR products were visualised on an AlphaImager 2200 and 
a digital image of the gel obtained.   
2.6.9 PCR clean up, cycle sequencing and DNA precipitation for mtDNA 
sequencing 
PCR products were taken to a 1:2 dilution and purified using TSAP (Promega). 
Purification of DNA to remove excess primers was achieved by adding 1.5l of TSAP, 
previously combined with 50l Exonuclease 1 (Thermo Scientific), to 5l of diluted 
DNA product, which was subsequently heated at 37
o
c for 15 minutes, followed by 80
o
c 
for 15 minutes. PCR products were then cycle sequenced using BigDye v3.1 terminator 
cycle sequencing chemistries (Applied Biosystems) and M13 universal primer for 
sequencing of the entire mitochondrial genome. To enable direct sequencing of the 
m.5024 region of the mouse mtDNA genome specific sequencing primers were 
employed during the cycle sequencing stage: forward 5’-cactcatagcaataatagctc-3’ and 
reverse 5’-caggaaacagctatgaccacagtttcgtaggtttaattcctgcc3-’, that are designed to anneal 
at 58
o
c.  
The PCR programme was as follows: 
Cycles Process Temperature Time 
1 Initial Denaturation 96
o
C 1 minute 
25 Denaturation 
Primer annealing 
Extension 
9
o
C 
50
o
C 
60
o
C 
10 seconds 
5 seconds 
4 minutes 
 
The DNA was precipitated by adding 2l 125mM EDTA, 2l 3M sodium acetate and 
70l 100% EtOH, before sealing the samples, inverting and leaving at room 
temperature for 15 minutes. Samples were then spun down at 2000g for 30 minutes and 
inverted to leave the remaining pellet. The pellet was washed in 70% (v/v) EtOH, spun 
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at 1650g for 15 minutes and inverted, prior to being air-dried in the dark for a minimum 
of 20 minutes. 10µl of HiDi® Formamide (Applied Biosystems) was added to each 
DNA pellet; samples were then denatured at 95
o
c for 2 minutes and were sequenced on 
an ABI3130xl Genetic Analyser (Applied Biosystems). The mtDNA sequence for each 
cell was aligned to the C57Bl/6J mouse reference sequence (GenBank Accession 
number NC_005089) and additionally to the consensus DNA sequence from 
homogenate colon tissue for each mouse for single PolgA
+/mut
 colonic crypts using 
SeqScape software (Applied Biosystems) to determine the somatic mtDNA point 
mutations present in the colonic crypts. This was repeated and DNA products 
resequenced to confirm the somatic mtDNA mutations detected. Heteroplasmy levels 
were estimated based upon the relative peak height of electropherograms.  
2.6.10 M.5024C>T mutation quantification using pyrosequencing 
PCR products (20µl) were combined with dH2O, PyroMark binding buffer (Qiagen) and 
Streptavidin sepharose
TM
 high performance beads (GE Healthcare) to give an 80µl 
volume and samples were agitated for 10 minutes, to assist DNA binding to the beads. 
Samples were transferred to the Pyromark Q24 workstation (Qiagen), where a hedgehog 
(Qiagen) attached to a 2511 Dry vacuum pump/compress (Welch) was used to pass 
samples through a series of reservoirs containing: 70% EtOH (5 seconds), denaturation 
solution (0.2M NaOH, 5 seconds) and 1 x PyroMark wash buffer (x10, Qiagen) (10 
seconds). Beads were released by immersing the hedgehog probes into 25µl aliquots of 
PyroMark annealing buffer (Qiagen) containing the m.5024C>T pyrosequencing primer 
(5’tgtaggatgaagtcttaca3’, m.5001-5020) in a shallow 24 well pyrosequencing plate. 
Samples were heated at 80
o
c for 2 minutes to denature the DNA and the plate was 
transferred to the Pyromark Q24 machine (Qiagen), where it was left to cool at room 
temperature for a minimum of 5 minutes to ensure annealing of the pyrosequencing 
primer to the DNA amplicon strand. PyroMark Gold Q24 Reagents (5 x 24, Qiagen), 
were used to load the PyroMark Q25 Cartridge (Qiagen) with the appropriate volumes 
of enzyme mix (DNA polymerase, ATP sulfurylase, luciferase and apyrase), substrate 
mix (adenosine 5’ phosphosulfate and luciferin) and dNTPs. Pyrosequencing was 
completed on the Pyromark Q24 platform (Qiagen) using the specific m.5024C>T assay 
and each run employed a WT mouse DNA sample as a control, with no detectable or 
low level m.5024C>T heteroplasmy (≤4%) and a cloned fragment with high 
heteroplasmy (m.5024C>T >98%).  The m.5024C>T mutation load was quantified 
using the allele quantification application of Pyromark’s proprietary Q24 software 
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(Qiagen) and statistical analysis employed Prism v.5 software. All samples were 
performed in triplicate and an average mutation load calculated. 
 
2.6.11 RNA quantification and quality control 
The RNA concentration, quality of total RNA and the RIN algorithm for micro-
dissected COX positive and COX deficient colonic crypt samples was assessed using an 
Agilent 2100 bioanalyzer, using a 1:2 dilution of the lysate (Agilent RNA 6000 
PicoChip). A RIN score of ≥7 was classified as good quality RNA and a total mass of 
10ng RNA (1ng/μl RNA) was optimum for gene expression analysis by RNA 
sequencing. RNA lysates were stored at -80
o
c before shipment to BGI Tech Solutions 
(Honkong) CO., Limited for RNA sequencing. cDNA libraries were prepared from 
>10ng of total RNA using the SMARTer Library construction and sequencing (11 Gb 
per sample) method. Illumina HiSeq 2000 sequencers were used for sequencing of RNA 
and generation of paired-end libraries, with two technical replicates generated for each 
sample (BGI Tech Solutions). 
2.7 Bioinformatic analysis  
2.7.1 RNA sequencing data  
All bioinformatic analysis of RNA sequencing data was performed by Dr Graham 
Smith, Bioinformatics support unit, Newcastle University. This was successfully 
completed for 6 biological samples (a COX deficient and COX positive sample from 3 
PolgA
+/mut
 animals), with RNA sequencing data from the other two animals still 
remaining to be produced at the time this thesis was completed.  
Quality control analysis of paired-end reads was performed using FastQC software 
(http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc) to check that samples were of 
adequate quality and there was an absence of any bias that could have been caused by 
RNA degradation. Paired-end reads were subsequently aligned to the mouse genome 
Mus_musculus.GRCm38.75.dna.toplevel.fa  and gene set annotation 
Mus_musculus.GRCm38.75.gtf (http://www.ensembl.org/info/data/ftp/index.html) 
using STAR (Dobin, Davis et al. 2013). The technical replicates for each sample were 
summed and the number of reads that mapped to the mouse genome 
(Mus_musculus.GRCm38.75.gtf) was determined using Ht-seq count, a component of 
HTSeq (Anders, Pyl et al. 2014) to quantify the level of expression for each gene in 
each sample. To examine gene expression levels a criterion was used, such that at least 
76 
 
20 reads were required to map to a gene in at least two out of the six biological samples, 
for a gene to be used in downstream pathway analysis. Differential gene expression 
between COX positive and COX deficient colonic crypt samples was assessed using the 
DESeq2 Bioconductor package version 1.2 and the Wald test (Love, Huber et al. 2014) 
with a Benjamini-Hochberg (BH) adjusted p value of <0.05. Differential gene 
expression was further filtered on the basis of a measurable log2 fold change of <-1 or 
>1. Differentially expressed (DE) genes were mapped to biological pathways using 
KEGG pathways (Kanehisa and Goto 2000; Kanehisa, Goto et al. 2006) and Reactome 
(Joshi-Tope, Gillespie et al. 2005; Croft, Mundo et al. 2014). The over-representation of 
DE genes was evaluated in KEGG using KEGG.db and GOstats Bioconductor packages 
(Falcon and Gentleman 2007) and for Reactome using the reactome.db and reactomePA 
Bioconductor package Yu G. ReactomePA: Reactome Pathway Analysis. R package 
version 1.8.1). Mapping of DE genes to biological pathways was filtered further through 
the use of an absolute expression criterion for pathway completeness, such that >50% of 
genes had to be expressed basally in a pathway mapped to KEGG and Reactome. 
Annotation of gene function was performed using Uniprot, GO Terms and Pubmed for 
all significantly DE genes mapped to both KEGG and Reactome. 
Gene Set Enrichment Analysis (GSEA) (Subramanian, Tamayo et al. 2005) was also 
performed using KEGG and Reactome to identify those pathways that demonstrated a 
general up or down regulation in gene expression of several genes, which individually 
may not have reached significance but in combination could potentially  cause a general 
up or down regulation in activity of a given biological pathway. GSEA analysis of gene 
expression was measured by calculating the average log2 fold-change of all genes that 
were differentially expressed, with a false discovery rate (FDR) q value of 0.05. An 
absolute criterion for GSEA pathway analysis was employed such that a pathway had to 
contain a minimum of 15 genes and a maximum of 750 genes and 50% of genes had to 
be basally expressed for pathway completeness.  
2.8 In silico modelling  
In silico modelling was used to determine how the incidence of mtDNA mutations 
observed in PolgA
+/mut
 mouse colonic crypt stem cells was influenced by the mtDNA 
mutation rate. The model was designed and developed using MATLAB (version 8.0 
MathWorks, Massachusetts, United States) by Craig Stamp, Mitochondrial Research 
Group, Newcastle University. The replication and segregation of both mutant and wild-
type mtDNA molecules to daughter cells during stem cell division was based upon 
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certain assumptions documented within the literature (Coller, Khrapko et al. 2001; 
Elson, Samuels et al. 2001; Taylor, Barron et al. 2003). The model assumes that each 
stem cell contains a constant number of 200 mtDNA molecules (Coller, Khrapko et al. 
2001) and that COX deficiency occurs when more than 75% of mtDNA molecules are 
mutant. During each stem cell division there is a given probability that a mutated 
mtDNA molecule will be replicated (equivalent to the mtDNA mutation rate) and will 
be retained by the stem cell pool during asymmetric division. If a mutant mtDNA 
molecule is retained in the stem cell pool, it can clonally expand to become the 
dominant species within a stem cell and give rise to COX deficiency. To determine the 
mechanism by which mtDNA mutations clonally expand within PolgA
+/mut
 mouse 
colonic crypts a parameter scan of the mtDNA mutation rate required to match the 
experimental calculations of COX deficiency observed in an ageing series of 
WT(Greaves, Barron et al. 2011) , PolgA
+/mut
 and PolgA
mut/mut 
mice, was completed. A 
total of 1000 stem cells undergoing 1080 cell divisions, during the life course of a 
mouse (36 months), were simulated for each mtDNA mutation rate and an average was 
taken to determine the mtDNA mutation rate and the mechanism for mtDNA point 
mutation accumulation in ageing PolgA
+/mut
 mouse colonic crypts.  
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Chapter 3 
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Chapter 3. Results: Age-related clonally expanded somatic mtDNA 
mutations are similar in the colon of PolgA
+/mut
 mice and humans 
3.1 Introduction 
3.1.1 Somatic mtDNA point mutations in ageing mitotic tissues  
The identification that clonally expanded mtDNA point mutations result in focal 
respiratory chain deficiency in a number of ageing human replicative tissues (Taylor, 
Barron et al. 2003; McDonald, Greaves et al. 2008; Fellous, Islam et al. 2009; 
Gutierrez-Gonzalez, Deheragoda et al. 2009), has suggested that mtDNA point 
mutations could play a role in tissue dysfunction the ageing process. In the ageing 
human colon, respiratory chain deficiency has been associated with a mild phenotype 
characterised by a decrease in cell proliferation and a mild decrease in crypt cell number 
(Nooteboom, Johnson et al. 2010). However, this is the only study to examine the 
functional consequences of age-related somatic mtDNA point mutations in a human 
mitotic tissue, with evidence for a causal role of somatic mtDNA point mutations in 
human stem cell ageing still lacking.  
Performing functional studies in human mitotic tissues is very challenging, not only due 
to the limited availability of human replicative tissues and the static nature of samples 
only being available at one time point, but also due to a lack of robust human stem cell 
markers and the difficulty of performing functional interventions. As such there is the 
need to establish an animal model that demonstrates a similar age-related mitochondrial 
dysfunction phenotype to that observed in humans, to enable detailed phenotyping of 
the functional effects of somatic mtDNA point mutations and focal respiratory chain 
deficiency in ageing replicative tissues. Robust stem cell markers are available for 
mouse tissue (Barker, Van Es et al. 2007; Itzkovitz, Lyubimova et al. 2012) and the use 
of mice enables the routine collection of replicative tissues at multiple stages throughout 
lifespan, ideal for an ageing study.  
3.1.2 Overview of animal models 
Normal- ageing WT mice accumulate very low levels of mtDNA point mutations 
(Vermulst, Bielas et al. 2007) and demonstrate a significantly lower incidence of COX 
deficient colonic crypts, reaching a maximum of only ~1.5% in 36 month old mice 
(Greaves, Barron et al. 2011), compared to aged humans (~15%) (Taylor, Barron et al. 
2003). As such WT mice are not a suitable model for the investigation of clonally 
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expanded somatic mtDNA point mutations in ageing mitotic tissues. Given that somatic 
mtDNA mutations are believed to clonally expand by random genetic drift in ageing 
mitotic tissues, it may simply be that the short lifespan of a mouse is too minimal to 
facilitate the clonal expansion of a mutation to high enough levels to reach the threshold 
level necessary to give a mutant phenotype. Indeed, this has been supported by 
modelling studies examining the incidence of COX deficiency in post-mitotic tissues of 
rats, where it was hypothesised that random genetic drift could not explain the clonal 
expansion of mtDNA deletions in post-mitotic tissues of short lived mammals and could 
only apply to much longer lived mammals (~100 years old) (Kowald and Kirkwood 
2013). 
The original modelling studies that proposed random intracellular drift as the 
mechanism by which mtDNA mutations clonally expand, suggested that this 
mechanism was likely to be affected by the rate of mtDNA mutagenesis (Elson, 
Samuels et al. 2001). As such an increase in the rate of mtDNA mutagenesis could lead 
to the accelerated accumulation of cells containing clonally expanded mtDNA 
mutations and result in an age-related mitochondrial dysfunction phenotype, even in 
animals with a shorter lifespan. Evidence from the PolgA
mut/mut
 mouse, which shows an 
accelerated accumulation of mtDNA point mutations (x3-5 fold) leading to respiratory 
chain deficiency and a premature ageing, supports this phenomenon (Trifunovic, 
Wredenberg et al. 2004). Indeed multiple studies have been performed that demonstrate 
early onset stem cell dysfunction in response to the accumulation of mtDNA point 
mutations in PolgA
mut/mut
 mice, with effects seen on: downstream differentiation events 
resulting in the production of abnormal progeny; decreased stem cell self-renewal 
capacity and the number of quiescent stem cells and altered proliferative capacity of 
stem cells (Norddahl, Pronk et al. 2011; Ahlqvist, Hämäläinen et al. 2012; Fox, 
Magness et al. 2012). Seemingly the accumulation of mtDNA point mutations has a 
profound effect upon stem cell function. PolgA
mut/mut
  mice, however display a disease-
like phenotype and accumulate a much higher degree of mtDNA point mutations than 
seen in normal human ageing (Khrapko, Kraytsberg et al. 2006). Furthermore mtDNA 
mutations occur during embryogenesis in these mice and are evenly distributed across 
tissues, unlike in humans where mutations are heterogeneous and occur sporadically 
over time (Khrapko, Kraytsberg et al. 2006). Moreover ageing phenotypes in the 
PolgA
mut/mut
 mice are caused solely by mtDNA mutations, an exaggerated molecular 
defect, whereas normal human ageing is a multi-factorial process driven by interactions 
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between multiple molecular mechanisms, such as ROS, protein damage and DNA 
damage. Significant interactions between different forms of molecular damage in the 
ageing process are therefore absent and as such the PolgA
mut/mut
 mouse is not a suitable 
model for determining the effects of clonally expanded somatic mtDNA point mutations 
in the context of normal human ageing.  
Mice that are heterozygous (PolgA
+/mut
) for the D257A mutation also accumulate 
mtDNA point mutations but to a lesser extent than the PolgA
mut/mut
 mice, displaying ~4 
point mutations per molecule of mtDNA (Kraytsberg, Simon et al. 2009). These mice 
do not display signs of premature ageing or a reduced lifespan (Vermulst, Bielas et al. 
2007) but have been found to show evidence of respiratory chain deficiency in the heart 
and duodenum, reaching ~20% COX deficiency in the duodenum of 15 month old mice 
(Vermulst, Wanagat et al. 2008). It could therefore be expected that the enhanced rate of 
mtDNA mutagenesis in PolgA
+/mut
 mice would increase the pool of available mutations 
for clonal expansion, thereby increasing the probability that an mtDNA mutation would 
clonally expand to reach the critical threshold level during the short lifespan of a mouse. 
As such the frequency of respiratory chain deficiency in PolgA
+/mut
 mice would increase 
and could result in a similar mitochondrial dysfunction phenotype to that which is seen 
in normal human ageing.  
 
An age-related accumulation of respiratory chain deficient cells has been detected in the 
colon of 18-48 week old PolgA
+/mut
 mice, with 48 week old animals displaying ~10% 
COX deficient colonic crypts (Holly Baines, MRes project). Colonic crypts were 
detected with both full and partial COX deficiency in PolgA
+/mut 
mice, demonstrating a 
mosaic, intracellular pattern of respiratory chain deficiency, which is a hallmark of 
normal human ageing (Taylor, Barron et al. 2003). Whole mtDNA genome sequencing 
of 6 COX deficient colonic crypts from two 48 week old animals, revealed the presence 
of 18 clonally expanded somatic mtDNA mutations. Base transitions accounted for the 
majority of the point mutations, which predominantly occurred within protein-encoding 
genes, specifically subunits of complexes I and IV (Holly Baines, MRes project). The 
prevalence of base transitions and mutations in protein encoding genes was similar to 
that observed in the ageing human colon (Taylor, Barron et al. 2003; Greaves, Barron et 
al. 2010). Though the incidence of respiratory chain deficiency in 48 week old 
PolgA
+/mut
 mice was lower than that seen in the normal ageing human colon (~15%), 
this preliminary data suggested that the PolgA
+/mut
 mouse had the potential to be a good 
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animal model of clonally expanded somatic mtDNA point mutations and the resulting 
respiratory chain deficiency.  
3.2 Aims 
The aim of this study was to perform detailed characterisation of the magnitude of focal 
respiratory chain deficiency and the spectrum of somatic mtDNA point mutations in 
colonic crypts of aged PolgA
+/mut
 mice. Colonic epithelial tissue was studied in the 
PolgA
+/mut
 mouse, given that the majority of studies investigating somatic mtDNA point 
mutations in ageing human mitotic tissues have been performed in the human colon, 
and would therefore allow for more extensive comparisons when establishing a 
potential model. 
I aimed to determine whether the incidence of COX deficiency in aged PolgA
+/mut
 mice 
reached a level more comparable to that observed in the ageing human colon, and to 
perform extensive mutational analysis of the mtDNA defects responsible for the COX 
deficiency, through whole mtDNA genome sequencing of single COX positive and 
COX deficient colonic crypts. I aimed to determine whether the spectrum of somatic 
mtDNA point mutations was comparable between the PolgA
+/mut
 mouse and the ageing 
human colon with respect to mutation type, location and pathogenicity as well as 
investigating the clonal expansion of these mutations with respect to the action of any 
selective constraints and the plausibility of random genetic drift.  
3.3 Results 
3.3.1 Respiratory chain deficiency in PolgA+/mut mouse colonic crypts 
PolgA
+/mut
 mice have previously been shown to accumulate COX deficient colonic 
crypts with age, reaching ~10% by 48 weeks old (Holly Baines, MRes project). This is 
only half the natural lifespan of a PolgA
+/mut
 mouse and so these mice cannot be 
considered to be aged and indeed would not be representative of aged human colonic 
epithelial tissue. As such colon sections (10μm) were subject to dual COX/SDH 
histochemistry on colon samples from 59 (n=1) and 81 (n=3) week old PolgA
+/mut
 mice, 
to determine whether the level of COX deficiency accumulated further with age and 
reached a level more comparable to the ageing human colon. Aged PolgA
+/mut
 mice 
were provided by James Stewart and Nils-Göran Larsson, Max Planck Institute for 
Biology of Ageing, Cologne, Germany, which were derived from the PolgA
mut/mut
 
mouse model generated by Trifunovic and colleagues (Trifunovic, Wredenberg et al. 
2004). The incidence of COX deficient colonic crypts was calculated in longitudinal 
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and transverse colon sections, across multiple different levels, with > 500 colonic crypts 
analysed per colon sample. A Haematoxylin and Eosin stain was also performed on 
colonic epithelial tissue to demonstrate normal crypt morphology.  
Aged PolgA
+/mut
 mice continued to display colonic crypts with both full and partial 
COX deficiency, distributed in a random, mosaic pattern throughout the tissue; a 
hallmark of normal human ageing (Taylor, Barron et al. 2003) (Figure 3-1a,b). Analysis 
of longitudinal colonic crypts revealed that COX deficiency extended from the crypt 
base (the stem cell compartment) along the whole length of the crypt to the apex, which 
is similar to the observations in the ageing human colon (Taylor, Barron et al. 2003) 
(Figure 3-1b). In aged PolgA
+/mut
 mice the magnitude of fully COX deficient colonic 
crypts increased further with age, with 81-week-old mice displaying an average of 14% 
COX deficient colonic crypts (Figure 3-1c). The number of crypts displaying partial 
COX deficiency also increased with age, from 0% in 18 week old animals to 8% in 81 
week old PolgA
+/mut
 mice. Upon comparing the magnitude of focal respiratory chain 
deficiency between PolgA
+/mut
 mice (~14%) and ageing human colon (15%) (Taylor, 
Barron et al. 2003), there was no significant difference between the two (p = 0.854, 
unpaired t test). As such, both the level and patterns of COX deficient colonic crypts 
were considered similar between 81 week old PolgA
+/mut
 mice and aged humans, >70 
years old. 
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Figure 3-1: Respiratory chain deficiency in colonic crypts of ageing PolgA+/mut mice.  
COX/SDH histochemistry on 81 week old PolgA+/mut colon sections showing (a) a transverse section through the 
crypts and (b) a longitudinal section through the crypts. Scale bars: 100μm. Crypts stained brown are positive for 
COX activity (red arrow), those stained blue are COX deficient (green arrow), and crypts stained purple/grey display 
partial COX deficiency (yellow arrow). (c) Magnitude of COX deficient colonic crypts in PolgA+/mut mice aged 18-48 
weeks old (Holly Baines, MRes project) and 59-81 week old mice. Linear regression analysis, p= 0.0028. (d) Mean 
incidence (±SEM) of COX deficient colonic crypts in 81 week old PolgA+/mut mice and aged humans >70 years old 
(Taylor, Barron et al. 2003), p= 0.854 (unpaired t test).Image taken from (Baines, Stewart et al. 2014). 
3.3.2 MtDNA genome analysis of PolgA+/mut mouse colonic crypts 
Single cell analysis and whole mtDNA genome sequencing of 6 COX deficient colonic 
crypts from two 48 week old PolgA
+/mut
 mice, had previously revealed the presence of 
somatic mtDNA point mutations (Holly Baines, MRes project).  Preliminary mutational 
analysis revealed that the majority of these point mutations were base transitions and 
occurred within protein encoding genes, similar to what is seen in the ageing human 
colon (Taylor, Barron et al. 2003),. To further characterise the mtDNA defects 
underlying COX deficiency in the PolgA
+/mut
 mouse colon, single COX positive (>4 per 
mouse) and COX deficient (>8 per mouse) colonic crypts were laser micro-dissected  
from three 81 week old PolgA
+/mut
 mice and lysed in a standard lysis buffer. To identify 
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the presence of somatic mtDNA point mutations in colonic crypts PCR amplification of 
the whole mtDNA genome was performed in a single stage PCR reaction using 30 
overlapping pairs of forward and reverse primers. Samples were sequenced on an 
ABI3130xl Genetic Analyser (Applied Biosystems) and the mtDNA sequence for each 
cell was analysed using SeqScape software (Applied Biosystems). Long range PCR was 
performed, courtesy of Dr Laura Greaves, to identify whether large-scale mtDNA 
deletions were present in PolgA
+/mut
 mouse colonic crypts. 
In human colonic crypts, previous studies have revealed an absence of clonally 
expanded mtDNA deletions (Taylor, Barron et al. 2003). To confirm that mtDNA 
deletions were not present and could not contribute to the COX deficiency in colonic 
crypts from PolgA
+/mut
 mice, long range PCR was performed on the single COX 
deficient and COX positive colonic crypts, courtesy of Dr Laura Greaves. Long-range 
PCR confirmed an absence of large scale mtDNA deletions in colonic crypts from 
PolgA
+/mut
 mice, with both COX deficient and COX positive colonic crypts displaying 
only the WT ~14.5kb mtDNA molecule, and an absence of any smaller deleted mtDNA 
molecules (Figure 3-2) 
 
Figure 3-2: Absence of large scale mtDNA deletions in PolgA+/mut mouse single colonic crypts.  
Agarose gel electrophoresis image showing long range-PCR products in single COX positive and COX deficient 
colonic crypts, courtesy of Dr Laura Greaves. The WT mtDNA band (~14.5kb) was present in all COX positive and 
COX deficient colonic crypts, with no smaller deleted mtDNA molecules detected. Image taken from (Baines, 
Stewart et al. 2014). 
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3.3.2.1 Respiratory chain deficiency is caused by random somatic mtDNA point 
mutations in PolgA
+/mut
 mouse colonic crypts. 
Whole mtDNA genome sequencing was performed on the single cell lysate from COX 
positive and COX deficient colonic crypts from PolgA
+/mut
 mice for the detection of 
somatic mtDNA point mutations. The sequence for each crypt was aligned to the 
C57Bl/6J mouse reference sequence (NC_005089) and the consensus DNA sequence 
from homogenate colon DNA for that mouse to determine the somatic mtDNA point 
mutations that accumulated in the crypts over time. Heteroplasmy levels were estimated 
based upon the relative peak height of electropherograms.  
In addition to the 18 point mutations previously detected in COX deficient crypts of 48 
week old animals (Holly Baines, MRes project), a further 223 mtDNA point mutations 
were detected in colonic crypts of 81 week old PolgA
+/mut
 mice (see Appendix C), with 
point mutations detected in both the homoplasmic and heteroplasmic form (Figure 3-3). 
Some colonic crypts contained only one clonally expanded somatic point mutation, 
while many contained multiple somatic mtDNA point mutations (see Appendix C). 
Example electropherograms, illustrating the presence of homoplasmic and 
heteroplasmic point mutations affecting protein encoding genes and an mt-rRNA gene 
present in COX deficient crypts are shown in Figure 3-3.   
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Figure 3-3: Detection of somatic mtDNA mutations in PolgA+/mut colonic crypts. 
Example sequencing electropherograms showing the presence of mtDNA point mutations in COX deficient crypts 
from PolgA+/mut mice. (a) Electropherogram showing a homoplasmic m. 568 G>A transition in mt-srRNA. (b) 
Electropherogram showing the heteroplasmic (75%) m.5647 C>T transition. This change predicts a proline to leucine 
amino acid change in mt-CO1. (c) Electropherogram showing the homoplasmic m.11012 A>T transversion. This 
change predicts a leucine to phenylalanine amino acid change in mt-ND4. Wild-type homogenate sequences are 
shown in panels (d-f). Image taken from (Baines, Stewart et al. 2014). 
Somatic mtDNA point mutations (n=55) were detected in COX positive colonic crypts, 
of which a substantial proportion (67%) were present a low heteroplasmy (≤50%), and 
were therefore unlikely to affect mitochondrial protein function (Figure 3-4a). No 
homoplasmic point mutations were detected in COX positive colonic crypts. The 
overwhelming majority of point mutations were base transitions (80%) (Figure 3-4b) 
and 49% of the base changes occurred within subunits of complex I (Figure 3-4c), 
which was unsurprising given the large portion of the mtDNA genome occupied by 
genes encoding subunits of complex I. In COX deficient colonic crypts, again ~80% of 
changes were base transitions, of which 49% were C>T changes and 17% were G>A 
changes (Figure 3-4b). Mutations predominantly occurred within protein encoding 
genes, of which 34% of changes affected complex I subunits and 27% affected subunits 
of complex IV (Figure 3-4c). In COX deficient colonic crypts 73% of mutations were 
present at high heteroplasmy (≥50%) (Figure 3-4a) and were non-synonymous 
mutations, predicted to cause amino acid changes. Homoplasmic and heteroplasmic 
point mutations (≥75%) were frequently detected in mt-rRNA and mt-tRNA genes, 
accounting for 25% of the total number of point mutations (Figure 3-4c).  
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Figure 3-4: The frequency, type and location of somatic mtDNA point mutations in PolgA+/mut mouse COX 
positive and COX deficient colonic crypts.  
(a) The frequency of mtDNA point mutations present within the different heteroplasmy classes from PolgA+/mut 
mouse COX deficient and COX positive colonic crypts. There was a significantly higher frequency of mtDNA point 
mutations in the higher heteroplasmy classes in the COX deficient crypts (p = 0.0439, x2 analysis). (b) Types of 
changes observed in COX deficient and COX positive colonic crypts. There was no significant difference in the types 
of changes between the two datasets (p = 1.000, x2 test). (c) Gene location of point mutations in individual mtDNA 
encoded genes in COX deficient and COX positive colonic crypts. There was a significant difference between the 
location of the mtDNA point mutations detected in COX positive and COX deficient crypts ( p = <0.0001, x2 test). 
Image taken from (Baines, Stewart et al. 2014). 
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In the ageing human colon somatic mtDNA point mutations have been show to 
accumulate randomly throughout the genome, with an absence of any mutational 
hotspots (Greaves, Elson et al. 2012). To determine whether random mutagenesis was 
also observed in colonic crypts of PolgA
+/mut
 mice the frequency of mtDNA point 
mutations were grouped according to gene location. Taking into account the relative 
portion of the genome occupied by each gene, there was no significant difference found 
between the frequency of mtDNA point mutations observed in each gene type and that 
which would be expected if the mutations were falling randomly on the genome (p= 
0.139, X
2
)(Figure 3-5a).  To determine whether there was a bias towards the clonal 
expansion of more deleterious mtDNA point mutations and a higher frequency of non-
synonymous changes in the higher heteroplasmy classes the relative frequency of point 
mutations in each heteroplasmy class was examined.  No significant difference in the 
frequency of synonymous: non-synonymous changes was identified in the different 
heteroplasmy classes (p=0.6765, X
2
 test) (Figure 3-5b), supporting that the clonal 
expansion of somatic mtDNA point mutations appears to be random in PolgA
+/mut
 
colonic crypts.   
 
Figure 3-5: MtDNA mutations occur randomly in PolgA+/mut mouse colonic crypts. 
(a) Positional mutation frequency of observed vs expected (number of mutations/base pairs) somatic mtDNA 
mutations in the different mtDNA encoded genes detected in PolgA+/mut colonic crypts (p= 0.0139, X2 test) 
Abbreviations: oriL, origin of light strand replication; CR, control region. Non-coding mtDNA refers to the 25bp in 
between genes that do not code for anything within the mtDNA genome. Only 0.322 mutations are expected in non-
coding mtDNA, hence the absence of a mutation frequency bar here. (b) The mutation frequency of non-synonymous, 
synonymous and “other” changes across the different heteroplasmy classes in the PolgA+/mut mouse colonic crypts. 
Contingency analysis using Χ2 test where a p value of <0.05 is statistically significant (p= 0.6765). Abbreviations: 
Nsyn, non-synonymous and syn, synonymous changes. Image taken from (Baines, Stewart et al. 2014). 
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3.3.2.2 The levels of clonally expanded somatic mtDNA point mutations in the 
PolgA
+/mut 
mouse colon are comparable to the ageing human colon.  
To determine whether the PolgA
+/mut
 mouse is a representative model of age-related 
mitochondrial dysfunction, the nature and spectrum of clonally expanded somatic 
mtDNA point mutations observed in PolgA
+/mut
 mouse colonic crypts was compared to 
the data available for the human colon (Table 3-1) (Taylor, Barron et al. 2003; Greaves, 
Preston et al. 2006; Greaves, Barron et al. 2010; Greaves, Elson et al. 2012), to identify 
whether the mtDNA point mutations responsible for age related respiratory chain 
deficiency were consistent between the two species.   
 
Table 3-1: A comparison of the location, types and frequency of mtDNA point mutations in COX positive and 
COX deficient colonic crypts from PolgA+/mut mice and aged humans (Greaves, Elson et al. 2012).  
Abbreviations: Ins/Dels, insertions and deletions. Table taken from (Baines, Stewart et al. 2014). 
The gene location of mtDNA point mutations in COX deficient colonic crypts was not 
significantly different between the PolgA
+/mut
 mouse and human colon, with the 
majority of changes occurring in protein-encoding genes (~60%), specifically subunits 
of complexes I and IV as well as 25% of changes occurring within mt-tRNA and mt-
rRNA (non-coding RNA) genes in both datasets (p =0.2204, X
2
 test) (Figure 3-6a). A 
comparison of the types of changes (transitions, transversions, insertions/deletions) 
detected in COX deficient colonic crypts did however reveal a significant difference 
between the PolgA
+/mut
 mouse and ageing human colon (p=< 0.0001, X
2
) (Figure 3-6b). 
Approximately 10% of changes in the ageing human colon are caused by insertion/ 
deletion mutations (Greaves, Elson et al. 2012); however there was an absence of 
insertions/ deletions detected in colonic crypts of the PolgA
+/mut
 mice. Transversion 
mutations have also been detected at a higher frequency in the ageing human colon 
(19%) than in the PolgA
+/mut 
mouse colon (5%). Nevertheless the majority of changes in 
both datasets were indeed base transitions (~80%). Given that the aim of this study was 
to determine whether the PolgA
+/mut
 mouse was a good model of age-related focal 
respiratory chain deficiency caused by clonally expanded somatic mtDNA mutations 
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seen in the human colon, the pathogenicity of somatic mtDNA point mutations was 
determined to identify the mechanism responsible for COX deficiency in the colonic 
crypts. Somatic mtDNA point mutations were assigned pathogenicity according to the 
following criteria: changed an amino acid or occurred in an mt-tRNA or mt-rRNA gene; 
present at >50% heteroplasmy; associated with decreased activity of a respiratory chain 
complex (COX deficiency) (Taylor, Barron et al. 2003; Greaves, Barron et al. 2010); 
and not previously identified as a polymorphic variant. Point mutations detected in 
PolgA
+/mut
  colonic crypts were compared to mutations previously reported in Mus 
musculus mtDNA sequences deposited in Genbank and to mutations transmitted 
through the PolgA
mut/mut 
 germline (Stewart, Freyer et al. 2008) to eliminate previously 
identified variants in mouse mtDNA. The percentage of COX deficient colonic crypts 
that contained at least one pathogenic mtDNA point mutation was 62% in the PolgA
+/mut
 
colon and 59% in the human colon, with no significant difference between the two 
(p=0.8194, X
2
 test) (Figure 3-6c). This suggests that the clonal expansion of at least one 
pathogenic mtDNA point mutation is causal in the COX deficiency observed in ~60% 
of colonic crypts in both PolgA
+/mut
 mice and humans with age.   
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Figure 3-6: Gene type, location and pathogenicity of somatic mtDNA point mutations in COX deficient colonic 
crypts in the ageing PolgA+/mut mouse and human colon. 
(a) Gene location of point mutations in individual mtDNA encoded genes in COX deficient colonic crypts p = 
0.2204, x2 test. (b) Types of changes observed in COX deficient colonic crypts. There was a significantly higher 
frequency of insertion/deletion mutations in the human crypts (p = <0.001, x2 test). (c) Percentage of COX deficient 
colonic crypts containing at least one pathogenic mtDNA point mutation in the PolgA+/mut mouse and human colon (p 
= 0.8194, x2 test). Image taken from (Baines, Stewart et al. 2014). 
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3.3.2.3 Absence of evidence for purifying selection on the clonal expansion of somatic 
mtDNA point mutations in PolgA
+/mut
 mouse colonic crypts  
In the ageing human colon the accumulation of somatic mtDNA point mutations is 
random and their expansion is not subject to selective constraints (Greaves, Elson et al. 
2012). To determine whether somatic mtDNA point mutations in the ageing PolgA
+/mut
 
mouse colon were subject to selective constraints the PolgA
+/mut
 mouse mutation dataset 
was compared to: mtDNA variants reported in Mus musculus mtDNA sequences 
downloaded from Genbank and to mtDNA point mutations transmitted through the 
PolgA
mut/mut
 germline (Stewart, Freyer et al. 2008). Comparison to Mus musculus 
sequences gives an estimate of the natural mutation/ selection balance in mice and 
comparison to the PolgA
mut/mut 
germline mutations ensures that selective constraints are 
only examined in the context of somatic mtDNA point mutations. Each mutation 
transmitted through the PolgA
mut/mut 
germline was scored once, and only mutations 
observed in 2 or more related animals were counted to filter out false positives.  
 
Somatic mtDNA point mutations in PolgA
+/mut
 mouse colonic crypts were frequently 
non-synonymous mutations, where the ratio of non-synonymous substitutions per site 
(dN) to synonymous substitutions per site (dS) gave a value of 0.783, providing little 
evidence of purifying selection against amino acid changes in protein encoding genes 
(values approaching 1 signify an absence of purifying selection) (Figure 3-7). A 
Fischer’s exact test failed to reject the null hypothesis that observed mtDNA mutations 
evolve neutrally in PolgA
+/mut
 mouse colonic crypts (dN/dS=1 null) (p= 0.3402). This 
was significantly different to mutations observed in the PolgA
mut/mut
 mouse germline 
(dN:dS= 0.0310) and normal mouse strains (dN:dS= 0.0640), where mutations were 
more frequently synonymous changes (Figure 3-7). Furthermore a Fischer’s exact test 
rejected the neutral null hypothesis (dN/dS=1) for observed mtDNA point mutations in 
both the PolgA
mut/mut
 mouse germline (p=<0.0001) and normal mouse strains (p= 
<0.0001). This data therefore suggests that somatic mtDNA point mutations evolve 
neutrally in the PolgA
+/mut
 mouse colon and indicates there is no evidence for purifying 
selection.   
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Figure 3-7: Genetic consequences of somatic mtDNA point mutations in the PolgA+/mut mouse colon.  
The ratio of non-synonymous mutations: synonymous mutations in PolgA+/mut mouse colonic crypts, the PolgAmut/mut 
mouse germline and normal mouse strains. The ratio of non-synonymous to synonymous mutations is significantly 
higher in PolgA+/mut mouse colonic crypts compared to the PolgAmut/mut germline and normal mouse strains 
(p=<0.0001, Fisher’s exact test). Image taken from (Baines, Stewart et al. 2014). 
In PolgA
+/mut
 mouse colonic crypts a considerably higher number of point mutations 
were also detected in the first and second codon positions of protein encoding genes, of 
which many were non-synonymous changes (Figure 3-7a) compared to the PolgA
mut/mut
 
germline (Figure 3-7b) and normal mouse strains (Figure 3-7c). This further supports 
that somatic mtDNA point mutations in the ageing PolgA
+/mut
 mouse colon are not 
subject to selective constraints, as changes in the first and second codon positions 
frequently cause amino acid substitutions. Furthermore a significantly higher number of 
point mutations were also detected in mt-tRNA and mt-rRNA genes in the PolgA
+/mut
 
mouse colon than the PolgA
mut/mut
 germline and normal mouse strains (p=<0.0001, X
2
 
test) (Figure 3-7a-c). Too few somatic mtDNA mutations were detected in the control 
region of PolgA
+/mut
 colonic crypts and so appropriate comparisons could not be made 
here. The random mutagenesis observed in PolgA
+/mut
 colonic crypts (Figure 3-5a) was 
also significantly different to the genome distribution of mtDNA point mutations 
observed in the PolgA
mut/mut
 germline (p = 0.0005, X
2
 test) and normal mouse strains (p= 
<0.0001, X
2
 test), where there was a mutation bias towards mt-tRNA and non-coding 
mutations, with purifying selection against mutations in protein-encoding genes (Figure 
3-7d, e). As such it appears that somatic mtDNA point mutations in the ageing 
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PolgA
+/mut 
colon are indistinguishable from random and that their clonal expansion is 
not subject to selective constraints. 
 
Figure 3-8:Positional mutation frequency and mutation distribution by codon position and gene reveals an 
absence of evidence for purifying selection on somatic mtDNA point mutations in PolgA+/mut colonic crypts  
(a) Positional mutation frequency (observed mutations per base pair) of somatic mtDNA point mutations observed in 
PolgA+/mut colonic crypts compared to (b) mtDNA mutations observed, transmitted through the PolgAmut/mut mouse 
germline (Stewart, Freyer et al. 2008) and (c) mtDNA sequences of mouse strains from Genback , Mus musculus. To 
compare between the classes the sum of the 3rd codon position was taken and standardized as 1 (value/ 3rd codon 
sum). Abbreviations: CP1-3, codon positions 1-3. (d) Positional mutation frequency (number of mutations/base pairs) 
of observed vs expected (based on a random distribution) mtDNA point mutations transmitted through the 
PolgAmut/mut mouse germline (Stewart, Freyer et al. 2008) (p= <0.0001, X2 test) and (e) mtDNA sequences of mouse 
strains from Genbank , Mus musculus (p= <0.0001, X2 test). Contingency analysis using X2 test with Bonferroni 
correction for multiple testing was carried out on the frequency of changes in each gene type category where p= 
<0.025 was statistically significant. Non-coding mutations were excluded from the contingency analysis as values 
were frequently below 5. Image taken from (Baines, Stewart et al. 2014). 
3.3.2.4 The clonal expansion of somatic mtDNA point mutations in the ageing colon of 
PolgA
+/mut
 mice can be explained by random genetic drift. 
Somatic mtDNA mutations have been proposed to clonally expand by random genetic 
drift, causing age-related focal respiratory chain deficiency in both post-mitotic and 
mitotic human tissues (Coller, Khrapko et al. 2001; Elson, Samuels et al. 2001). Recent 
experimental data from the human colon and buccal epithelium strongly supports the 
early life hypothesis for the origin of mtDNA point mutations and that clonal expansion 
occurs throughout adulthood (Greaves 2014). A study in short lived animals, 
hypothesised that random genetic drift cannot explain the clonal expansion of mtDNA 
deletions and the incidence of COX deficiency observed in post-mitotic tissues of rats 
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(Kowald and Kirkwood 2013). This study, however did not examine the clonal 
expansion of mtDNA point mutations in mitotic tissues of short-lived animals, and so it 
remains unknown whether the high cell division in replicating tissues could influence 
clonal expansion and whether random genetic drift would indeed be sufficient to explain 
the incidence of COX deficiency in mitotic tissues of short-lived animals.  
The original modelling studies in humans suggested that the rate of mtDNA 
mutagenesis could influence the clonal expansion of mtDNA mutations by random 
genetic drift (Elson, Samuels et al. 2001). A computational model, based upon 
previously published models and experimental data (Coller, Khrapko et al. 2001; Elson, 
Samuels et al. 2001; Taylor, Barron et al. 2003; Vermulst, Bielas et al. 2007), was 
therefore developed, courtesy of Craig Stamp, to determine whether changing only the 
mtDNA mutation rate could lead to accelerated clonal expansion of somatic mtDNA 
point mutations and the levels of COX deficiency observed experimentally in short-
lived animals. The model involved the simulation of 1000 cells, assuming that each cell 
contained 200mtDNA molecules (Coller, Khrapko et al. 2001)and underwent cell 
division once a day every day for 3 years. The mean of 1000 simulation runs of 1080 
divisions during the 36 month lifespan of mice was performed to determine the mtDNA 
mutation frequency. Parameter scans for different mtDNA mutation rates were 
performed to simulate the level of COX deficiency produced at each rate, assuming that 
>75% mutated mtDNA was required to confer COX deficiency (Taylor, Barron et al. 
2003), and this was subsequently matched to experimental data for the WT (Greaves, 
Barron et al. 2011), PolgA
+/mut
 and PolgA
mut/mut
 mice, given that these mice exhibit 
different rates of mtDNA mutagenesis.  
Dual COX/SDH histochemistry was performed on 3 (n=5), 6 (n=5), 9 (n=7) and 12 
(n=6) month old PolgA
mut/mut
 mouse colon tissue to determine the incidence of age-
related COX deficiency (Figure 3-9) at a high rate of mtDNA mutagenesis, to be 
included in the simulations. The computer modelling (Figure 3-10) demonstrated that 
changing only the mtDNA mutation rate could lead to enhanced clonal expansion of 
somatic mtDNA point mutations and the incidence of COX deficiency observed 
experimentally in WT (Greaves, Barron et al. 2011), PolgA
+/mut
 (Figure 3-1) and 
PolgA
mut/mut
 (Figure 3-9) mouse colon tissue. As such random genetic drift was 
sufficient to explain the clonal expansion of somatic mtDNA point mutations in colonic 
epithelial tissue of ageing mice, which parallels what we see in the ageing human colon 
(Taylor, Barron et al. 2003; Greaves, Elson et al. 2012). 
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Figure 3-9:  Respiratory chain deficiency in ageing PolgAmut/mut mouse colon.  
 
COX/SDH histochemistry on (a) 3 month old and (b) 12 month old PolgAmut/mut mouse colon tissue. Crypts stained 
brown are positive for COX activity, those stained blue are COX deficient and those stained purple/grey display 
intermediate COX deficiency. (c): Mean incidence (± SEM) of COX deficient colonic crypts in 3, 6, 9 and 12 month 
old PolgAmut/mut mice. Image taken from (Baines, Stewart et al. 2014). 
 
 
Figure 3-10:Random genetic drift can explain the clonal expansion of mtDNA point mutations and the 
incidence of COX deficiency in colonic crypt stem cells of ageing mice. 
In silico modelling demonstrates that the percentage of simulated cells containing >75% mutant mtDNA molecules 
(simCOXdeficient cells) at the different indicated mtDNA mutation rates, closely matches the incidence of COX 
deficiency observed experimentally in WT (Greaves, Barron et al. 2011) PolgA+/mut (Figure 3.1) and PolgAmut/mut 
mice (Figure 3-9). Image taken from (Baines, Stewart et al. 2014). 
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3.4 Discussion 
Clonally expanded somatic mtDNA point mutations, leading to respiratory chain 
deficiency are frequently observed in ageing human stem cell populations, yet the 
functional significance of such mutations remains largely unknown. As such there is the 
need to establish a good animal model that displays a similar age-related mitochondrial 
dysfunction phenotype so that more detailed phenotyping can be performed of the 
functional consequences of clonally expanded somatic mtDNA point mutations in 
ageing mitotic tissues. 
I have previously shown that PolgA
+/mut
 mice accumulate COX deficient colonic crypts 
with age and that such COX deficiency was associated with somatic mtDNA point 
mutations (Holly Baines, MRes project). The aim of this study was to determine 
whether the incidence of COX deficiency in aged PolgA
+/mut
 mice reaches a level more 
comparable to that observed in the ageing human colon and to determine whether the 
nature, spectrum and clonal expansion of somatic mtDNA point mutations underlying 
the COX deficiency was similar between the two species. Results from this study 
revealed that by 81 weeks of age, PolgA
+/mut
 display a similar level and pattern of COX 
deficiency in colonic crypts as ageing humans (>70 years old) (Taylor, Barron et al. 
2003) and confirm that the mtDNA defects underlying the COX deficiency are clonally 
expanded somatic mtDNA point mutations. Point mutations were found to occur 
randomly within the genome, and paralleled those observed in the ageing human colon 
in terms of gene location and pathogenicity (Greaves, Elson et al. 2012). Moreover 
somatic mtDNA mutations were not subject to purifying selection, confirming that their 
clonal expansion was indeed random. Computer modelling also demonstrated that 
random genetic drift can explain the clonal expansion of somatic mtDNA point 
mutations in the ageing PolgA
+/mut
 mouse colon, suggesting a similar mechanism for the 
clonal expansion of somatic mtDNA point mutations in the colon between mice and 
humans.   
Differences in the types of mtDNA point mutations were observed between the 
PolgA
+/mut 
mouse and ageing human colon, which was principally due to a lack of 
frameshift mutations in the PolgA
+/mut 
colon. This was not unexpected, given that 
PolgA
+/mut
 mice are heterozygous for an allele that disrupts the proof-reading function 
of mtDNA Polγ, which induces mutations in mtDNA during replication through the 
misincorporation and miscopying of bases (Zheng, Khrapko et al. 2006). Indeed, a 
recent study involving extensive mutational analysis of 442 mutations in the PolgA
mut/mut 
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mice revealed that <1% of mutations were frameshift mutations (Ross, Stewart et al. 
2013), with strong purifying selection observed on the transmission of insertion/deletion 
mutations in transgenic mouse models that carry mtDNA mutations (Fan, Waymire et 
al. 2008; Stewart, Freyer et al. 2008; Ross, Stewart et al. 2013). Furthermore, the rare 
mtDNA deletions that are observed in PolgA
mut/mut
 mice only persist in mt-tRNA genes 
and the oriL (Stewart, Freyer et al. 2008; Ross, Stewart et al. 2013). As such it was 
unlikely that any frameshift mutations would be detected in the PolgA
+/mut
 mutation 
dataset, given the modest size of 241 mutations coupled with the low frequency of 
insertion/deletion mutations observed in these mouse strains. A lower incidence of 
transversion mutations was also observed in the PolgA
+/mut
 mouse colon, which again is 
likely to be due to the defective mtDNA Polγ. Nevertheless the frequency of 
transversion mutations in the PolgA
+/mut
 mouse and human colon was only moderate, 
highly suggesting that few age-related somatic mtDNA mutations are induced by 8-oxo-
deoxyguanine mediated mutagenesis and oxidative damage. In both datasets the 
overwhelming majority of changes were base transitions, confirming that age-related 
somatic mtDNA point mutations appear to occur during early development from Polγ 
mediated replication errors and/or spontaneous cytosine deamination (Zheng, Khrapko 
et al. 2006; Vermulst, Bielas et al. 2007), with somatic mtDNA mutations clonally 
expanding throughout the lifespan (Coller, Khrapko et al. 2001; Elson, Samuels et al. 
2001). 
In this study COX deficient colonic crypts, frequently presented with clonally expanded 
mtDNA point mutations in genes other than mtDNA encoded subunits of Complex IV, 
confirming that mutations in other genes can result in COX deficiency. Point mutations 
in mt-tRNA and mt-rRNA genes accounted for the majority of these mutations, which 
are likely to precipitate COX deficiency through translational defects that cause a 
reduction in protein levels and therefore activity of respiratory chain subunits. However, 
occasionally a PolgA
+/mut
 COX deficient colonic crypt presented with just one 
pathogenic mutation in a complex I gene. A definitive explanation for this observation 
still remains to be elucidated, however complex I defects are frequently associated with 
complex IV defects in the ageing human colon (Greaves, Barron et al. 2010) and 
multiple respiratory chain defects have been observed in mitochondrial DNA disease 
patients that harbour pathogenic mutations in a mt-ND genes (Hinttala, Smeets et al. 
2006). Furthermore respiratory chain complexes are believed to exist as ‘respirasomes’, 
where complexes I, III and IV associate to form supercomplexes (Schägger and Pfeiffer 
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2000). Complex I is believed to be fundamental in the assembly and activation of such 
supercomplexes (Moreno-Lastres, Fontanesi et al. 2012; Winge 2012) and indeed a 
respirasome will not form in the absence of one of the respiratory chain complexes 
(Acín-Pérez, Fernández-Silva et al. 2008). As such it is not surprising that a single 
pathogenic point mutation in a complex I gene could affect the structural support and 
activity of complex IV, thus leading to COX deficiency. Colonic crypts were observed 
that did not contain a single pathogenic mtDNA point mutation. Such crypts, however 
frequently contained multiple heteroplasmic point mutations, which in combination, 
could potentially precipitate COX deficiency.  
Mutational analysis of mtDNA point mutations in the PolgA
mut/mut 
mouse germline has 
previously revealed strong purifying selection against mutations in the first and second 
codon positions of protein encoding genes (Stewart, Freyer et al. 2008). In contrast, this 
study revealed that somatic mtDNA point mutations in the PolgA
+/mut
 mouse were 
subject to random mutagenesis and showed an absence of evidence for purifying 
selection. In ageing humans an absence of selective constraints acting on somatic 
mtDNA point mutations was not restricted to the ageing human colon, but was also 
considered to be true for other human somatic tissues (Greaves, Elson et al. 2012). As 
such, although this study primarily focused on the colonic epithelium of the PolgA
+/mut
 
mouse, it is expected that these findings would be replicated in other mitotic tissues. 
This study therefore supports that mtDNA mutations are subject to different selective 
constraints in germ cells and somatic cells (Greaves, Elson et al. 2012; Greaves 2014). 
A hypothesis derived from the Disposable Soma theory of ageing (Kirkwood 1977) has 
been postulated as an explanation for this phenomenon. This implies that the existence 
of selective constraints in germ cells may be due to selection for mitochondrial fitness 
during oocyte development (Cummins 1998), preventing the transmission of pathogenic 
mtDNA mutations to offspring via the genetic bottleneck (Stewart, Freyer et al. 2008). 
Pooling all available resources into reproduction to maintain species fitness would result 
in a lack of resources later in life and as such an absence of selective mechanisms in 
somatic tissues. Even in the presence of such selective mechanisms, low level 
heteroplasmic mtDNA point mutations are still frequently inherited through the 
germline (Li, Schönberg et al. 2010; Payne, Wilson et al. 2013) and data looking at the 
transmission of mutations in PolgA
mut/mut
 suggests that pre-existing germline mtDNA 
point mutations can exacerbate somatic mutagenesis during ageing (Ross, Stewart et al. 
2013). Given that PolgA
+/mut
  mice display a higher frequency of inherited mtDNA point 
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mutations than WT mice (Vermulst, Bielas et al. 2007) the higher incidence of 
respiratory chain deficiency and somatic mtDNA point mutations observed in the colon 
of ageing PolgA
+/mut 
mice compared to normal ageing WT mice, (Greaves, Barron et al. 
2011) further supports this phenomenon.   
In silico modelling revealed that random genetic drift was sufficient to explain the 
clonal expansion of somatic mtDNA point mutations in colonic epithelial tissue from 
ageing PolgA
+/mut
 mice, providing evidence for a similar mechanism for clonal 
expansion in the ageing mouse and ageing human colon. Given that a recent study 
hypothesised that random genetic drift cannot explain the clonal expansion of mtDNA 
deletions in post-mitotic tissues of short-lived animals (Kowald and Kirkwood 2013), 
this study can be said to lend further support to the fact that the clonal expansion of 
somatic mtDNA mutations appears to be governed by the type of defect (point 
mutation/ deletion) and the tissue type (post-mitotic/ mitotic) (Nekhaeva, Bodyak et al. 
2002; Krishnan, Reeve et al. 2008), with cell division and mitotic activity playing a 
fundamental role. Different tissue segregation of mtDNA in mice, has previously been 
shown in a mouse heterozygous for two different mtDNA genotypes (Jenuth, Peterson 
et al. 1997). In this study it was shown that colonic crypts in young mice displayed a 
mixture of the two mtDNA genotypes, later forming two diverse populations of crypts, 
each containing a different genotype in aged animals (Jenuth, Peterson et al. 1997). This 
differed somewhat to the distribution of mtDNA in the liver, kidney, spleen and blood 
of these mice, where a bias towards one mtDNA genotype over the other was observed 
(Jenuth, Peterson et al. 1997).It would therefore appear that evolution of mtDNA in 
colonic crypts is subject to neutral drift, whereas post-mitotic tissues appear to exhibit 
different selection pressures. A study examining clonally expanded somatic mtDNA 
mutations in different human mitotic tissues, has also revealed different mutation 
frequencies in the intestine, liver, pancreas and skin with the colon displaying the 
highest frequency of clonal expansions (Fellous, McDonald et al. 2009). Taken together 
these studies highly suggest that the clonal expansion of somatic mtDNA point 
mutations with age is strongly influenced by tissue specific differences. Therefore, 
whilst somatic mtDNA point mutations appear to clonally expand by random genetic 
drift in colonic crypts of both PolgA
+/mut
 mice and humans; this may not be a suitable 
mechanism for other tissues. 
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3.4.1 Future work 
Given the normal lifespan and absence of premature ageing phenotypes seen in 
PolgA
+/mut
 mice, this mouse model would enable the investigation of clonally expanded 
somatic mtDNA point mutations in the context of normal ageing. This mouse model 
could therefore be useful for studying the interaction between mtDNA mutations and 
other forms of molecular damage that drive the ageing process together. A fundamental 
relationship between mtDNA damage, ROS and senescence is beginning to emerge 
within ageing (Passos, Saretzki et al. 2007) and so it would be beneficial to determine 
whether replicative tissues such as the colon demonstrate co-localization of mtDNA 
defects, such as complex IV deficiency, with senescent markers such as SA- β-GAL 
staining; ΥH2A.X staining and DNA damage foci (Hewitt, Jurk et al. 2012). 
 
Future work would indeed involve using the PolgA
+/mut
 mouse to investigate the 
functional consequences of clonally expanded somatic mtDNA point mutations and 
respiratory chain deficiency in ageing mitotic tissues to help identify how mtDNA 
mutations may contribute to age related tissue dysfunction. This will be addressed 
further in chapter 4. 
3.5 Conclusion 
In this study I have presented evidence for a conserved mechanism for the clonal 
expansion of somatic mtDNA point mutations by random genetic drift, with an absence 
of any selective constraints, resulting in age-related respiratory chain deficiency in 
colonic epithelial tissue of both PolgA
+/mut
 mice and ageing humans. This suggests that 
the PolgA
+/mut
 mouse will be a valuable tool for studying the cellular consequences 
caused by the random intracellular pattern of mitochondrial dysfunction that occurs with 
age. Given that stem cell markers are much more robust in mouse tissues (Barker, Van 
Es et al. 2007) functional studies using the PolgA
+/mut
 mouse could provide valuable 
insights into the role of clonally expanded somatic mtDNA point mutations in human 
stem cell ageing, age-related tissue dysfunction and disease. 
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Chapter 4 
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Chapter 4. Results: How does age-related mitochondrial respiratory 
chain dysfunction affect the gene expression profile of colonic crypts 
and what are the potential functional effects of this upon cellular 
processes?  
4.1 Introduction 
4.1.1 Stem cell ageing 
A decline in the replicative and regenerative function of adult stem cell populations 
plays a major role in age related frailty and disease (Sharpless and DePinho 2007).  
Typical features of ageing such as decreased wound repair in the skin, diminished 
immunity, hair greying and hair loss, suggest that there is deregulation of the 
homeostatic and regenerative properties of these tissues, due to altered stem cell 
function with age (Sharpless and DePinho 2007). The unique self-renewing properties 
of stem cells means that they accumulate age-related damage due to both chronological 
and replicative ageing (Liu and Rando 2011). As such genomic damage is likely to be at 
the forefront of age-related stem cell dysfunction, particularly in stem cells that reside in 
rapidly replicating tissues, such as the gut, skin and blood (Liu and Rando 2011).  The 
age-related accumulation of molecular damage in stem cells has been hypothesised to 
cause changes in their normal fate or that of their progeny by three possible mechanisms 
(Liu and Rando 2011): 
1. A decline in the stem cell pool, arising either due to replicative senescence or 
reduced self-renewal capacity (Maslov, Barone et al. 2004; Nishimura, Granter 
et al. 2005) 
2. Malignant transformation and a predisposition to cancer (Liu and Rando 2011) 
3. Altered differentiation and the production of abnormal progeny cells (Rossi, 
Bryder et al. 2005). 
Dissecting and understanding the molecular mechanisms responsible for age-related 
changes in stem cells is vital if we want to try and maintain normal tissue homeostasis 
and prolong tissue repair/ regeneration in order to improve health and quality of later 
life. 
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4.1.2 Mitochondria and stem cell ageing 
The age-related accumulation of somatic mtDNA point mutations resulting in focal 
respiratory chain deficiency has been reported in a number of mitotic, replicative tissues 
that rely on stem cells for self-renewal (Taylor, Barron et al. 2003; McDonald, Greaves 
et al. 2008; Fellous, McDonald et al. 2009). Stem cells are the only constant, surviving 
cells in mitotic tissues and so it is believed that somatic mtDNA mutations must occur 
and clonally expand within the stem cells (Kirkwood 2008), suggesting a potential role 
for mtDNA point mutations in stem cell ageing. Given the specific structural 
architecture of colonic crypts (see Chapter 1, section 1.6.1), the colon is an ideal tissue 
in which to study stem cell populations. Indeed the only functional study looking at the 
effects of somatic mtDNA point mutations has been performed in ageing human colonic 
colon crypts (Nooteboom, Johnson et al. 2010). As such the effects of mtDNA point 
mutations upon stem cell fate and function still remains largely unknown, with it still 
possible that these defects may simply be a biomarker or consequence of the ageing 
process. 
4.1.2.1 MtDNA mutations and colorectal cancer 
Colorectal cancer is one of the most prevailing types of cancer in both the United States 
and Europe, for which ageing is a dominant risk factor (Ferlay 2001; Health 2006). 
Given that cancer cells typically demonstrate a decrease in OXPHOS and a dramatic 
increase in glycolytic activity, a phenomenon known as the Warburg effect (Warburg 
1930) it has long been considered that mitochondrial (respiratory chain) dysfunction 
plays a role in tumorigenesis and carcinogenesis. The role of mitochondria in apoptosis 
further supports that mitochondria become dysfunctional during cancer development, 
given that mutant, neoplastic cells persist and continue to proliferate, escaping cell death 
(Cavalli and Liang 1998). Elevated oxidative stress (Toyokuni 1995), a raised 
mitochondrial membrane potential (Chen 1988) and reduced expression and activity of 
respiratory chain complexes (Carew and Huang 2002) are also well documented 
features of cancer cells, supporting a potential role for mitochondrial dysfunction in 
cancer development.  
MtDNA point mutations have been reported in a number of different cancers including 
gastric, lung, liver, colorectal, breast, prostate, kidney and haematological malignancies 
(Ivanova, Lepage et al. 1998) (Jerónimo, Nomoto et al. 2001; Nomoto, Yamashita et al. 
2002; Tan, Bai et al. 2002; Lee, Yin et al. 2005). In colorectal cancer mtDNA point 
mutations have been reported in the D-loop of mtDNA (Lee, Yin et al. 2005; Lièvre, 
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Chapusot et al. 2005) and throughout the mtDNA genome (Polyak, Li et al. 1998; 
Nishikawa, Oshitani et al. 2005; Sui, Zhou et al. 2006). Both homoplasmic and 
heteroplasmic mtDNA point mutations have been detected in colorectal cancers 
(Polyak, Li et al. 1998; Coller, Khrapko et al. 2001; Sui, Zhou et al. 2006), with 
heteroplasmic mutations associated with increased tumour growth (Park, Sharma et al. 
2009). A study examining an mt-ND5 mutation in colorectal cancer suggested that 
mtDNA mutagenesis actually contributed to early carcinogenesis through changes in 
ROS production/ signaling and apoptosis (Park, Sharma et al. 2009). Other studies have 
also demonstrated the presence of mtDNA point mutations in precancerous lesions of 
gastrointestinal epithelial tissue as well as invasive tumors, suggesting that damage to 
the mtDNA genome occurs during early cell transformation and tumorigenesis (Sui, 
Zhou et al. 2006). As such it has been suggested that mtDNA point mutations can serve 
as an early diagnostic biomarker in colorectal cancer. Mutations in the mtDNA genome 
may also be an important prognostic indicator for cancer progression and survival 
(Lièvre, Chapusot et al. 2005), as studies have shown that a functional mitochondrial 
respiratory chain and intact mtDNA genome are necessary for effective treatment with 
anti-cancer therapies (Joshi, Li et al. 1999; Singh, Russell et al. 1999).  
Whether mtDNA mutations have a causal role in early tumorigenesis and cancer 
development or are a result of the enhanced oxidative stress and instability of cancer 
cells, still remains to be elucidated. Given the stem cell hypothesis of cancer and the 
fact that somatic mtDNA mutations accumulate in stem cells with age, it is however 
plausible that the age-related accumulation of somatic mtDNA point mutations could 
render stem cells selectively vulnerable to malignant transformation and contribute to 
early tumorigenesis, giving a predisposition to cancer (Liu and Rando 2011). 
Understanding the cellular changes that occur in response to the accumulation of 
somatic mtDNA point mutations in stem cells is therefore fundamental for both normal 
tissue ageing and the development of age-related diseases, such as cancer. 
4.1.3 Mouse models 
Given the inherent limitations of studies using human replicative tissues (as outlined in 
chapter 3) it is difficult to study the impact of somatic mtDNA point mutations upon 
stem cell function and the potential role in age-related disease and cancer development.  
The progressive accumulation of mtDNA point mutations has been shown to induce a 
profound early-onset stem cell dysfunction in PolgA
mut/mut
 mice, driving the ageing 
phenotypes seen in these animals (Norddahl, Pronk et al. 2011; Ahlqvist, Hämäläinen et 
107 
 
al. 2012; Fox, Magness et al. 2012) (see Chapter 3, section 3.1.2 for more detail or 
(Baines, Turnbull et al. 2014)). Whilst the mitochondrial dysfunction phenotype 
observed in PolgA
mut/mut
 mice is not representative of normal human ageing, these 
studies demonstrated that mtDNA mutations do have a direct effect upon stem cell 
function, which could contribute to age-related stem cell dysfunction in humans in a 
similar manner, but to a reduced extent (Baines, Turnbull et al. 2014). Given that 
PolgA
+/mut
 mice display a similar age-related mitochondrial dysfunction phenotype to 
that seen in the normal ageing human colon (see chapter 3 and (Baines, Stewart et al. 
2014)), the PolgA
+/mut
 mouse  appears to be a sensible model in which to study the 
functional effects of somatic mtDNA mutations and respiratory chain deficiency in a 
stem cell population in the context of normal human ageing and disease.  
4.2 Aim of the study 
To identify any changes in gene expression and the potential impact this could have 
upon cellular processes, caused by respiratory chain deficiency and clonally expanded 
somatic mtDNA point mutations in colonic crypts, using the PolgA
+/mut
 mouse as a 
representative model of the normal ageing human colon.  I aimed to use RNA 
sequencing of laser-microdissected COX positive and COX deficient colonic crypts to 
examine their gene expression profiles and provide preliminary insights into the 
potential cellular responses invoked by age-related respiratory chain dysfunction and the 
implications this may have for disease development. 
Prior to the submission of this thesis no validation experiments were performed to 
confirm the changes in gene expression observed in the RNA sequencing dataset. All 
results presented in this chapter are therefore preliminary and all discussions about the 
potential functional effects upon cellular processes and disease associations are 
hypothesis driven, indicating potentially interesting avenues to follow up on. 
4.3 Experimental procedures  
The transcriptome of a cell comprises the whole set of mRNAs expressed from all genes 
within the cell.  As such transcriptomic analysis can be used to determine differences in 
gene expression between cells and any potential alterations in cellular and physiological 
processes that may result. RNA sequencing is an innovative tool that can be used to 
accurately determine the gene signature and level of transcripts within a cell, which can 
detect low level changes in gene expression and can be used on relatively small 
quantities of RNA (Wang, Gerstein et al. 2009).  
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To determine differences in the transcriptome conferred by respiratory chain deficiency 
in a stem cell population, RNA was extracted from laser microdissected COX deficient 
and COX positive colonic crypts from PolgA
+/mut
 mice and was subjected to RNA 
sequencing, to examine the crypt specific gene expression profiles. RNA degradation 
and a reduction in RNA quality has a significant impact on gene signature profiles, and 
can result in a false bias towards the downregulation of a number of mRNAs.  To 
overcome RNA degradation during laser microdissection, histological identification of 
COX deficient crypts was combined with cresyl violet acetate alcoholic staining on 
colon sections cut at 20μm intervals on PEN slides, from which colonic crypts were 
then laser microdissected (Figure 4-1). Fixing and staining using alcoholic solutions 
dehydrates the tissue sections and prevents RNase activity, preserving RNA integrity 
for up to 90 minutes during microdissection  (Clément-Ziza, Munnich et al. 2008). 
Laser microdissection was used to cut a population of COX positive (n=250) and COX 
deficient (n=250) colonic crypts from five 12 month old PolgA
+/mut
 animals. Colonic 
crypts were collected into buffer RLT (Qiagen RNeasy Micro Kit) containing β-
mercaptoethanol, to prevent RNA degradation by RNases during collection and storage 
of the samples and RNA was extracted using the RNeasy Micro Kit (Qiagen). 
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Figure 4-1: Combined COX/SDH histochemistry and Cresyl violet acetate alcoholic staining on colon sections 
for the identification of COX deficient and COX positive colonic crypts during laser microdissection.  
COX/SDH histochemistry on colon sections from (a) PolgA+/mut mouse 23 and (b) PolgA+/mut mouse 45. Cresyl violet 
acetate alcoholic staining on sequential colon sections from (c) PolgA+/mut mouse 23 and (d) PolgA+/mut mouse 45 that 
were then used during laser- microdissection. Crypts that correspond between the two staining procedures are 
indicated by the numbers.  
The RNA integrity number (RIN) gives  a quantitative value for the relative proportion 
of 28S:18S rRNA within a sample, acting as a measure of the amount of RNA 
degradation within a sample and thus indicates the quality of the RNA (Schroeder, 
Mueller et al. 2006). The RIN score (RNA quality) and RNA concentration for the COX 
positive and COX deficient samples from each of the 5 PolgA
+/mut
 mice was determined 
using an Agilent 2100 bioanalyzer. Example RIN image outputs generated from the 
bioanalyzer are shown in Figure 4-2 and the RNA concentration and integrity for each 
of the ten samples is described in Table 4-1. BGI Tech solutions required a RIN score 
>7 and 10ng of RNA per sample for RNA sequencing. Samples were shipped to BGI 
Tech Solutions, China and RNA sequencing was performed using the SMARTer 
Library construction and sequencing (11Gb per sample) method. 
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Figure 4-2: RIN output images showing the relative proportion of 28S:18S in a sample.  
RIN output for (a) PolgA+/mut mouse 42 COX +ve crypt sample (RIN 8.5) and (b) PolgA+/mut mouse 44 COX-ve crypt 
sample (RIN 8.7). 
Sample RNA Conc (pg/μl) RIN 
PolgA
+/mut
 23 COX +ve crypts 1410 7.8 
PolgA
+/mut
 25 COX +ve  crypts 1919 8.1 
PolgA
+/mut
 42 COX +ve crypts 1298 8.5 
PolgA
+/mut
 44 COX +ve crypts 685 9.1 
PolgA
+/mut
 45 COX +ve crypts 3130 8.5 
PolgA
+/mut
 23 COX –ve crypts 574 7.3 
PolgA
+/mut
 25 COX –ve crypts 856 7.8 
PolgA
+/mut
 42 COX –ve crypts 454 7.9 
PolgA
+/mut
 44 COX –ve crypts 997 8.7 
PolgA
+/mut
 45 COX –ve crypts 673 7.9 
Table 4-1:  RNA concentration and RIN scores for each COX positive and COX deficient sample from the 5 
PolgA+/mut mouse samples. 
4.4 Results 
Six RNA samples, a COX positive and COX deficient sample from 3 of the PolgA
+/mut
 
mice (animals 25, 44 and 45) were successfully sequenced and bioinformatic analysis 
performed on RNA reads, prior to completion of this thesis. Quality control analysis, 
statistical analysis and mapping to biological pathways, was completed by Dr Graham 
Smith, Bioinformatics support unit, Newcastle University. 
To determine the quality of the RNA sequencing reads and identify whether any bias 
had resulted from RNA degradation, quality control analysis was performed using 
FastQC software (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc). This software 
determines the integrity of RNA based upon a number of parameters including the: 
sequence content and whether all the correct bases were identified in the reads; GC base 
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content; the length of RNA sequencing reads; sequence duplication and whether certain 
sequences were overrepresented in the dataset. All 6 biological samples satisfied the 
quality control checks and sequencing reads were subsequently mapped to the mouse 
genome (Mus_musculus.GRCm38.75.fa) using STAR (Dobin, Davis et al. 2013). RNA 
sequencing of each COX positive and COX deficient sample generated two technical 
replicates, which were individually mapped to the genome. The number of reads 
mapping to each gene was calculated using Ht-seq count for each replicate (Anders, Pyl 
et al. 2014) and replicate counts were then summed for each sample, giving a mean read 
count for each sample. The mean read count therefore acted as a direct measure of gene 
expression for each sample, giving a measure of gene expression for each gene in each 
of the three COX deficient samples and the three COX positive crypt samples. For a 
gene to be considered to be expressed in a sample an absolute gene expression criterion 
was used, such that at least 20 reads had to map to a gene in at least two out of the six 
biological samples, which was similar to the approach taken in (McLoughlin KE 2014). 
This revealed that 13943 genes out of a possible 39144 Ensembl mouse genes were 
expressed in the RNA sequencing dataset.  
4.4.1 Significant differentially expressed genes in PolgA+/mut COX deficient colonic 
crypts 
To identify any significant changes in gene expression between COX positive and COX 
deficient colonic crypts statistical analysis was performed using the DESeq2 
Bioconductor package version 1.2 (Love, Huber et al. 2014).  This used a Wald test to 
estimate the difference in the mean read counts (expression level) for each gene in the 
COX deficient crypts (all three samples combined) compared to the mean read counts 
(expression level) for each gene in the COX positive crypts (all 3 samples combined). 
This therefore estimated the difference in mean expression level for each gene between 
the two sample populations (similar to a paired t test) for normally distributed data. 
When comparing the mean read counts (expression level) for each gene between the 
COX deficient and COX positive crypts the Wald test also takes into account the 
variation (standard deviation) in the difference between the read counts for each mouse. 
In simple terms the difference in gene expression (read counts) is calculated between 
the COX deficient and COX positive sample from the first mouse and then the same for 
the second mouse and the third mouse, and the difference between these is averaged 
across the three mice and used to calculate the standard deviation, which is corrected for 
the effect of the baseline variability between the animals. The estimate of the standard 
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deviation is then stabilised for each gene using an Empirical Bayes correction (Smyth 
2004), which incorporates evidence from the variability of other genes with similar 
expression levels in the dataset i.e. it assumes that genes with more or less the same 
expression level will tend to have more or less the same variability.  A p value of <0.05, 
adjusted using a Benjamini-Hochberg (BH) correction, was used to identify those genes 
that were significantly differentially expressed (DE) between the COX deficient crypts 
and the COX positive. The BH correction was used to correct for the expected number 
of false positives within the dataset, based on the assumption that 5% of the total 
number of genes (13947) would be expected to be false positives (697 genes) if an 
unadjusted p value of <0.05 was used. Throughout this chapter COX deficient crypts 
refers to all three samples combined and COX positive crypts refers to the three COX 
positive crypt samples combined. 
Using the above criteria, COX deficient colonic crypts displayed 280 genes that were 
significantly differentially expressed compared to COX positive colonic crypts, of 
which 126 were significantly upregulated and 154 were significantly downregulated. 
When the BH correction was applied 14 of these genes were expected to be false 
positives, and as such this is taken into consideration when the test determines the 
statistical significance for each gene. Given the large number of genes that were 
significantly different between the two populations, a log2 fold change (FC) (<1 or >1) 
was also applied, such that the expression level had to have increased by more than 
double in COX deficient crypts compared to COX positive (>1) or the expression level 
had to have decreased by more than half in the COX deficient crypts (<1). This 
identified 63 genes that were significantly upregulated and 58 genes that were 
significantly downregulated in the COX deficient colonic crypts compared to COX 
positive crypts (Figure 4-3). 
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Figure 4-3: Genes that were significantly differentially expressed, with the highest log fold change in the COX 
deficient crypts versus the COX positive crypts.  
(a) DESeq2 MA plot (log2 FC versus the number of reads mapped for each gene) representing the mean expression 
level of genes. Note that genes are shown here (to the left of the plot) that only have 1 read mapping to them. (b) A 
volcano plot (logFC versus the log of the adjusted p value) showing all DE genes in COX deficient colonic crypts (all 
3 samples combined) compared to COX positive crypts (all three samples combined). Red dots represent those 
significant DE genes (BH adjusted p <0.05) with the highest log2FC (<1 or >1) and black dots represent those DE 
genes that were filtered out based on either: a lack of statistical significance or did not meet the fold change criteria. 
Figures courtesy of Dr Graham Smith. 
Genes that were significantly differentially expressed (BH adjusted p value <0.05) and 
had more than doubled/ halved in their expression levels (log2FC of <1 or >1) in COX 
deficient crypts compared to COX positive crypts (n=120) were subsequently mapped 
to biological pathways using both KEGG (Kanehisa and Goto 2000; Kanehisa, Goto et 
al. 2006) and Reactome (Joshi-Tope, Gillespie et al. 2005; Croft, Mundo et al. 2014), to 
identify the cellular processes these genes were involved in and develop potential 
hypotheses for the functional consequences these changes could have. Two biological 
pathway mapping packages were used as they differ in the number of genes they contain 
and the gene annotation to biological pathways, which is mainly due to differences in 
the modification and updates of the two systems, with Reactome being updated much 
more recently than KEGG. Pathways in Reactome also show a hierarchial arrangement 
of the genes, whereas those in KEGG do not, such that sometimes only genes that are 
crucial to the function of a pathway will be described, and other genes, such as those 
that facilitate cross-talk between pathways, may be missed out. Furthermore many 
pathways in KEGG relate to disease processes and in Reactome they are predominantly 
cellular processes. As such both biological pathway packages were used in the analysis 
to enable the mapping of a greater number of genes to a greater number of cellular 
processes, with certain significant DE genes in COX deficient crypts only mapping to 
cellular processes in KEGG pathways and others only mapping to pathways in 
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Reactome. Out of the 39144 Ensembl mouse genes identified, 6660 of these map to 225 
biological pathways in KEGG and 6422 genes map to 1402 pathways in Reactome. 
Upon mapping of significant DE genes to biological pathways in both KEGG and 
Reactome a further filter was applied, such that >50% of genes had to be normally 
expressed in a given pathway, to act as a further control on the data. This criterion was 
used given that a local minimum of 0.5 for the fraction of genes expressed in both 
KEGG and Reactome was observed (Figure 4-4). Given the difference in gene number 
and annotation to cellular processes in KEGG and Reactome (see above), when this 
criteria was applied 13 significant DE genes were mapped to the same biological 
pathway in both KEGG and Reactome (Table 4-2), 11 significant DE genes mapped to 
pathways in KEGG alone (Table 4-3) and 11 genes mapped to Reactome pathways 
alone (Table 4-4). Note that the pathway completeness criterion only eliminates ~10% 
of pathways mapped to both KEGG and Reactome (Figure 4-4), and the substantial 
reduction in the number of DE genes mapped to pathways (from 121 to 55) is primarily 
due to the fact that only a sixth of all possible mouse Ensembl genes have been 
annotated to biological pathways in KEGG and Reactome (see above).   
 
Figure 4-4: The fraction of genes expressed in biological pathways at different pathway completeness’s for (a) 
KEGG pathways and (b) Reactome pathways.  
A local minimum of 0.5 is observed in both cases and so a pathway completeness of >50% was chosen for basal gene 
expression in biological pathways using both pathway packages. Figures courtesy of Dr Graham Smith. 
The function of each gene and the role within cellar processes was determined using 
Uniprot, Gene ontology (GO) Terms and Pubmed for all significant DE genes mapped 
to biological pathways in both KEGG and Reactome to form potential hypotheses for 
how the change in gene expression may affect cellular processes. Functional analysis of 
genes revealed a significant difference in the gene expression profiles of COX deficient 
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colonic crypts compared to COX positive crypts, namely genes associated with: the cell 
cycle, proliferation and differentiation; cell adhesion and epithelial permeability; DNA 
maintenance and repair and the immune response (Figure 4-5). I will therefore 
predominantly discuss those genes associated with these cellular processes, the potential 
effects this may have upon function of a pathway and any potential associations this 
may have with disease.  
 
 
Figure 4-5: Gene ontology categories of the significant DE genes in COX deficient colonic crypts compared to 
COX positive colonic crypts.  
Those genes expressed on other cell types are likely to be irrelevant to changes in colonic crypts as their function 
only concerns immune or neuronal cells. This may be a result of contamination in the samples. 
4.4.1.1 KEGG and Reactome combined 
Thirteen significant DE genes mapped to the same cellular pathway in both KEGG and 
Reactome, which are described in Table 4-2.  
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Table 4-2: Significant DE genes mapped to biological pathways in both KEGG and Reactome.  
BH: Benjamini-Hochberg adjusted p value. FC: fold change.  
Three significant DE genes, Espl1, Zbtb17 and Fgf7, in COX deficient crypts were 
associated with the cell cycle and cell proliferation. Espl1 is responsible for 
chromosome segregation during the cell cycle and was upregulated in COX deficient 
crypts. Studies have suggested that Espl1 is an oncogene as overexpression is associated 
with premature separation of chromosomes and aneuploidy in tumours (Zhang, Ge et al. 
2008), and it is upregulated in a number of malignancies, where it is associated with an 
increased risk of metastasis and a poor prognosis (Meyer, Fofanov et al. 2009). Zbtb17, 
suppresses negative regulators of the cell cycle that cause growth arrest, namely p21 
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(Vousden 2002) and prevents cell death by inducing expression of the anti-apoptotic 
factor BCL2 (Patel and McMahon 2007) and suppressing tumour necrotic factor (TNF) 
induced apoptosis (Liu, Yan et al. 2012). It could be hypothesised therefore that 
overexpression of Zbtb17 in COX deficient crypts could prevent cell cycle arrest/ cell 
death and cause progression through the cell cycle, potentially leading to aberrant 
proliferation and growth. Fgf7, which was significantly downregulated in COX 
deficient crypts, positively regulates cell proliferation and growth, particularly cells in 
the intestinal epithelium. Expression of Fgf7 prolongs the survival of intestinal crypts, 
particularly in response to cancer therapies (Booth and Potten 2001; Potten, O'Shea et 
al. 2001). As such decreased expression of Fgf7 in COX deficient crypts could be 
associated with reduced crypt survival, which has previously been documented in the 
ageing human colon (Nooteboom, Johnson et al. 2010) and a poor response to anti-
cancer therapies. Changes in these three transcripts associated with the cell cycle could 
therefore be associated with aberrant cell growth, potentially playing a role in early 
tumorigenesis, as well as cancer progression, given the association with a poorer 
prognosis.  
Significant DE genes were also identified in COX deficient colonic crypts with 
functions in focal cell adhesion, polarisation and epithelial permeability (Itgb7 and 
Pard6g). Itgb7 is principally involved in cell-cell adhesion and cell-matrix adhesion and 
decreased expression is associated with reduced cellular adhesion (Neri, Ren et al. 
2011).  Itgb7 is also involved in the recruitment of lymphocytes to intestinal tissues 
(Gorfu, Rivera-Nieves et al. 2010). As such decreased expression of Itgb7 in COX 
deficient crypts could lead to diminished cell adhesions and have implications for 
immune responses.  Pard6g forms part of the centriole and is important for asymmetric 
cell division, cell polarisation and the formation of epithelial tight junctions. Decreased 
expression of Pard6g has been associated with disturbed cell adhesion and cell 
migration due to disorganization of microtubules within the cytoskeleton (Dormoy, 
Tormanen et al. 2013). As such depletion of Pard6g in COX deficient crypts could 
result in decreased cell adhesion, along with Itgb7, and potentially decrease the 
formation of epithelial tight junctions. This could have implications for inflammatory 
bowel diseases (IBD) as increased epithelial cell permeability, caused by decreased 
maintenance of epithelial tight junctions, is implicated in the pathogenesis of IBD 
(Hollander 1992; McKay 2005; Mankertz and Schulzke 2007). Moreover this could also 
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indicate a potential increase in cell migration, which could also have implications for 
the invasion and metastasis of neoplastic cells. 
The gene expression profile of COX deficient crypts was also different in terms of 
genes concerning DNA maintenance and repair (Ercc4 and Ippk), which showed a 
general upregulation in activity. Ercc4 was upregulated in COX deficient crypts. This is 
the catalytic element of a DNA repair endonuclease enzyme that protects against 
genome instability and is involved in telomere maintenance (McDaniel and Schultz 
2008). Genes involved in the nucleotide excision repair pathway and telomere 
maintenance, such as Ercc4, are thought to predispose to cancer and contribute to 
aberrant growth of damaged cells; however studies have failed to find a correlation 
between abnormal Ercc4 and an increased risk of cancer (Shi, He et al. 2012; Gong, He 
et al. 2013). Ippk, involved in phosphatidylinositol signalling, is also involved in DNA 
repair pathways, principally non-homologous end joining and this gene was 
significantly upregulated in COX deficient crypts. The upregulation of genes involved 
in DNA repair pathways in COX deficient colonic crypts could indicate a response to 
the instability of the mtDNA genome caused by somatic point mutations. Alternatively, 
it could be hypothesised that this could also enable damaged, mutagenic cells to persist 
by preventing cell cycle arrest/death, as with Ippk, where studies have shown that Ippk 
induced production of inositol hexakiphosphate 6 can prevent TNF induced apoptosis 
(Verbsky and Majerus 2005).  
Two genes concerned with the immune response were also significantly differentially 
expressed in COX deficient colonic crypts. H2-DMb2 forms part of the major 
histocompatibility complex, involved in antigen presentation in immune responses, and 
is required for intestinal IgA production against bacteria. Illrap is essential for 
interleukin 1 signalling, which is involved in immune and inflammatory responses. 
Given that both of these genes were downregulated, along with Itgb7 (see above) in 
COX deficient crypts, this could indicate that immune responses are decreased. 
However, Il-1 signalling also plays a role in apoptosis, for which there are two different 
forms of the Illrap co-receptor, one which promotes and one which prevents apoptosis 
(Jensen and Whitehead 2003). It is unknown which form of this receptor was 
downregulated in COX deficient colonic crypts, however if it is the pro-apoptotic co-
receptor, this could also play a role in the persistence of damaged, unstable cells. IL-1 
receptor signalling is also important for NFκB activation of transcription and DNA 
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repair pathways, and so downregulation of this co-receptor could impact upon genome 
stability in COX deficient crypts. 
Interestingly, Per2, a core component of the circadian clock, was also significantly 
downregulated in COX deficient crypts, possibly suggesting that COX deficient crypts 
have become unsynchronised from COX positive crypts in their circadian cycle. 
Disturbance of this rhythm is known to play a role in ageing, cancer and metabolic 
syndromes. Per2 functions as a transcriptional repressor and is thought to be an 
important tumour suppressor gene through the regulation of several cell cycle 
checkpoints. A number of human malignancies display a depletion in Per2 (Mazzoccoli, 
Piepoli et al. 2012; Hwang-Verslues, Chang et al. 2013) and loss of Per2 is associated 
with abnormal growths and colon tumours in mice (Fu, Pelicano et al. 2002; Wood, 
Yang et al. 2008; Soták, Polidarová et al. 2013; Kelleher, Rao et al. 2014). A loss of 
Per2 is associated with enhanced cell proliferation, and this has been shown to be 
associated with overexpression of the ‘cancer causing genes’ c-MYC and β-catenin  
(Kelleher, Rao et al. 2014). Furthermore depleted Per2 also suspends the onset of DNA 
damage responses (Yang, He et al. 2012). As such the downregulation of Per2, coupled 
with the significant alterations in cell cycle and proliferation genes mentioned above, 
could suggest a potential link between mtDNA genome instability and respiratory chain 
deficiency with malignant transformation and carcinogenesis in colonic crypts.  
4.4.1.2 KEGG only 
As mentioned previously the fact that KEGG and Reactome contain a different number 
of genes annotated to different biological pathways, the hierarchial arrangement of 
genes is different and the different packages have been updated at different time points, 
some significant DE genes were only mapped to cellular pathways using KEGG. This 
identified an additional 11 significant DE genes in COX deficient crypts that mapped to 
cellular processes (Table 4-3).  
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Table 4-3: Significant DE genes mapped to KEGG pathways alone.  
BH: Benjamini-Hochberg adjusted p value. FC: fold change.  
Three of the DE genes were associated with cellular proliferation and differentiation.  
CD37 and Sema4b were both upregulated in COX deficient crypts; however they are 
unlikely to convey any changes to the colonic crypts themselves, given that all known 
functions of CD37 concern B and T lymphocytes and Sema4b is a signalling peptide 
that governs axonal extension and is therefore only concerned with neuronal 
differentiation. An explanation as to why somatic mtDNA mutations in the COX 
deficient colonic crypts could be associated with gene expression changes concerning 
other cell types is unknown; however the potential disturbance in the circadian rhythm 
could be a plausible explanation. Pwp2 was significantly upregulated in COX deficient 
crypts and this gene is involved in the G1 phase of the cell cycle and determines cell 
cycle progression, predominantly in highly proliferative tissues (Jayasena, Trinh et al. 
2011). Pwp2 regulates entry into the cell cycle through ribosome biogenesis, such that if 
ribosome biogenesis is reduced, entry into the cell cycle is delayed (Jayasena, Trinh et 
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al. 2011). Thus an overexpression of pwp2 in COX deficient colonic crypts could 
potentially increase entry into the cell cycle and enhance cell proliferation. 
Epha2 is expressed in stem cells (Funk and Orr 2013) and is involved in cell 
proliferation, differentiation and cell adhesion through bidirectional signalling. Epha2 
was significantly upregulated in COX deficient colonic crypts and an upregulation of 
Epha2 has been shown to have an oncogenic effect (Funk and Orr 2013). 
Overexpression of Epha2 has been reported in a number of human cancers, where it 
correlates with enhanced tumour invasion and metastasis, due to a lack of cell-cell 
adhesion and increased cell migration (Biao-Xue, Xi-Guang et al. 2011). Epha2 is 
commonly overexpressed in early stage colorectal cancer (Kataoka, Igarashi et al. 2004) 
and is associated with an increased prevalence of liver metastases (Saito, Masuda et al. 
2004), a common site of metastasis from colorectal malignancies. Increased expression 
of Epha2 in COX deficient colonic crypts could therefore have implications for 
carcinogenesis and increase the risk of metastasis, given the increased potential for cell 
migration. Overexpression of Epha2 has also been documented in patients with IBD and 
Crohn’s disease (Hafner, Meyer et al. 2005). Reln, associated with focal cell adhesions, 
was also significantly upregulated in COX deficient crypts. Expression of this gene is 
reported in the colon; however most of the literature is concerned with neuronal cell 
adhesion and migration. As such it is unclear whether upregulation of Reln could also 
affect cell migration in the colon.  Llgl1 was also overexpressed in COX deficient 
crypts, which is involved in cell polarity and maintaining epithelial cell integrity. The 
potential association of this gene with tumorigenesis is unclear given that the human 
homolog is downregulated in certain end-stage, progressive malignancies, but it is 
expressed in other cancers (Schimanski, Schmitz et al. 2005). Overexpression of this 
gene is, however associated with reduced formation of epithelial cell junctions and so 
overexpression could potentially contribute to enhanced cell migration in COX deficient 
crypts. Alternatively reduced formation of epithelial cell junctions, could also have 
implications for the development of IBD due to increased epithelial permeability 
(Hollander 1992; Mankertz and Schulzke 2007), as mentioned previously. 
Mus81 was also identified in KEGG pathways, which is a crossover junction 
endonuclease with a role in DNA damage responses. Downregulation of this gene in 
COX deficient colonic crypts could therefore have implications for DNA repair and 
enhance genome instability, which could have implications for early cell transformation 
during carcinogenesis. Interestingly an ABC transporter gene, Abcc4, was also 
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significantly upregulated in COX deficient colonic crypts. This is a multidrug resistance 
protein, known to suppress the action of certain anti-cancer drugs (Tian, Zhang et al. 
2005). Indeed the expression of Abcc4 has been reported in a number of cancer cell 
lines (Szakács, Annereau et al. 2004) and is associated with poor prognosis in certain 
malignancies (Steinbach, Lengemann et al. 2003; Norris, Smith et al. 2005). As such 
overexpression of this protein in COX deficient colonic crypts could hold implications 
for responses to anti-cancer therapies and contribute to enhanced tumour progression.  
4.4.1.3 Reactome Only 
Mapping of significant DE genes to Reactome pathways revealed a further 11 genes and 
cellular processes, not identified in Reactome due to reasons mentioned previously, that 
could also be affected by COX deficiency in colonic crypts Table 4-4).  
 
Table 4-4: Significant DE genes mapped to Reactome pathways alone.  
BH: Benjamini-Hochberg adjusted p value. FC: fold change.  
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Two of these, Faap100 and Terf2 are associated with DNA maintenance and repair and 
hold potential links with cancer development. Faap100 is a core component of the 
Fanconi anemia complex, involved in DNA repair, and this was significantly 
downregulated in COX deficient colonic crypts. Decreased expression of this gene is 
associated with a high frequency of mutations, chromosomal abnormalities and DNA 
cross-linking in cells (Ling, Ishiai et al. 2007). As such a downregulation of this gene in 
COX deficient crypts could suggest reduced DNA repair and enhanced genome 
instability, which could hold implications for cellular transformation. Terf2 is 
responsible for maintaining telomere length and is therefore thought to prevent 
activation of cell cycle checkpoints that lead to cell arrest and senescence (Takai, 
Smogorzewska et al. 2003), thus promoting cell proliferation and aberrant growth. 
Terf2 was significantly upregulated in COX deficient colonic crypts and elevated 
expression of Terf2 has been documented in a number of malignancies in epithelial 
tissues, including gastric carcinomas, where overexpression was associated with a 
reduced response to anti-cancer therapies (Matsutani N 2001; Cookson 2009). Terf2 
tends to be overexpressed during the invasive stage of carcinogenesis and is also 
associated with a reduced stimulation of natural killer (NK) cells that are involved in 
immune responses mounted against malignant cells (Biroccio A 2013). As such 
overexpression of Terf2 in COX deficient colonic crypts could prevent cell cycle arrest 
facilitating aberrant growth that could have a tumorigenic effect.  
DE genes associated with immune responses were also identified in Reactome 
pathways. Btla, a negative regulator of B and T lymphocytes, was downregulated in 
COX deficient crypts, potentially indicating that proliferation of B and T lymphocytes 
may be elevated in the gut, potentially leading to an overactive immune response. 
However, btla is proinflammatory when it is overexpressed, as it interacts with the 
HVEM receptor in the gut, which has been shown to play a role in IBD pathogenesis 
(Shui, Steinberg et al. 2011). Downregulation of btla is therefore unlikely to be 
associated with an inflammatory response in COX deficient colonic crypts. The 
downregulation of LyZ1 in COX deficient crypts was the largest downregulation in the 
whole dataset. LyZ1 encodes a lysozyme involved in the destruction of bacteria, and so 
reduced expression of this gene could suggest a decreased immune response against 
bacteria in the COX deficient crypts and potentially increase susceptibility to infection. 
Cadm1 also has a role in the immune response through the activation of NK cells, and is 
believed to be a tumour suppressor. Cadm1 was significantly downregulated in COX 
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deficient colonic crypts and this gene has been reported to be downregulated in a 
number of malignancies, predominantly those of epithelial origin, where it has been 
associated with metastasis and a poor prognosis (Nakahata and Morishita 2012). 
Similarly to Terf2, it could therefore be hypothesised that Downregulation of Cadm1 in 
COX deficient colonic crypts could enhance carcinogenesis by potentially suppressing 
an immune response against malignant cells. Most notably, however Cadm1 is known 
for its function in cell-cell adhesions and the organization of cell junctions. As such a 
downregulation of this gene may also affect cell organization and disrupt epithelial 
permeability, with possible implications for the pathogenesis of IBD (Hollander 1992; 
Mankertz and Schulzke 2007). 
Itgax and Pfn2 are two other genes that were differentially expressed in the COX 
deficient crypts and are associated with cell-cell interactions. Itgax is a dendritic cell 
receptor that was overexpressed in COX deficient crypts. Overexpression of this gene is 
associated with reduced cellular interactions and has been reported in certain 
malignancies (Venyo 2014) and as such one could hypothesise that it could be 
associated with enhanced cell migration and metastasis, due to disturbed cellular 
adhesion in COX deficient colonic crypts. Pfn2 suppresses epithelial cell migration, and 
as such the decreased expression in COX deficient crypts could again contribute to 
enhanced cell migration. This gene is predominantly associated with neuronal 
responses, however reduced expression has been reported in oral squamous cell 
carcinomas and was associated with worse disease progression (Ma, Zhang et al. 2011). 
Therefore whilst these cell-adhesion genes are associated with other cell types that are 
independent of colonic crypts, their abnormal expression has been associated with 
tumorigenesis in other tissues and could therefore indicate that such changes in COX 
deficient crypts could potentially be associated with tumour development. 
The transporter gene, Slc29a1, was also significantly upregulated in COX deficient 
colonic crypts compared to COX positive crypts. High expression of this nucleoside 
transporter has been associated with a low response to 5- fluorouracil, a common anti-
cancer treatment used in patients with colorectal cancer (Phua, Mal et al. 2013). As such 
it would appear that COX deficiency in colonic crypts could be associated with 
enhanced expression of transporters that convey resistance to anti-cancer therapies (see 
also Abcc4 above), which could have important implications for the progression of 
colorectal cancer. Finally of interest was the upregulated expression of Cyp41b in COX 
deficient colonic crypts. This enzyme is involved in fatty acid (β) oxidation, and as such 
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could suggest that COX deficient crypts are attempting to compensate for the 
dysfunctional respiratory chain by boosting processes that would increase the substrates 
available for OXPHOS and ATP production. 
4.4.2 Gene set enrichment analysis  
The gene expression profile of COX deficient colonic crypts was also compared to 
COX positive crypts using Gene Set Enrichment Analysis (GSEA) (Subramanian, 
Tamayo et al. 2005) to further identify the potential functional consequences that COX 
deficiency may have on colonic crypts. GSEA identifies pathways that contain a 
number of genes that were up or down regulated, that individually did not reach 
statistical significance, but in combination could affect the activity of that cellular 
process. Again given the difference in genes, their annotation and updates of the two 
biological software packages GSEA analysis was performed separately for both KEGG 
and Reactome, to identify potential differences that may occur in cellular processes in 
COX deficient colonic crypts. GSEA analysis of gene expression was measured on the 
basis of log2 fold-change, the unadjusted nominal p value (<0.05) and the false 
discovery rate (FDR) q value, which was used to correct for false positives, given the 
small sample sizes of only n=3 for the two populations. Again a pathway completeness 
criterion was applied, such that >50% of genes had to be expressed basally in a given 
pathway, and a pathway was required to contain a minimum of 15 genes and a 
maximum of 750 genes to further filter the results and identify those cellular processes 
that could be different in COX deficient colonic crypts compared to COX positive 
crypts. All pathways identified showed a combination of both up and down regulated 
genes, which were combined to give an average logFC for that pathway. Thus a broadly 
upregulated pathway would, and did contain genes that were downregulated, giving a 
fairly minimal average logFC, as seen in Table 4-5and Table 4-6.  
The GSEA analysis of pathways broadly affected in COX deficient colonic crypts gave 
complementary results to those genes and pathways identified with significant 
differential expression, showing potential alterations in pathways predominantly 
concerning: DNA maintenance and repair; cell adhesion; immune responses and energy 
metabolism.  
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4.4.2.1 GSEA analysis of Reactome pathways 
GSEA analysis with Reactome pathways revealed a general upregulation of genes in 8 
pathways and a general downregulation of genes in 9 pathways in COX deficient 
colonic crypts compared to COX positive crypts (Table 4-5).  
 
Table 4-5: Cellular pathways identified in Reactome that are broadly upregulated and broadly downregulated 
in COX deficient colonic crypts compared to COX positive. 
FDR q value: the adjusted p value. P way size: the number of genes that belong to the pathway, Nseen: the number of 
genes in the pathway that were expressed in the RNA sequencing dataset. 
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Reactome pathways in which DE genes were broadly upregulated, indicating that 
activity of these processes could be increased in COX deficient crypts, were principally 
involved in chromosome/telomere maintenance (Extension of telomeres, Telomere C 
strand synthesis and chromosome maintenance). Given that telomere shortening is a 
dominant trigger of replicative senescence and cell cycle arrest, it is well established 
that factors which maintain/ elongate telomeres play a fundamental role in aberrant cell 
growth, transformation and carcinogenesis (Meyerson, Counter et al. 1997; Cech 2004; 
Reddel 2014). As such the upregulation of these pathways acting to maintain 
chromosomes and telomeres in COX deficient crypts could indicate that growth arrest 
of damaged cells was suppressed, promoting aberrant cell growth and transformation. A 
number of genes involved in biological pathways concerning meiosis were also broadly 
upregulated in COX deficient crypts; however these are largely irrelevant in the colon, 
given that meiosis only occurs in germ cells. A broad upregulation in gluconeogenesis, 
the pathway responsible for metabolising non-carbohydrate carbon molecules into 
glucose, was also observed in COX deficient crypts. Gluconeogenesis predominately 
occurs in the liver; however it has been reported in the intestine (Mithieux, Rajas et al. 
2004). As glucose is the primary substrate for glycolysis, a potential increase in glucose 
production in COX deficient crypts could indicate a switch in energy metabolism from 
OXPHOS to glycolysis, which is a hallmark of malignant cells (Warburg 1930). 
Unsurprisingly pathways that were broadly downregulated in COX deficient crypts did 
indeed concern the respiratory electron transport chain and associated ATP production. 
This was to be expected given that these crypts show reduced/ absent activity of 
complex IV, suggesting a potential reduction in ATP production via OXPHOS. A 
number of pathways involved in immune responses, also negatively correlated with the 
COX deficient phenotype in crypts. Interferon gamma signalling and MHC class II 
presentation are important in the adaptive immune response, and as such a potential 
downregulation in their activity could indicate decreased mucosal immune responses to 
bacteria in COX deficient crypts. Interferon gamma signalling is also important for 
activation of NK cells, and downregulated activity of this pathway could therefore 
imply a reduction in NK cell responses (Gattoni, Parlato et al. 2006), which could have 
implications for immune responses against tumour cells (Moretta 1994).  
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4.4.2.2 GSEA analysis of KEGG pathways 
GSEA analysis with KEGG revealed 4 pathways that showed a general upregulation in 
gene expression and 13 pathways with a general downregulation in gene expression in 
COX deficient colonic crypts (Table 4-6).  
 
Table 4-6: Cellular pathways mapped to KEGG that are broadly upregulated and broadly downregulated in 
COX deficient colonic crypts compared to COX positive. 
 FDR q value: the adjusted p value.  P way size: the number of genes that belong to the pathway, Nseen: the number 
of genes in the pathway that were expressed in the RNA sequencing dataset. 
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Interestingly the broadly upregulated pathways in COX deficient colonic crypts were all 
involved in sugar metabolism, that function to produce glucose, the primary substrate 
for glycolysis, from the catabolism of complex sugars, amino acids and nucleotides. 
Fructose and mannose metabolism, which were upregulated in COX deficient crypts, 
can also directly feed into and drive glycolysis. As such a potential upregulation in 
activity of these pathways could suggest that COX deficient crypts show enhanced 
glycolysis, again indicating that there is switch in energy metabolism from OXPHOS to 
glycolysis, a well-established feature of malignant cells, which have a high glucose 
demand (Warburg 1930; Carew and Huang 2002). 
Broadly downregulated pathways in KEGG again revealed DE genes involved in 
OXPHOS, with a substantial number of DE genes in both Complexes I and IV of which 
many were downregulated, suggesting a possible decrease in activity of these 
complexes. All components of complex III were also differentially expressed and as 
such altered activity of these three complexes lends support to the fact that they 
associate to form respirasomes (Schägger and Pfeiffer 2000). The general 
downregulation of a number of genes involved in OXPHOS again supports a switch in 
energy metabolism from OXPHOS to glycolysis in COX deficient crypts, which may 
have a potential role in priming cells for early transformation and increasing sensitivity 
to carcinogenesis (Warburg 1930). 
A number of KEGG pathways containing DE genes that were negatively correlated with 
COX deficiency in colonic crypts were involved in specific disease development and 
are irrelevant in the colon, such as Leishmaniasis, Parkinson’s disease and Rheumatoid 
arthritis. However, a change in gene expression in these pathways could indicate a 
potential role for somatic mtDNA mutations and respiratory chain deficiency in the 
disease pathogenesis of these disorders. Pathways involving cell adhesion molecules 
again contained DE genes, which were broadly downregulated and included Cadm1 and 
Itgb7which are mentioned above. Downregulated expression of cell adhesion molecules 
could affect cell adhesion and epithelial permeability, lending support to a potential role 
in IBD pathogenesis (Hollander 1992; Mankertz and Schulzke 2007). Alternatively it 
could indicate that there would be disturbances in cellular organization that may 
encourage cell migration, playing a role in metastasis (Nakahata and Morishita 2012). 
Furthermore the intestinal production of IgA, a critical component of mucosal immunity 
(Peterson and Artis 2014) was also broadly downregulated in COX deficient crypts, 
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which could hold implications for the mucosal immune response and the epithelial 
barrier function in COX deficient crypts. 
Given that a number of biological pathways in KEGG are associated with disease 
processes, GSEA analysis using KEGG also revealed that a substantial number of genes 
were differentially expressed in pathways involved in cancer and colorectal cancer in 
COX deficient crypts compared to COX positive crypts. These pathways were not listed 
in the above tables due to filtering based on the absolute basal gene expression criterion 
used for GSEA analysis. Nevertheless such a high number of DE genes in these 
pathways is very interesting and indicates that they could be affected in COX deficient 
crypts, providing further evidence for a potential link between age-related respiratory 
chain deficiency in colonic crypts, a selective vulnerability to malignant transformation 
and a predisposition to cancer. 
4.5 Discussion 
Clonally expanded somatic mtDNA point mutations and respiratory chain deficiency 
have been reported in a number of ageing mitotic tissues (Taylor, Barron et al. 2003; 
McDonald, Greaves et al. 2008; Fellous, Islam et al. 2009; Gutierrez-Gonzalez, 
Deheragoda et al. 2009); however the effects of these mutations upon stem cell fate and 
function still remain to be elucidated. To begin to address this problem I employed 
RNA sequencing of COX deficient and COX positive colonic crypts from PolgA
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mice, previously shown to be a good model of age related mitochondrial dysfunction in 
the ageing human colon, (see Chapter 3 and (Baines, Stewart et al. 2014)) to examine 
the gene expression profiles and uncover any possible changes in cellular processes that 
might be associated with age-related respiratory chain deficiency. Given that no 
validation experiments were performed prior to the completion of this thesis it is 
important to emphasize that all changes in cellular processes and the potential disease 
associations discussed here are all based on hypotheses that simply highlight potentially 
interesting relationships. Preliminary data from the RNA sequencing results in this 
study indicated that COX deficient crypts show a differential gene expression profile, 
largely with respect to: the cell cycle, proliferation and differentiation; DNA 
maintenance and repair; immunity; cell adhesion and epithelial permeability and energy 
metabolism. Furthermore these observations indicated a potential association of age-
related COX deficiency in colonic crypts with tumorigenesis and a predisposition to 
colorectal cancer as well as the disease pathogenesis of IBD.  
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4.5.1 Potential implications for aberrant cell growth and tumorigenesis in colonic 
crypts 
It has been proposed that the clonal expansion of somatic mtDNA mutations in ageing 
human colonic crypts could contribute to genome instability and potentially prime stem 
cells for early transformation playing a role in cancer initiation and development 
(Taylor, Barron et al. 2003; Greaves, Preston et al. 2006). Preliminary results from this 
study suggested that age-related COX deficiency could be associated with cancer 
initiation and development in colonic crypts through potential changes in the cell cycle, 
proliferation, DNA repair and cell migration. The altered gene expression profile 
between COX deficient crypts and COX positive crypts revealed 5 potential 
mechanisms by which such changes could play a role in tumorigenesis:  
1. Enhanced progression through the cell cycle and aberrant cell proliferation by: 
increasing entry into the cell cycle (Pwp2); suppressing negative regulators of 
the cell cycle (Zbtb17) and enhancing genes/pathways that maintain DNA and 
telomeres (Ercc4, Ippk, Terf2 and upregulation of pathways concerning 
chromosome maintenance and the extension/synthesis of telomeres) that could 
enable cells to bypass cell cycle checkpoints and prevent cell cycle arrest, 
potentially leading to aberrant cell growth and the persistence of damaged cells.  
2. Reduced cell adhesion and enhanced cell migration, potentially promoting 
invasion and metastasis of malignant cells (Epha2, Pfn2, Llgl1 and 
downregulation in pathways concerning cell adhesion molecules).  
3. Genome instability and chromosomal aberrations (Espl1, Faap100 and Mus81). 
4. Increased expression of transporters associated with resistance to anticancer 
therapies (Abcc4 and Slc29a1). 
5. Switch in energy metabolism from OXPHOS to glycolysis (downregulated gene 
expression in the ETC and OXPHOS pathways and enhanced expression of 
genes involved in pathways that produce glucose that could enhance glycolysis). 
As such there are a number of potential mechanisms by which the differential gene 
expression profile of COX deficient colonic crypts could be associated with cancer 
initiation and development lending support to a potential association between age-
related mitochondrial dysfunction in colonic crypts, an increased vulnerability to 
malignant transformation and a predisposition to the development of age-related 
colorectal cancer (Taylor, Barron et al. 2003; Greaves, Preston et al. 2006). Indeed 
previous studies do support similar changes in gene expression associated with 
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mitochondrial respiratory chain defects as cells with mitochondrial dysfunction have 
been shown to harbour altered expression of genes that regulate cell cycle progression 
and growth (Crimi 2005; Cortopassi, Danielson et al. 2006; Compton, Kim et al. 2011) 
as well as the “cancer causing gene” c-Myc (Miceli and Jazwinski 2005; Cortopassi, 
Danielson et al. 2006). Alterations in genome stability have also been reported (Elstner 
and Turnbull 2012) and metabolic defects have been directly associated with COX 
deficiency in rat skeletal muscle fibers (Herbst, Johnson et al. 2013).  
The mechanism by which somatic mtDNA point mutations and respiratory chain 
deficiency could predispose to the development of cancer is unknown. However, a 
simple explanation could simply be the reduced OXPHOS capacity of respiratory chain 
deficient cells, which could promote a switch in energy metabolism and prime stem 
cells for early transformation contributing to tumour initiation and development 
(Warburg 1930). Alternatively it could be hypothesised that mitochondrial respiratory 
chain dysfunction could affect the sensitivity of cells to transformation by affecting 
pathways in which Ca
2+
 is a key signalling molecule i.e. pathways implicated in cancer 
in which Per2 and Fgf7 were downregulated. Calcium sequestration in mitochondria is 
dependent upon the negative mitochondrial membrane potential, maintained by the ETC 
and defects in the ETC have been shown to affect Ca
2+
 homeostasis, as seen in the 
TFAM knockout mouse with mitochondrial diabetes (Silva, Köhler et al. 2000). 
Alterations in Ca
2+
 homeostasis, caused by the defective respiratory chain in COX 
deficient crypts, could therefore affect the above signalling pathways, providing a 
potential link between COX deficiency and the alterations seen in pathways concerning 
cellular proliferation. 
An alternative hypothesis could be that somatic mtDNA point mutations may drive 
cellular changes that increase sensitivity to tumorigenesis through altering ROS 
production. Enhanced ROS production was observed in a human colorectal cancer cell 
line carrying a mtDNA point mutation, and this was shown to promote tumour 
development (Park, Sharma et al. 2009). Furthermore studies in the PolgA
mut/mut 
mouse 
have recently shown that mtDNA mutations are associated with an increase in ROS 
production with age (Logan, Shabalina et al. 2014) and studies in replicative tissues of 
these mice have shown that stem cell function is sensitive to slight changes in redox 
status (Ahlqvist, Hämäläinen et al. 2012). Moreover ROS are critical signalling 
molecules in stem cell proliferation and differentiation events (Hamanaka and Chandel 
2010; Shao, Li et al. 2011) and the accumulation of mtDNA mutations in the intestine 
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of PolgA
mut/mut  
has been directly associated with enhanced proliferation and cell growth 
 
(Fox, Magness et al. 2012). Microarray analysis of cells with mitochondrial dysfunction 
representative of that which occurs in mitochondrial disease, has also revealed gene 
expression changes in genes associated with ROS(Van der Westhuizen, Van den Heuvel 
et al. 2003). Thus it could be hypothesised that somatic mtDNA point mutations in 
colonic crypt stem cells could cause slight alterations is ROS production, affecting 
pathways involved in the cell cycle and proliferation, which could render stem cells 
more sensitive to early cell transformation and predispose to the development of age-
related colorectal cancer (Baines, Turnbull et al. 2014). 
Given that cell transformation and cancer initiation is dependent upon a number of 
cellular insults (Grizzi, Di Ieva et al. 2006) if mtDNA mutations do contribute to 
tumorigenesis it could be that mtDNA mutations are associated with cellular changes in 
colonic crypts through a combination of the above mechanisms. The differential gene 
expression analysis in this study revealed a potential association between age-related 
respiratory chain deficiency and events that are typical in early cell transformation as 
well as events involved in cancer development/ progression. However, whether or not 
somatic mtDNA point mutations are predominantly involved in the early development 
of colorectal cancer by priming stem cells for transformation or are more of a prognostic 
biomarker playing a role in cancer progression and response to anti-cancer therapies, 
still remains to be elucidated. Nevertheless this potential association remains a very 
interesting avenue of research to follow up on, for which validating changes in gene 
expression and any functional effect on protein expression will be crucial. 
4.5.2 Potential implications for epithelial permeability and the pathogenesis of 
inflammatory bowel disease in the colon 
An up and downregulation of cell adhesion genes (Itgb7, Pard6g, Epha2, Cadm1 and 
Llgl1 and cell adhesion molecule pathways) was also associated with COX deficiency 
in colonic crypts, with functional analysis suggesting that this could negatively impact 
upon cellular interactions, organization and the formation of epithelial tight junctions. A 
lack of tight junction formation, could increase epithelial permeability, which has in fact 
been proposed as an early event in the pathogenesis of IBD (Hollander 1992; Mankertz 
and Schulzke 2007).The formation and preservation of tight junctions is energy 
dependent, and so it would be unsurprising that respiratory chain deficient crypts, with a 
decreased capacity to produce ATP via OXPHOS, could show defects in tight junction 
formation and increased epithelial permeability (McKay 2005). It is therefore possible 
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that mitochondrial dysfunction, through alterations in epithelial permeability, could be 
associated with a predisposition to the development of IBD. Given that Ca
2+
 is a key 
signalling molecule involved in the formation of intercellular junctions, for example 
through Adcy1 signalling (KEGG pathways), it could also be hypothesised that 
respiratory chain deficiency could influence intercellular junctions and epithelial 
permeability through changes in Ca
2+ 
ion homeostasis due to disturbances in the 
mitochondrial membrane potential. Patients with ulcerative colitis, a form of IBD have 
been shown to harbour significantly more mtDNA point mutations than controls 
(Nishikawa, Oshitani et al. 2005) and histochemical analysis of colonic biopsies from 
patients with colitis has previously revealed clusters of respiratory chain deficient crypts 
(unpublished data from this lab), indicating a significant level of mitochondrial 
dysfunction in these patients.  As such age-related mitochondrial respiratory chain 
dysfunction could have implications for inflammatory problems and abnormal bowel 
movements in aged individuals.  
4.5.3 Potential implications for the immune response and sensitivity to bacterial 
infection in colonic crypts 
Differential gene expression concerning immune responses (LyZ1, Illrap, H2-DMb2, 
Itgb7, Cadm1, interferon signalling and intestinal production of IgA) appeared to be 
predominantly downregulated in COX deficient colonic crypts, suggesting that immune 
responses could have been diminished. This could be deemed surprising given the 
potential association between COX deficient crypts and the pathogenesis of IBD, as you 
would expect there to be an overactive immune response, given that inflammation is a 
hallmark of inflammatory bowel disease (Fiocchi 1998). Functional analysis implied 
that adaptive immune responses, particularly those against bacteria could be reduced, 
which could hold implications for sensitivity to bacterial infections in aged individuals. 
Ca
2+
 is a fundamental signalling molecule in the adaptive immune response and the 
activation of lymphocytes, especially T cells, which are highly sensitive to intracellular 
Ca
2+ 
levels (Cahalan and Chandy 2009). Therefore if mitochondrial respiratory chain 
dysfunction could affect the sequestration of Ca
2+
 ions and Ca
2+
 homeostasis this could 
affect signalling pathways involved in the adaptive immune response, providing a 
potential explanation for the changes observed in COX deficient colonic crypts. 
Interestingly a number of changes in COX deficient crypts were associated with 
decreased activation of NK cells, which hold an important role in immune defence 
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against malignant cells (Moretta 1994), again lending support to a potential association 
between mitochondrial dysfunction and a predisposition to colorectal cancer with age.  
Whilst a lot of interesting observations, that have important implications for disease 
processes, have come to light from the RNA sequencing of COX positive and COX 
deficient colonic crypts of PolgA
+/mut
 mice, all results discussed in this chapter are 
preliminary and hypothesis based. As such these results simply highlight potentially 
interesting changes and give initial insights into how somatic mtDNA point mutations 
and respiratory chain deficiency could affect cellular processes. Validation of 
differential gene expression via either real-time PCR to look at mRNA levels or 
immunohistochemistry/ immunofluorescence to look at protein expression, will 
therefore be vital to confirm gene expression changes, determine whether this has a 
functional effect on proteins and as such whether activity of a particular cellular process 
is likely to be affected. Furthermore at the time this thesis was completed successful 
RNA sequencing and bioinformatics analysis had only been completed on COX 
deficient and COX positive crypts from 3 PolgA
+/mut
 mice. Successful sequencing of the 
laser microdissected samples I collected from the other 2 PolgA
+/mut
 animals, which is 
currently underway, will be important to confirm whether the differences in gene 
expression observed are consistent across more samples, making the statistics more 
robust. This would also enable better selection of genes that should be targeted for 
validation experiments  
4.5.4 Future work 
Given that all results presented in this chapter were preliminary and all potential 
associations are based on hypotheses, validation experiments looking at mRNA and 
protein expression levels need to be performed to confirm changes in gene expression 
and that this elicits a functional effect in COX deficient colonic crypts. It would be 
particularly interesting to develop antibodies against several of the cell cycle and cell 
adhesion genes, with implications in carcinogenesis, and look at protein expression 
levels via immunohistochemistry/ immunofluorescence on PolgA
+/mut
 colon sections. 
This could be done for genes such as Per2, Espl1 and Pfn2, all of which showed a fairly 
high log2FC, and may be more likely to convey a significant difference in protein 
expression. Looking at expression of Per2 in combination with β-catenin and complex 
IV protein expression, could also prove very interesting, given that a depletion in Per2 
is thought to cause enhanced expression of β-catenin, driving tumorigenesis (Kelleher, 
Rao et al. 2014). Furthermore looking for changes in markers of nuclear DNA damage, 
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telomere length and senescence (Hewitt, Jurk et al. 2012) could also help uncover the 
potential relationship between somatic mtDNA mutations and other forms of molecular 
damage that occur with age. 
Whilst studies have indicated that the PolgA
+/mut
 is a good representative model of 
mitochondrial dysfunction in the ageing human colon ( see chapter 3 and (Baines, 
Stewart et al. 2014), and this study has provided useful insights into some potential 
functional effects that somatic mtDNA point mutations may have in ageing replicative 
tissues, ultimately similar experiments would want to be performed on ageing human 
colonic crypts. This would determine whether respiratory chain deficiency and somatic 
mtDNA point mutations do elicit similar functional effects in the two species and would 
help to determine whether mtDNA defects are causal in age-related tissue dysfunction 
and disease development.   
4.6 Conclusion 
In this study I have provided preliminary data suggesting that somatic mtDNA point 
mutations and age-related COX deficiency in colonic crypts could be associated with 
alterations in: the cell cycle and proliferation; DNA maintenance and repair; cell 
adhesion and tight junction formation; the adaptive immune response and energy 
metabolism. Such changes hold a number of potential implications and associations 
between mitochondrial respiratory chain dysfunction and the initiation and development 
of cancer as well as the pathogenesis of inflammatory bowel disease. The data suggests 
that age-related mitochondrial dysfunction could be associated with the development of 
age-related colorectal cancer, indicating that mtDNA defects may cause an alteration in 
colonic stem cell fate and function, through potentially priming stem cells for malignant 
transformation. Examining protein expression of a number of genes highlighted in this 
study will therefore be key to establish a suitable relationship between age-related COX 
deficiency, changes in the above cellular processes and the potential implications this 
may have for disease. Only then will we be able to determine the consequences of 
somatic mtDNA point mutations upon normal tissue homeostasis and begin to 
understand their potential contribution to stem cell ageing and disease development. 
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Chapter 5. Results: M.5024 C>T tRNAAla mutation: a candidate allele 
for modelling mitochondrial disease in mice. 
5.1 Introduction 
MtDNA diseases are an extremely heterogeneous group of disorders that present with a 
variety of different clinical symptoms and different ages of onset, even in patients with 
the same mutation and functional deficit (Jacobs 2003; McFarland, Taylor et al. 2007). 
Heteroplasmy and the threshold effect, clonal expansion, the genetic bottleneck, mitotic 
segregation and tissue specificity are just a few of the factors believed to influence the 
heterogeneity amongst patients (Taylor and Turnbull 2005); however the functional 
consequences of specific point mutations and the molecular mechanisms that govern 
disease diversity remain largely unknown. Understandably there is a keen interest to 
develop models of mitochondrial DNA disease to begin to uncover such molecular 
mechanisms.  
5.1.1 Models of mtDNA disease  
Experimental models of mtDNA disease have proved challenging to develop given the 
difficulty/inability to directly manipulate the mtDNA genome due to: the high copy 
number of mtDNA within a cell, its enclosure within double-membraned mitochondria 
and the negligible recombination that mtDNA experiences. 
Transmitochondrial cybrids, created through fusing rho
0
 cells that are depleted of 
mtDNA, with enucleated cytoplasts from patient cell lines containing a specific mtDNA 
mutation (King and Attardi 1989), have proved valuable tools for studying the 
relationship between specific mtDNA mutations and different nuclear backgrounds 
(Dunbar, Moonie et al. 1995), heteroplasmy and the consequences upon cellular 
function and physiology (Hayashi, Ohta et al. 1991; Chomyn, Martinuzzi et al. 1992). 
However, given that cybrids are developed from tumour cells it is unknown whether 
aneuploidy could affect mitochondrial function and the cellular transcriptome. 
Furthermore tumour cells are largely glycolytic and so any OXPHOS dysfunction 
caused by a mtDNA mutation is unlikely to precipitate the same functional effect in 
cybrids as would be encountered by patients (Swerdlow 2007). 
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Yeast models have also proved beneficial; given that it is possible to directly introduce 
mtDNA mutations into the mtDNA genome of Saccharomyces cerevisiae through 
biolistic transformation and homologous recombination (Bonnefoy and Fox 2001). The 
sequence and structure of certain mt-tRNAs is comparable between Saccharomyces 
cerevisiae and humans and as such yeast models have been valuable for studying the 
pathogenicity of certain mt-tRNAs mutations (De Luca, Besagni et al. 2006; Montanari, 
Besagni et al. 2008) and serious mitochondrial dysfunction. However, similarities 
between yeast and human mt-tRNAs are indeed limited to a select few and mutations in 
Saccharomyces cerevisiae are characteristically homoplasmic, preventing the study of 
heteroplasmy and the threshold effect, which are significant factors that influence the 
diverse genotype: phenotype relationship observed in patients.  
5.1.2 Mouse models of mtDNA disease  
Whilst the above model systems have been useful for studying the pathogenicity of 
certain mtDNA mutations and the influence of nuclear backgrounds, the ultimate model 
of mtDNA disease would indeed be a living mammalian model, that would display 
characteristic features of mtDNA disease (Taylor and Turnbull 2005). Given the rapid 
life cycle, simple breeding and homology between the human and mouse mtDNA 
genome (Bibb, Van Etten et al. 1981), it is unsurprising that there is keen interest to 
create mice that carry pathogenic mtDNA mutations to model disease. Not only would 
mouse models enable the study of specific disease mechanisms and pathogenesis 
associated with a specific mtDNA mutation but they would also potentially enable 
research into: mitotic segregation and tissue specificity; disease progression, by looking 
at multiple stages of their lifespan; the transmission and inheritance of pathogenic 
mtDNA mutations through multiple generations and the development of potential 
treatments, through various interventions and follow-up studies.   
Technologies that enable the direct recombinant modification of mouse mtDNA in a 
living animal model are however still very much lacking. As such, many studies have 
employed indirect methods to introduce mtDNA mutations into mouse models. Fruitful 
attempts have been achieved in creating mice that carry mtDNA deletions by using: a 
somatic mtDNA deletion that occurred in a cell line (Inoue, Nakada et al. 2000); 
manipulating nuclear encoded genes that caused the progressive accumulation of 
mtDNA deletions (Tyynismaa, Mjosund et al. 2005) and using mitochondrial targeted 
restriction endonucleases (Srivastava and Moraes 2005). Generating mice that carry 
mtDNA point mutations has however proved much more challenging. All successful 
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attempts have  focused on using mouse cell lines that carry naturally occurring 
pathogenic mtDNA point mutations, which have resulted in the successful transmission 
and creation of mice harbouring the following point mutations: mt-CO1 (T6589C), mt-
ND6-13885insC, mt-ND6-G13997A, mt-tRNA
Lys
 G7731A (Kasahara, Ishikawa et al. 
2006; Fan, Waymire et al. 2008; Yokota, Shitara et al. 2010; Lin, Sharpley et al. 2012; 
Shimizu, Mito et al. 2014). These mouse models are described in more detail in chapter 
1, section 1.5.3. 
The above mouse models provided useful insights into the pathogenesis and germline 
transmission of specific mtDNA point mutations, of which some did indeed display 
characteristic features of mtDNA disease. However, generating mice carrying mtDNA 
point mutations through donor cell lines is very restricted, as only a few cell lines are 
available that carry pathogenic mtDNA point mutations, of which very few are 
equivalent to pathogenic mutations that cause human disease. Moreover, maintaining 
stable heteroplasmic cell lines has proved difficult and we are still lacking 
heteroplasmic mouse lineages, with all, except one of the above model systems 
(Shimizu, Mito et al. 2014) generating homoplasmic mutant mice. Heteroplasmy, the 
threshold effect and mitotic segregation are significant factors believed to contribute to 
the heterogeneity observed in mtDNA disease patients that harbour the same mutation, 
and as such there remains the need to generate different mice that carry and transmit 
pathogenic heteroplasmic mtDNA point mutations, in order to improve our 
understanding of different mtDNA diseases.  
5.2 Breeding of mice harbouring specific mtDNA point mutations 
All breeding experiments and the propagation of mouse lineages was performed by 
James Stewart and Nils-Göran Larsson, Max Planck Institute for Biology of Ageing, 
Cologne, Germany. The original purpose of the PolgA
mut/mut
 mouse was to generate 
mice that accumulated mtDNA point mutations to high levels, so that specific mutations 
could then be isolated and segregated into different mouse lineages, thus creating mouse 
models of specific pathogenic mtDNA point mutations. As such female PolgA
mut/mut
 
mothers were employed in a breeding strategy to transmit heteroplasmic mtDNA point 
mutations into true-breeding female lineages of mice. This resulted in mouse lineages 
enriched for point mutations in tRNA and rRNA genes and a moderate number of 
amino acid substitutions in protein encoding genes, generating a profile of mutations 
comparable to those seen in human mtDNA disease (Stewart, Freyer et al. 2008). 
However, mouse lineages carried 16-20 mutations per mtDNA molecule (Freyer, Cree 
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et al. 2012), resulting in complications with attributing  phenotypes to a specific 
mutation, compounded by the synergistic action of multiple point mutations acting 
together. Given that PolgA
+/mut
 mice harbour only 1-3 mutations per mtDNA genome 
(Kraytsberg, Simon et al. 2009), female PolgA
+/mut
 mice were instead employed as the 
founders in the breeding strategy. Female PolgA
+/mut
 mice were backcross mated with 
pure wild-type (WT) male mice, to produce female progeny that expressed wild-type 
mtDNA polymerase, but transmitted mutated mtDNA (PolgA
+/+
 mice) (Figure 5-1). 
This resulted in the successful transmission of mtDNA point mutations to offspring, 
which were subsequently segregated into independent mouse lineages using the 
breeding strategy outlined in below (Figure 5-1).  
 
Figure 5-1: Germline mtDNA mutagenesis and breeding strategy using PolgA+/mut female mice to segregate 
specific mtDNA mutations into mouse lineages. 
MtDNA mutagenesis was initiated by mating C56Bl/6N female mice with PolgA+/mut males to generate PolgA+/mut 
females. Resulting PolgA+/mut females were backcross mated with C57Bl/6N male mice, to produce female progeny 
that expressed wild-type mtDNA polymerase, but transmitted mutated mtDNA (PolgA+/+ mice). Female progeny 
were subsequently mated with WT (PolgA+/+) male mice to propagate the mouse lineages and segregate specific 
mutations into specific mouse lineages. 
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5.3 Can dual COX/SDH histochemistry in the colonic epithelium be used as an 
early experimental screening tool for evidence of mitochondrial dysfunction 
and identifying potential pathogenic mtDNA point mutations in the breeding 
of mice harbouring specific mtDNA point mutations?   
MtDNA point mutations transmitted to offspring in the above mouse lineages were 
identified through a standard sequencing procedure, performed by James Stewart, Max 
Planck Institute for Biology of Ageing, Cologne, Germany. Whilst sequencing can be 
used to identify point mutations in the mouse lineages, the initial selection of mice 
chosen for sequencing was blind and random, and as such sequencing multiple mouse 
lineages became extensive and expensive, especially given that not all mice would 
harbour a mutation of interest.  There was therefore the need to develop an early, in vivo 
experimental screening tool in these animals that could be used to determine whether a 
point mutation caused any mitochondrial dysfunction and could be pathogenic. This 
would subsequently identify whether an mtDNA point mutation could serve as a 
candidate allele for modelling mtDNA disease and a specific mouse lineage was worth 
propagating.   
It is well established that pathogenic mtDNA point mutations result in reduced function 
of the mitochondrial respiratory chain and cells harbouring clonally expanded mtDNA 
mutations can be readily identified by dual COX/SDH histochemistry (Sciacco M 1994; 
Kaido, Fujimura et al. 1995). The colonic epithelium is proposed to be a permissive 
environment, given that mtDNA point mutations clonally expand to high levels in 
colonic crypts and result in focal respiratory chain deficiency, undergoing higher rates 
of clonal expansion than other tissues (Taylor, Barron et al. 2003; McDonald, Preston et 
al. 2006; Fellous, McDonald et al. 2009). Studies in mouse small intestinal stem cells 
suggest that mtDNA copy number is quite low (Barker, Van Es et al. 2007) and as such 
this is also believed to be true of the colonic epithelium. The threshold level for 
precipitating a biochemical defect and mitochondrial dysfunction could therefore be 
expected to be lower in the colon, given that there would be less WT mtDNA molecules 
able to maintain normal mitochondrial function. As such it was hypothesised that if an 
mtDNA point mutation was pathogenic, that COX deficiency and mitochondrial 
dysfunction would ensue much earlier in the colonic epithelium of these mice and could 
be used as an early experimental screening tool for identifying candidate pathogenic 
alleles in the breeding of mouse lineages.  
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Given that my research has involved a long standing collaboration with James Stewart 
and Nils-Göran Larsson, colon samples from 2 mice were provided from a potential 
mouse lineage to perform the COX/SDH histochemistry on colonic epithelial tissue. 
This revealed the presence of colonic crypts with both full and partial COX deficiency 
(Figure 5-2) providing early evidence of mitochondrial dysfunction and an indication 
that this specific mouse lineage may be carrying a pathogenic mt-tRNA point mutation 
and was worth propagating as an interesting mouse lineage. 
 
Figure 5-2: Dual COX/SDH histochemistry screen on colonic epithelium of a mouse lineage created via the 
PolgA+/mut breeding strategy.  
Colon sections showing a transverse section through the colonic crypts. Crypts stained brown are positive for COX 
activity, crypts stained blue are COX deficient (green arrows) and crypts with partial COX deficiency are a mixture 
(yellow arrow). 
5.3.1 Identification of a candidate allele and breeding of mice with a m.5024 C>T 
tRNA
Ala
 mutation 
Following the discovery of COX deficiency in the above colonic epithelium, whole 
mtDNA genome sequencing was performed on tail biopsies, previously collected from 
these mice, by James Stewart, to identify any mtDNA point mutations. This revealed a 
C>T mutation at position m.5024 of the mouse mtDNA genome in the tRNA
Ala
 gene, in 
a region associated with two alleles that cause human mitochondrial disease (Finnilä, 
Tuisku et al. 2001; Swalwell, Deschauer et al. 2006; McFarland, Swalwell et al. 2008). 
Both the m.5650G>A and m.5591G>A mutations in human tRNA
Ala
 are associated with 
pure mitochondrial myopathies, where patients displayed profound muscle phenotypes, 
a combined respiratory chain defect and high levels of COX deficiency in muscle 
biopsies, with which the mutation segregated (Swalwell, Deschauer et al. 2006; 
McFarland, Swalwell et al. 2008). The m.5024C>T mutation is in fact on the opposite 
side of the amino acid stem to the human m.5650G > A tRNA
Ala
 allele, disrupting the 
same base pair within the acceptor stem of the tRNA (Figure 5-3) (Finnilä, Tuisku et al. 
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2001; McFarland, Swalwell et al. 2008). The m.5024 C>T mutation was therefore 
identified as a candidate allele to potentially model mtDNA disease in mice and this 
mouse lineage was propagated, with stable transmission of the m.5024C>T mutation 
achieved after the 6
th
 generation. Earlier generations still transmitted the allele, however 
they also harboured additional mtDNA variants, which had been transmitted from the 
founder PolgA
+/mut
 mother and the PolgA
+/+
 mothers. Standard tail biopsies were taken 
from mice at weaning (3 weeks old) to measure the m.5024 C>T heteroplasmy in each 
animal by RFLP, completed by James Stewart. This mouse lineage is currently 
producing the 14
th
 backcross generation and will be referred to from now on as tRNA
Ala
 
mutant mice. 
 
 
Figure 5-3: Clover leaf structure of the human and mouse mt-tRNAAla.  
Mutations are displayed on the tRNA as the mutation in the DNA sequence. The m.5591G>A and the m.5650G>A 
mutations are indicated on the human tRNAAla, with the m.5024C>T mutation indicated on the mouse tRNAAla. The 
m.5024C>T mutation is on the opposite side of the amino acid stem to the human m.5650G>A mutation in the 
tRNAAla gene disrupting the same base pair. Image (adapted) courtesy of James Stewart. 
5.3.2 Early molecular characterisation of m.5024C>T tRNAAla mutant mice 
All initial experiments examining young mutant tRNA
Ala 
mice (<22 weeks old) were 
engineered around breeding, transmission of the allele and molecular characterization of 
the tRNA defect, all of which were performed by James Stewart. RFLP analysis of the 
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heteroplasmy in tail clippings revealed an apparent threshold level for transmission of 
the mutation, with an absence of any pups generated exceeding 77% m.5024 C>T 
(Figure 5-4a). Characterization studies revealed a defect in the tRNA in young mice 
with high m.5024 C>T heteroplasmy (>60%), which displayed decreased steady levels 
of tRNA
Ala
 and decreased in organello translation of mitochondrial proteins in heart 
mitochondria (Figure 5-4back).  
 
Figure 5-4: Molecular characterization of young tRNAAla mutant mice. 
(a) Transmission of the m.5024C>T mutation from mother to offspring demonstrates non-random transmission of the 
m.5024TC>T allele and an apparent threshold of 77% in offspring. (B) Northern blots reveal reduced steady state 
levels of tRNAAla in skeletal muscle in m.5024C>T tRNAAla mutant mice. (c) In organello translation in heart 
mitochondria for mitochondrial proteins: ND5, COXI, ND4, CytB, ND2, ND1, COXIII, COXII, ATP6, ND6, 
ND3and ATP8/ND4L, showing decreased efficiency and truncated protein products in mice with high levels of the 
mutation (>60% ). Figures provided by James Stewart. 
This data therefore suggested that the m.5024 C>T mutation was associated with a 
defect in the tRNA and a disruption in protein translation in the tRNA
Ala
 mutant mice; 
however evidence of phenotypic mitochondrial dysfunction and information regarding 
the pathogenicity of the mutation still remained to be elucidated.  
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5.4 Aims of the study 
1. Perform detailed characterisation of the in vivo mitochondrial dysfunction 
observed in the colonic epithelium of young m.5024 C>T tRNA
Ala
 mutant mice. 
I aimed to use mtDNA genome analysis of m.5024 C>T heteroplasmy in single 
colonic crypts to determine the pathogenicity of the mutation and whether or not 
it segregated with the COX deficiency in the colonic epithelium. This would 
further confirm whether dual COX/SDH histochemistry in the colonic 
epithelium is a good early experimental screening tool for detecting in vivo 
mitochondrial dysfunction and identifying pathogenic mtDNA point mutations 
in mouse lineages that harbour point mutations.   
2. Determine whether m.5024 C>T tRNAAla mutant mice are a good model of 
mtDNA disease caused by an mt-tRNA point mutation and could be used to 
uncover disease mechanisms associated with a heteroplasmic point mutation, 
using classical histochemical approaches?   
5.5 Results 
5.5.1 Do young tRNAAla mutant mice routinely display phenotypic evidence of 
mitochondrial dysfunction in the colonic epithelium? 
All m.5024 C>T tRNA
Ala
 mutant mice were sacrificed and tissue samples provided by 
James Stewart, Max Planck Institute for Biology of Ageing, Cologne, Germany. Colon 
sections (10μm) from 23 mutant tRNAAla mice (16 of which were <22 weeks old and 
surpassed the 6
th
 breeding generation) with variable m.5024 C>T tail heteroplasmy (see 
Appendix A), were subjected to dual COX/SDH histochemistry. Approximately ~500 
colonic crypts, in both transverse and longitudinal tissue sections, were assessed for 
COX activity per sample, to characterise the level of respiratory chain deficiency and 
phenotypic mitochondrial dysfunction in mice harbouring the m.5024 C>T mutation. 
Colonic crypts were identified that displayed both full and partial COX deficiency 
(Figure 5-5), with partial COX deficiency detected in all mutant tRNA
Ala
 mice, even 
those with a fairly moderate level of the mutation, ~30% (see Appendix D).  
In the first part of this study all animals beyond the 6
th
 generation (where stable, strong 
transmission of the allele was achieved) were <22 weeks old (young mutants), as the 
initial aim was to identify early evidence of phenotypic mitochondrial dysfunction in 
mice harbouring the m.5024C>T tRNA
Ala
 mutation. For young mutant tRNA
Ala
 mice 
the incidence of full and partial COX deficient crypts were combined and compared to 
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the m.5024 C>T tail heteroplasmy, to determine whether the incidence of COX 
deficiency was associated with the m.5024C>T tail heteroplasmy in animals. Higher 
levels of COX deficiency (~17%) were observed in mutant tRNA
Ala
 mice with higher 
tail heteroplasmy (>60%) compared to those with moderate to low-level heteroplasmy 
(COX deficiency =<9%) (p= <0.0001, one way ANOVA) (Figure 5-6), confirming that 
levels m.5024 C>T tail heteroplasmy did correlate with the magnitude of COX 
deficiency detected in the colonic epithelium. 
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Figure 5-5: Respiratory chain deficiency in colonic epithelial tissue of young m.5024C>T tRNAAla mutant mice. 
COX/SDH histochemistry on (a) + (b) Mouse 1623 (m.5024C>T75%) colon tissue, at x10 and x20 magnification 
respectively (c+d) Mouse 2267 (m.5024C>T77%) colon tissue, at x20 magnification. (e)+ (f) Mouse 1184 
(m.5024C>T59%) colon tissue, at x10 and x20 magnification respectively. Scale bars: 100μm. COX positive crypts 
are brown (red arrow), COX deficient crypts are blue (green arrow) and crypts with partial COX deficiency are a mix 
of blue and brown (yellow arrow). 
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Figure 5-6: The magnitude of COX deficiency in the colon correlates with m.5024C>T tail heteroplasmy in 
young tRNAAla mutant mice. 
The percentage of colonic crypts that lacked normal COX activity (COX deficient crypts + crypts with partial COX 
deficiency) was significantly higher in those mutant mice that possessed high m.5024C>T heteroplasmy in the tail, 
>60% (17.6 ±1.668), than animals with moderate, 50-60% (9.167±2.120) and low level heteroplasmy, <20% (0.400 
±0.400), p= <0.0001, one way ANOVA. 
Given that pure WT littermates cannot be generated from the same PolgA
+/+ 
 mother 
that transmits the m.5024 C>T mutation to her offspring, young animals with low levels 
of the mutation (<25%) were used as controls. Dual COX/SDH histochemsitry was 
completed on colon sections (10μm) from 6 low-level control animals (<22 weeks) and 
a negative control animal (TN139) carrying 16 known polymorphic variants in mtDNA 
(see Appendix A). All colonic crypts displayed normal COX activity, in all 6 low level 
control animals and the negative control (Figure 5-7). A lack of COX deficiency 
associated with any of the 16 alleles in animal TN139, further supported that the 
m.5024 C>T mutation was associated with phenotypic mitochondrial dysfunction in the 
colon and suggested that this mutation could be pathogenic. 
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Figure 5-7: Normal COX activity in colonic epithelial tissue of young control mice. 
COX/SDH histochemistry on (a) + (b) Mouse TN139 colon tissue, at x10 magnification. (b) Mouse 2430 
(m.5024C>T24%) colon tissue, at x20 magnification. (c) Mouse 2432 (m.5024C>T13%) colon tissue, at x20 
magnification. (d) Mouse 2489 (m.5025C>T7%) colon tissue at x20 magnification. Scale bars: 100μm.   
5.5.2  Is the m.5024C>T mutation pathogenic? Segregation of the m.5024C>T 
mutation with COX deficiency in colonic crypts of young mutant tRNA
Ala
 
mice. 
To determine whether a mtDNA mutation is pathogenic, standard criteria states that the 
mutation  has to segregate with the biochemical defect (DiMauro and Schon 2001) and 
the examination of single cells is considered to be the ‘gold-standard’ for determining 
pathogenicity of an mt-tRNA mutation (McFarland, Elson et al. 2004; Yarham, Al-
Dosary et al. 2011). MtDNA genome analysis was therefore performed on single micro-
dissected COX positive and COX deficient colonic crypts for the detection of the 
m.5024C>T mutation and correlation with the COX deficient phenotype.  
5.5.2.1 MtDNA genome analysis for the m.5024C>T mutation by Sanger sequencing 
Initial detection of the mutation involved mtDNA genome sequencing of a ~1.3kb 
region spanning the m.5024 site of the genome in COX positive (n=7) and COX 
151 
 
deficient (n=7) colonic crypts from two mice with moderate tail heteroplasmy from 
early breeding generations, <6th (471 and 472- see Appendix A) and two young (>6
th 
breeding generation) tRNA
Ala
 mutant mice with high tail heteroplasmy (1622 and 1623-
see Appendix A). The mtDNA sequence for each colonic crypt was aligned to the 
C57Bl/6J mouse reference sequence (GenBank Accession number NC_005089) and the 
consensus DNA sequence from homogenate colon tissue for a WT mouse. 
Heteroplasmy levels were estimated based upon the relative peak height of 
electropherograms. 
The m.5024C>T mutation was detected in the heteroplasmic state in all COX positive 
and COX deficient colonic crypts, confirming the presence of the mutation in single 
colonic crypts (Figure 5-8). Sequencing electropherograms, most notably from animals 
1622 and 1623, revealed an apparent segregation of the mutation with COX deficiency, 
with the m.5024C>T mutation presenting at high heteroplasmy (>75%) in COX 
deficient crypts and low heteroplasmy (<50%) in COX positive colonic crypts (Figure 
5-8e-h). M.5024C>T heteroplasmy did not appear to segregate with the COX deficiency 
in colonic crypts sequenced from animal 471, with COX deficient crypts recurrently 
displaying low heteroplasmy.  
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Figure 5-8: Sequencing electropherograms illustrating the presence of the m.5024C>T mutation in COX 
positive and deficient colonic crypts from mutant tRNAAla mice. 
(a+b) Electropherograms showing the m.5024 region of the mtDNA genome from WT mouse DNA in the forward 
and reverse directions respectively, showing the presence of the WT C base. Sequencing of this region in a (c) COX 
positive crypt from mouse 472 (m.5024C>T18%) revealed the presence of the WT C base and (d) in a COX deficient 
crypt revealed the presence of the m.5024C>T mutation, ~80% heteroplasmy. Sequencing of this region in a (e) COX 
positive crypt from mouse 1622 (m.5024C>T74%) revealed a heteroplasmic C>T change (~50%) at position m.5024 
and (f) in a COX deficient crypt revealed high heteroplasmy, ~80%. (g) Sequencing of this region in a COX positive 
crypt from mouse 1623 (m.5024C>T75%) revealed a heteroplasmic C>T change (~25%) at position m.5024 and (h) 
in a COX deficient crypt revealed high heteroplasmy, ~80%. The stars indicate the m.5024 position and the C>T base 
change in the mouse mtDNA sequence. 
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5.5.2.2 Quantification of the m.5024C>T mutation by pyrosequencing 
Sanger sequencing is principally used for the detection of mtDNA point mutations and 
is not an accurate and precise method of mutation quantification. Pyrosequencing is a 
sequencing by synthesis method that can be used to give an exact measure of 
heteroplasmy by quantifying the amount of light emitted when a nucleotide is 
incorporated into the growing DNA strand. As such, PyroMark assay design software 
v2.0 (Qiagen, Hilden, Germany) was used to design a m.5024C>T mutation specific 
assay and a trio of pyrosequencing primers in the reverse direction, for the accurate 
quantification of the m.5024 C>T mutation (see chapter 2, section 2.6.9). 
Pyrosequencing was performed on laser mico-dissected single COX positive (n=15) and 
COX deficient colonic (n=15) crypts, from the two animals with moderate tail 
heteroplasmy (471 and 472-see Appendix A) and four young animals (>6
th
 generation) 
with high tail heteroplasmy (1622, 1623, 2267 and 2269- see Appendix A) to determine 
whether the m.5024 C>T mutation segregated with the COX deficiency in the colon and 
fulfilled the standard pathogenicity criteria. A WT DNA sample (m.5024C>T <2%) and 
a cloned fragment (m.5024C>T >98%) were employed in pyrosequencing runs as 
controls. All pyrosequencing was performed in triplicate and an average mutation load 
calculated for each sample. 
Pyrosequencing revealed that the highest level of the m.5024C>T mutation segregated 
with the COX deficiency in colonic crypts from all mutant tRNA
Ala
 mice (p value= 
<0.0001, one way ANOVA), with COX deficient crypts displaying higher heteroplasmy 
(57.93 ± 2.814) than COX positive colonic crypts (43.39 ± 1.705) (p= <0.0001, 
unpaired t test). The young mutant tRNA
Ala
 mice with higher m.5024 C>T 
heteroplasmy (1622, 1623, 2267 and 2269) displayed a much clearer segregation of the 
m.5024 C>T mutation with the COX deficiency, with an absence of any segregation 
observed in animal 471, where COX deficient crypts actually displayed lower 
heteroplasmy  (18.0 ± 18.0%) than COX positive crypts (35.7 ± 20.5%). Mice 471 and 
472 were the original animals that underwent COX/SDH screening in this mouse 
lineage (Figure 5-2) and were from the very early breeding generations, in which the 
PolgA
+/+
 mother transmitting the m.5024 C>T mutation was also known to transmit 
other mtDNA alleles to her offspring (James Stewart, personal communication). Given 
that other mtDNA alleles could also have led to the COX deficiency and mutation 
segregation in the early breeding generations, animals 471 and 472 were excluded from 
the statistical analysis. This revealed a much clearer segregation of the m.5024C>T 
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mutation with COX deficiency in all young m.5024C>T tRNA
Ala
 mutant mice (p = 
<0.0001, one way ANOVA) (Figure 5-9a), with COX deficient colonic crypts 
displaying significantly higher m.5024 C>T heteroplasmy (71.18 ± 1.647) than COX 
positive colonic crypts (47.22 ± 1.614) (p= <0.0001, unpaired t test) (Figure 5-9b). A 
two way ANOVA test confirmed that COX activity significantly affected the m.5024 
C>T heteroplasmy in colonic crypts (p=<0.0001), accounting for 39% of the variance in 
heteroplasmy; however variation between mice had no significant effect (p = 0.3093), 
accounting for only 1.36% variance (Figure 5-9c). This data provided evidence that the 
m.5024C>T mutation was pathogenic and could therefore serve as a candidate allele for 
modelling mitochondrial disease caused by mt-tRNA mutations in mice. From here 
onwards all mutant tRNA
Ala
 mice studied exceeded the 6
th
 generation, where there was 
a lack of transmission of other mtDNA variants from mothers to offspring. 
 
 
 
 
 
155 
 
 
Figure 5-9: Pathogenicity and segregation of the m.5024C>T mutation with COX deficiency in single colonic 
crypts from young tRNAAla mutant mice. 
M.5024C>T heteroplasmy in single COX positive and COX deficient colonic crypts from young tRNAAla mutant 
mice, excluding mice 471 and 472. M.5024C>T heteroplasmy is significantly higher in COX deficient colonic crypts 
of all mice compared to COX positive crypts (p= <0.0001, one way ANOVA test). (b) M.5024C>T heteroplasmy in 
all COX negative (71.18 ± 1.647 N=72) and positive crypts (47.22 ± 1.614 N=83) (p= <0.0001, unpaired t test). (c) 
The effect of COX activity and mouse variability on the m.5024C>T heteroplasmy in single colonic crypts. COX 
activity significantly affected the m.5024C>T heteroplasmy in single colonic crypts (p= <0.0001) but variability 
between mice had no significant effect (p= 0.3093), two way ANOVA test. 
Pyrosequencing was also performed on single COX positive colonic crypts (n=>10) 
from three low level control animals (2431, 2432 and 2489), to confirm that the m.5024 
C>T mutation was present at higher levels in the colonic crypts of tRNA
Ala
 mutant mice 
compared to controls (Figure 5-10a). This revealed that m.5024 C>T heteroplasmy was 
significantly lower in COX positive colonic crypts from control animals (10.82 ± 1.396) 
than COX positive colonic crypts from tRNA
Ala
 mutant animals (47.22 ±1.614), (p= 
<0.0001, unpaired t test) (Figure 5-10b). 
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Figure 5-10: M.5024C>T heteroplasmy in single colonic crypts from young control animals.  
(a) M.5024C>T heteroplasmy in single COX positive colonic crypts from low level control mice, 
2431(m.5024C>T7%), 2432(m.5024C>T 13%) and 2489 (m.5024C>T 7%). (b) M.5024C>T heteroplasmy in COX 
positive colonic crypts from control animals (10.82 ± 1.396)  is significantly lower than COX positive colonic crypts 
from tRNAAla mutant animals (47.22 ±1.614), (p= <0.0001, unpaired t test).  
5.5.3 Is there evidence of respiratory chain deficiency in post-mitotic tissues of 
young m.5024C>T tRNA
Ala
 mutant mice? 
Given that the m.5024C>T mutation was shown to be pathogenic I then wanted to 
determine whether the mutant tRNA
Ala
 mice displayed signs of mitochondrial 
dysfunction and tissue phenotypes that typically present in patients affected by mtDNA 
disease. Cardiomyopathy and muscle myopathy are typical symptoms that present in 
mitochondrial disease patients with mt-tRNA point mutations, with heart and muscle 
biopsies frequently showing high levels of COX deficiency (Taniike, Fukushima et al. 
1992; Taylor, Giordano et al. 2003; Swalwell, Deschauer et al. 2006; McFarland, 
Swalwell et al. 2008). I therefore performed dual COX/SDH histochemistry on heart 
(8μm) and skeletal muscle (thigh and/or calf) (10μm) tissue supplied from young (<22 
weeks) mutant tRNA
Ala
 mice (n=8) and young (<22 weeks) low level control animals 
(n=6) to determine whether the mutant tRNA
Ala
 mice displayed typical signs of disease 
associated with an mt-tRNA mutation. 
All low level control animals displayed normal COX activity in heart tissue (Figure 
5-11a+b) and only 2 of the 8 young mutant tRNA
Ala
 mice displayed evidence of COX 
deficient heart fibers, reaching 2% in animal 1734 (Figure 5-11c+d) and 12% in animal 
2307 (Figure 5-11e+f). All other mutant tRNA
Ala
 mice maintained normal COX activity 
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throughout the heart tissue, even those with the highest tail heteroplasmy (Figure 
5-11g+h). It is worth noting at this point that animal 2307 had to be culled due to ill 
health at 12 weeks old and so additional complications or defects may have also led to 
the respiratory chain deficiency, accounting for the high incidence here.  
Similarly in the skeletal muscle, all low level control animals displayed normal COX 
activity in the thigh and calf muscle (Figure 5-12a+b) and only 2 mutant tRNA
Ala
 (1764 
and 2266), displayed evidence of COX deficient fibers in the thigh (Figure 5-12c-f), of 
which only a few were detected, amounting to 0.4% across the whole tissue section. 
Again, normal COX activity was preserved in the thigh and calf muscle of young 
mutant tRNA
Ala
 mice with the highest m.5024 C>T tail heteroplasmy (Figure 5-12g+h).  
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Figure 5-11: COX/SDH histochemistry on heart tissue from control and mutant m.5024C>T tRNAAla mutant 
mice. 
COX/SDH histochemistry on: (a) Control mouse 2431 (m.5024C>T7%) heart tissue at x10 magnification. (b) Control 
mouse 2432 (m.5024C>T13%) heart tissue at x20 magnification. (c)+ (d) Mouse 1734 (m.5024C>T60%) heart tissue, 
at x10 and x20 magnification respectively (e)+ (f) Mouse 2307 (m.5024C>T 51%) heart tissue, at x10 and x20 
magnification respectively. (g) Mouse 2267 (m.5024C>T77%) heart tissue at x20 magnification. (h) Mouse (2269 
m.5024C>T74%) heart tissue at x10 magnification. Scale bars: 100μm. COX positive heart muscle fibers are brown 
and COX deficient fibers appear blue (green arrows). 
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Figure 5-12: COX/SDH histochemistry on skeletal muscle from control and m.5024C>T tRNAAla mutant mice.  
COX/SDH histochemistry on: (a)+ (b) Control mouse 2431 (m.5024C>T7%) calf and thigh muscle at x10 and x20 
magnification. (c)+ (d) Mouse 1764 (m.5024C>T66%) thigh muscle at x10 and x20 magnification. (e)+ (f) Mouse 
2266 (m.5024C>T53%) thigh muscle, at x10 and x20 magnification respectively. (g)+ (h) Mouse 2269 
(m.5024C>T74%) calf and thigh muscle, at x10 and x20 magnification respectively. Scale bars: 100μm. COX 
positive fibers are brown, COX deficient fibers are blue (green arrows) and fibers with intermediate COX deficiency 
are purple (yellow arrows). 
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5.5.4 Does mitotic segregation affect m.5024C>T heteroplasmy across different 
tissues of young tRNA
Ala
 mutant mice? 
Mitotic segregation of mtDNA results in considerable variation in heteroplasmy 
between different tissues and even different cell lineages of the same tissue (Macmillan, 
Lach et al. 1993), and is a principal factor involved in disease heterogeneity (Taylor and 
Turnbull 2005). To determine whether mitotic segregation influenced the m.5024 C>T 
heteroplasmy in different tissues of the mutant tRNA
Ala
 mice, and whether this may 
explain the different respiratory chain phenotypes observed, pyrosequencing was 
performed on homogenate DNA taken from the heart, thigh, calf and colon tissue 
supplied for young mutant tRNA
Ala
 mice (n=8). Note that all four tissues were not 
always supplied for each animal, with animals 1734 and 1764 lacking calf muscle and 
1764 lacking a heart sample. Tail heteroplasmy was also taken into account, as recorded 
for each animal by RFLP, by James Stewart.  
M.5024C>T heteroplasmy was not significantly different across the different tissues 
from young tRNA
Ala
 mutant mice (p= 0.1971, One way ANOVA) (Figure 5-13a); 
however heteroplasmy in the colon was slightly lower compared to the other tissues, 
(p=0.0180, unpaired t test). This does however comply with the ~7% variation seen 
across multiple different tissues, including the blood and the skin, where even ~4% 
variation is seen in different skin patches (James Stewart, Personal communication).  
Nevertheless there was no segregation of the m.5024C>T mutation towards higher 
heteroplasmy in those tissues in which COX deficiency was observed (heart and 
skeletal muscle). Pyrosequencing of homogenate DNA from the different tissues from 
low level control animals also confirmed no significant difference in heteroplasmy 
across the tissues (p= 0.2835, One way ANOVA) (Figure 5-13b). 
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Figure 5-13: M.5024C>T heteroplasmy in different tissues of young mutant tRNAAla and control mice.  
M.5024C>T heteroplasmy recorded in whole tissue from tail clippings, colon, heart, calf and thigh in (a) Young 
mutant tRNAAla mice 2307, 1734, 1764, 2265, 2266, 2267, 2268 and 2269. The m.5024C>T heteroplasmy was not 
significantly different across different tissues of mutant animals (p= 0.1971, One way ANOVA). (b) Young low level 
control animals 2191, 2192, 2430, 2431, 2432 and 2489. The m.5024C>T heteroplasmy was not significantly 
different across different tissues of control animals (p= 0.2835, One way ANOVA).  
5.5.5 Do aged m.5024C>T tRNAAla mutant mice show evidence of enhanced 
mitochondrial dysfunction and a progressive mtDNA disease phenotype?  
Prior to this point, mutant tRNA
Ala
 mice (>6
th
 generation) were all young (<22 weeks 
old). MtDNA disease in humans can present at a variety of different ages of onset, with 
a substantial number of patients showing an absence of clinical phenotypes until 
adulthood (McFarland, Taylor et al. 2007). To determine whether aged animals 
displayed enhanced mitochondrial dysfunction and tissue phenotypes characteristic of 
human mitochondrial disease caused by an mt-tRNA mutation, m.5024 C>T tRNA
Ala
 
mutant mice were aged to >65 weeks old.  
5.5.5.1 Respiratory chain deficiency in mitotic and post-mitotic tissues of aged tRNAAla 
mutant mice 
Dual COX/SDH histochemistry was performed on colon (10μm) samples from 65 week 
(n=7) and 70 week (n=3) old mutant tRNA
Ala
 mice. Fully COX deficient colonic crypts 
were rarely detected in aged animals (see Appendix D); however a substantial 
proportion of colonic crypts with partial COX deficiency (mix of blue and brown) were 
detected in all aged mice (Figure 5-14). The presence of partial COX deficient crypts 
indicates that only a few stem cells in a given crypt harbour high levels of the mutation 
and give rise to COX deficient progeny cells (the blue parts) and other stem cells carry 
low levels of the mutation and repopulate the majority of the crypt with progeny cells 
that have normal COX activity (Taylor, Barron et al. 2003). When the incidence of fully 
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and partial COX deficient colonic crypts was combined and compared to the m.5024 
C>T tail heteroplasmy for each animal, there was an absence of correlation between the 
two (p= 0.2752, one way ANOVA) (Figure 5-15). In fact the two appeared to be more 
negatively correlated, with the highest percentage of combined COX deficiency 
detected at 50% (47% partial COX deficiency) in animal 2885 with the lowest m.5024 
C>T tail heteroplasmy (26%) and animals with high tail heteroplasmy (m.5024 C>T, 
>60%) showing the lowest incidence of COX deficiency (23% partial COX deficiency). 
This could suggest that colonic crypts are being repopulated predominantly by stem 
cells with lower levels of the mutation, especially in the high heteroplasmy mutant 
mice, raising the possibility that high levels of the m.5024C>T mutation could be 
selected against at the level of colonic crypt stem cells. 
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Figure 5-14: Respiratory chain deficiency in the colonic epithelium of 65 and 70 week old m.5024C>T tRNAAla 
mutant mice.  
COX/SDH histochemistry on mouse: (a) 2241, 65 weeks old (m.5024C>T68%) (b) 2200, 65 weeks old 
(m.5024C>T58%) (c) +(d) 2884, 70 weeks old (m.5024C>T66%) (e) 2885, 70 weeks old (m.5024C>T26%). (e) 
2887, 70 weeks old (m.5024C>T51%.) All images were taken at x20 magnification. Scale bars: 100μm. COX 
positive crypts are brown, COX deficient crypts appear blue (green arrow) and those with partial COX deficiency are 
a mixture of brown and blue (yellow arrow). 
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Figure 5-15: Absence of correlation between the magnitude of COX deficiency in the colon and the 
m.5024C>T tail heteroplasmy in aged (65 and 70 week old) mutant tRNAAla mice.  
The percentage of colonic crypts that lacked normal COX activity (COX deficient crypts + crypts with partial COX 
deficiency) was not significantly different in mutant mice with high m.5024C>T tail heteroplasmy >60% 
(12.60±3.750), than those with moderate levels of the mutation, 50-60% (17.25±5.764) or the one animal with a low 
level of the mutation (50%), p= 0.2752, one way ANOVA. 
Interestingly dual COX/SDH histochemistry on colon tissue from the aged mutant 
tRNA
Ala
 mice revealed the presence of COX deficient fibers in the colonic smooth 
muscle from 7 animals (Figure 5-16). Indeed COX deficiency in the colonic smooth 
muscle was never detected in the young (<22 week old) animals, indicating that muscle 
may just take longer to become afflicted by the m.5024 C>T mutation. Given the small 
size of the colonic smooth muscle fibers a Hue Saturation Value (HSV) colour space 
model was employed for automated detection of COX deficient (blue) fibers and COX 
positive (brown) fibers, courtesy of Craig Stamp (Figure 5-17a+b). A minimum of 15 
images across various sections were analysed for each animal using the HSV colour 
space model and an average percentage of COX deficiency calculated. The highest level 
of COX deficiency in the colonic smooth muscle was recorded at 4% in two aged 
mutant animals (see Appendix D). The presence of COX deficiency in the colonic 
smooth muscle provided the first evidence of muscle phenotypes in the mutant tRNA
Ala
 
mice.  
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Figure 5-16: Respiratory chain deficiency in the colonic smooth muscle of 65 and 70 week old m.5024C>T 
tRNAAla mutant mice.  
COX/SDH histochemistry on mouse: (a) 2241, 65 weeks old (m.5024C>T68%) (b) 2261, 65 weeks old 
(m.5024C>T64%) (c) 2200, 65 weeks old (m.5024C>T58%) (d)+ (e) 2884, 70 weeks old (m.5024C>T66%) (f) 2887, 
70 weeks old (m.5024C>T51%) All images were taken at x40 magnification. Scale bars: 50μm. COX positive fibers 
are brown (red arrow) and COX deficient fibers appear blue (green arrow). 
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Figure 5-17: Example image outputs generated using the HSV colour space model for the accurate detection 
and quantification of COX deficiency in colonic smooth muscle and heart fibers of aged tRNAAla mutant mice.  
Outputs show the original image, the image demonstrating the saturation for blue fibers (COX deficient), the image 
detecting brown fibers (COX positive) and a pie chart illustrating the percentage of COX deficiency for each image. 
Example outputs are shown for (a) Mouse 2200, 65 weeks old (m.5024TC>58%) colonic smooth muscle (b) Mouse 
2884, 70 weeks old (m.5024C>T66%) colonic smooth muscle (c) Mouse 2884 (m.5024C>T66%) heart tissue and (d) 
Mouse 2885, 70 weeks old (m.5024C>T26%) heart tissue. Images courtesy of Craig Stamp. 
To determine whether respiratory chain deficiency and a mitochondrial dysfunction 
phenotype were routinely observed in muscle tissues of aged tRNA
Ala
 mutant mice,  
COX/SDH histochemistry was performed on heart (8μm) and skeletal muscle (calf and 
thigh) (8μm) supplied for the three 70 week old animals (2884, 2885 and 2887). COX 
deficient heart fibers were detected in all three mice (Figure 5-18). Again, given the 
small size of the fibers coupled with their overlapping nature, the HSV colour space 
model was employed to determine the magnitude of COX deficiency in the heart 
(Figure 5-17c+d). This revealed a maximum of 9% COX deficiency in the heart of 
animal 2884 (m.5024 C>T 66%) (see Appendix D). Both the calf and thigh from all 
three aged mutant tRNA
Ala
 mice displayed fibers that lacked normal COX activity, 
presenting with intermediate COX deficient fibers (purple) and transitional COX 
deficient fibers (part brown and part blue) (Figure 5-19). The incidence of COX 
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deficiency was calculated subjectively, for ~500 muscle fibers across multiple different 
sections per tissue sample (see Appendix D). Fully COX deficient muscle fibers were 
only detected in the calf of animal 2884 (m.5024 C>T 66%), reaching a mere 1% across 
the whole tissue section. Nevertheless the percentage of fibers that lacked normal COX 
activity (intermediate and transitional fibers) frequently reached 5% in the calf and thigh 
of the three 70 week old mutant tRNA
Ala
 mice (see Appendix D). As such this data 
demonstrated that aged mutant tRNA
Ala
 mice displayed phenotypic evidence of 
mitochondrial dysfunction in muscle tissues, a common histological feature of disease 
caused by an mt-tRNA mutation (Taniike, Fukushima et al. 1992; Taylor, Giordano et 
al. 2003; Swalwell, Deschauer et al. 2006; McFarland, Swalwell et al. 2008).. 
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Figure 5-18: Respiratory chain deficiency in the heart of 70 week old m.5024C>T tRNAAla mutant mice.  
COX/SDH histochemistry on: (a)+(b) Mouse 2884 (m.5024C>T66%) heart (c)+(d) Mouse 2885 (m.5024C>T26%) 
heart  and (e)+(f) Mouse 2887 (m.5024C>T51%) heart. All images were taken at x40 magnification. Scale bars: 
50μm. COX positive cardiac muscle fibers are brown and COX deficient fibers appear blue (green arrows). 
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Figure 5-19: COX/SDH histochemistry on skeletal muscle tissue from 70 week old m.5024C>T tRNAAla mutant 
mice. 
COX/SDH histochemistry on: (a+b) Mouse 2884, 70 weeks old (m.5024C>T66%) thigh and (c) calf at x10 and x20 
magnification. (d+e) Mouse 2885 (m.5024C>T26%) thigh and (f) calf at x10 and x20 magnification. (g) Mouse 2887 
(m.5024C>T51%) thigh and (h) calf at x10 and x20 magnification respectively. Scale bars: 100μm. COX positive 
fibers are brown, COX deficient fibers appear blue (green arrow), those with intermediate deficiency appear a purple 
colour (yellow arrow) and those fibers with transitional COX deficiency appear part blue and part brown (orange 
arrows).   
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To determine whether the magnitude of COX deficiency observed in the colon (crypts 
and smooth muscle) heart and skeletal muscle (thigh and calf) was influenced by the 
m.5024 C>T tail heteroplasmy of aged tRNA
Ala
 mutant mice, the percentage of total 
COX deficiency (cells that lacked normal COX activity) for each tissue was categorized 
according to low, moderate and high tail heteroplasmy for animals and a two way 
ANOVA performed. This revealed that COX activity was significantly affected by the 
tissue type (p=0.0015), accounting for 76% variance in the percentage of COX 
deficiency, but was not significantly affected by the m.5024 C>T tail heteroplasmy of 
the animal (p=0.2860), which only accounted for 4% variance in COX activity (Figure 
5-20). One way ANOVA tests for each individual tissue type confirmed that m.5024 
C>T heteroplasmy of aged tRNA
Ala
 mice had no significant effect on COX deficiency 
in the: colonic crypts (Figure 5-15); colonic smooth muscle (p=0.2169); heart (p= 
0.3675) and skeletal muscle (p= 0.6495). However, the statistical analysis was only 
performed on 3 tissue samples for the post-mitotic tissues of aged animals and so 
appropriate and robust correlations cannot really be made here. In general, however the 
mice with higher m.5024C>T tail heteroplasmy did display the higher levels of COX 
deficiency, as seen in animal 2884 (m.5024C>T 66%), which presented with the highest 
COX deficiency in the heart (9%) and calf muscle (~5% of fibers lacked normal COX 
activity) (see Appendix D). As such I would expect this correlation to be more statically 
robust if more tissue samples were provided. Nevertheless, aged mutant tRNA
Ala
 mice 
did display evidence of respiratory chain deficiency and mitochondrial dysfunction in 
post-mitotic tissues, which are typical features of mt-tRNA disease (Taniike, Fukushima 
et al. 1992; Taylor, Giordano et al. 2003; Swalwell, Deschauer et al. 2006; McFarland, 
Swalwell et al. 2008). 
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Figure 5-20: The effect of m.5024C>T tail heteroplasmy and tissue variability on the incidence of COX 
deficiency in aged mutant tRNAAla mice. 
The percentage of cells that lacked normal COX activity comprised a combination of full COX deficient cells and 
those with partial/ intermediate and transitional COX deficiency. COX activity was significantly affected by the 
tissue type in aged tRNAAla mutant animals (p=0.0015) but m.5024C>T heteroplasmy had no significant effect on 
COX activity in colonic crypts, colonic smooth muscle, heart, thigh and calf muscle, p=0.2860, two way ANOVA 
test. 
Dual COX/SDH histochemistry was also completed on colon (n=4,10μm), heart (n=2, 
8μm) and skeletal muscle (thigh and calf) (n=2, 10μm) of pure WT control animals, 
aged 65-69 weeks old, used to maintain the m.5024 C>T tRNA
Ala
 breeding colony. All 
tissues displayed normal COX activity, with only one COX deficient crypt detected in 
animal 17066 (Figure 5-21). This confirmed an absence of respirtaory chain deficiency 
in normal ageing animals, supporting that the COX deficiency observed in the aged 
mutant tRNA
Ala
 mice was not associated with the normal ageing process but was due to 
the presence of the m.5024C>T mutation. 
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Figure 5-21:COX/SDH histochemistry on aged WT control mouse muscle tissues.  
Colonic crypts of (a) Mouse 17066, x10 magnification and (b) Mouse 17369, x 20 magnification. Colonic smooth 
muscle of (c) Mouse 17066 and (d) Mouse 17369, both at x40 magnification. Heart tissue of (e) Mouse 17066 and (f) 
Mouse 17369, both at x40 magnification. (g) Mouse 17066 thigh at x 10 magnification. (h) Mouse 17369 calf at x20 
magnification. Scale bars: 100μm. 
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5.5.5.2 Is there a selective loss of the m.5024C>T mutation in the colon of aged 
mutant tRNA
Ala
 mice? 
Given that the incidence of combined COX deficiency was lower in aged tRNA
Ala
 
mutant mice with high m.5024 C>T tail heteroplasmy, it appeared that the m.5024 C>T 
mutation may have been lost from the colonic epithelium over time. To determine 
whether the m.5024 C>T mutation was selected against in the colon of aged tRNA
Ala
 
mutant mice pyrosequencing was performed on homogenate colon DNA for all 65 
(n=7) and 70 (n=3) week old mice to quantify the m.5024 C>T heteroplasmy in the 
colon. This was subsequently compared to the tail the m.5024 C>T heteroplasmy, 
previously measured by RFLP by James Stewart. This revealed that m.5024 C>T 
heteroplasmy was significantly lower in the colon compared to the tail for each animal 
(p= <0.0001, paired t test), with all animals showing a reduction by more than half of 
m.5024 C>T heteroplasmy in the colon (mean difference= 27%) (Figure 5-22). The 
colon homogenate DNA would contain a small amount from the colonic smooth 
muscle; however, given that the overwhelming proportion of the colon consists of the 
colonic epithelium, this data suggests that the m.5024C>T mutation is being lost from 
the colonic epithelium.  
 
Figure 5-22: The m.5024C>T heteroplasmy in the colon compared to the tail in aged (65 and 70 week old) 
tRNAAla mutant mice.  
The m.5024C>T heteroplasmy is significantly lower in the colon than in the tail clippings for each 65 and 70 week 
old tRNAAla mutant mouse, p=<0.0001, paired t test. Mean of differences= 27.10%. M.5024C>T heteroplasmy in the 
tail was measured by RFLP by James Stewart. 
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5.5.5.3 Does mitotic segregation influence m.5024C>T heteroplasmy in different 
tissues in aged mutant tRNA
Ala
 mice?   
Given that the m.5024 C>T mutation appears to be selectively lost in the colonic 
epithelium of aged tRNA
Ala
 mutant mice (Figure 5-22), I wanted to determine whether 
mitotic segregation influenced the m.5024 C>T heteroplasmy in other tissues of these 
animals and whether the selective loss was limited to a mitotic tissue. Furthermore, 
when aged mutant tRNA
Ala
 mice were sacrificed they routinely showed an increased 
heart to body mass ratio (James Stewart, personal communication). As such I wanted to 
determine whether the heart displayed higher m.5024 C>T heteroplasmy and had 
become more afflicted over time. Heart, thigh and calf (calf was absent for animal 
2885), in addition to colon tissue, were provided for the three 70 week old tRNA
Ala
 
mutant mice, and so pyrosequencing of homogenate DNA from these tissues was 
completed to determine the m.5024 C>T heteroplasmy. This was also compared to the 
tail heteroplasmy, measured by RFLP by James Stewart. Heart and skeletal muscle were 
not provided for the 65 week old animals, and so this could not be performed.  
Pyrosequencing of the different tissues of 70 week mutant tRNA
Ala
 mice confirmed that 
the m.5024 C>T heteroplasmy was significantly lower in the colon compared to all 
other tissues (p= 0.0202, unpaired t test) (Figure 5-23). Furthermore heteroplasmy was 
not significantly different between the heart, skeletal muscle and tail (p=0.8964, one 
way ANOVA), demonstrating that the m.5024C>T mutation was maintained at constant 
levels in these tissues (Figure 5-23). Given that the colonic epithelium is mitotic and all 
other tissues examined were post-mitotic; this data suggests that the m.5024C>T 
mutation is selectively lost from actively dividing, mitotic cells. Furthermore this data 
does not indicate that the cardiomyopathy observed in aged animals was due to higher 
m.5024C>T heteroplasmy in the heart. 
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Figure 5-23: M.5024C>T heteroplasmy in different tissues of 70 week old mutant tRNAAla mice.  
M.5024C>T heteroplasmy recorded in whole tissue from tail clippings, colon, heart, calf and thigh in mice: 2884 
(m.5024C>T66%), blue data points; 2885 (m.5024TC>26%), red data points and 2887 (m.5024C>T51%), green data 
points. The m.5024C>T heteroplasmy is significantly lower in the colon than in the other tissues of 70 week mutant 
mice, p= 0.0202, unpaired t test.  
5.5.5.4 Is the m.5024C>T heteroplasmy lower in the colonic crypts of aged mutant 
tRNA
Ala
 mice? 
To determine what was happening to the m.5024C>T heteroplasmy in the colonic crypts 
of aged mutant tRNA
Ala
 mice, pyrosequencing was performed on single COX positive 
crypts (n=14) and crypts with partial COX deficiency (n=14). This was successfully 
achieved for the three 70 week old animals; however attempts in 65 week old animals 
failed. A freeze thaw issue upon shipment of the tissue provided for the 65 week old 
animals, resulted in problems with DNA degradation, with DNA smears observed on 
PCR gels and an absence of the single, clear 178bp fragment necessary for 
pyrosequencing of the m.5024 region (Figure 5-24).  
 
 
Figure 5-24: Example gel electrophoresis image following the pyrosequencing PCR of single colonic crypts 
from 65 week old tRNAAla mutant mice.  
Gel electrophoresis image showing the presence of DNA smears for single colonic crypts and an absence of a clear 
178bp fragment necessary for pyrosequencing, indicating DNA degradation within the samples. The one defined 
band is a WT control. 
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Successful pyrosequencing of single COX positive and partial COX deficient colonic 
crypts from the three 70 week old tRNA
Ala
 mutant mice revealed only moderate 
m.5024C>T heteroplasmy in all colonic crypts (Figure 5-25a). COX positive crypts 
actually displayed higher heteroplasmy (18.66 ± 2.165) than those with partial COX 
deficiency (11.70 ± 2.411) (p= 0.0367, unpaired t test) (Figure 5-25b). A two way 
ANOVA revealed that m.5024 C>T heteroplasmy in colonic crypts was mildly affected 
by COX activity (p= 0.0454) accounting for only ~5% variance in heteroplasmy, but 
that variability between mice had no significant effect (p=0.0686), accounting for ~6% 
variance (Figure 5-25c). Low m.5024C>T heteroplasmy in the partial COX deficient 
crypts suggests that the majority of crypt progeny cells are generated from stem cells 
that harbour only low levels of the mutation, indicating that any stem cell with high 
levels of the mutation are potentially being lost from the stem cell pool. If I had more 
time it would have been beneficial to laser mico-dissect and pyrosequence the COX 
positive portion and COX deficient portions of the partial crypts to determine whether 
there was a difference in heteroplasmy. As such this could indicate whether the different 
progeny cells were arising from different stem cells harbouring different m.5024C>T 
heteroplasmy.  
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Figure 5-25: M.5024C>T heteroplasmy in single colonic crypts from 70 week old mutant tRNAAla mice.  
(a) The m.5024C>T heteroplasmy is not significantly different in single COX positive colonic crypts and crypts with 
partial COX deficiency from tRNAAla mutant mice 2884 (m.5024C>T 66%), 2885 (m.5024C>T26%) and 2887 
(m.5024C>T51%) (p= 0.3046, one way ANOVA test). (b) M.5024C>T heteroplasmy in all COX positive colonic 
crypts (18.66 ± 2.165) is significantly higher than in crypts with partial COX deficiency (11.70 ± 2.411) (p= 0.0367, 
unpaired t test). (c) The effect of COX activity and mouse variability on the m.5024C>T heteroplasmy in single 
colonic crypts. COX activity significantly affected the m.5024C>T heteroplasmy in single colonic crypts (p= 0.0454), 
but variability between mice had no significant effect (p=0.0686), two way ANOVA test. 
5.5.5.5 Does the m.5024C>T mutation segregate with the muscle phenotype observed 
in the colon of aged mutant tRNA
Ala
 mice? 
To determine whether the m.5024 C>T mutation segregated with the COX deficiency in 
the colonic smooth muscle of aged tRNA
Ala 
mutant mice, mtDNA genome analysis of 
the m.5024 region was performed on COX positive and COX deficient colonic smooth 
muscle fibers. Again, given the DNA degradation issue in the colon of 65 week old 
animals this was only successfully completed for the 70 week old tRNA
Ala
 mutant mice. 
Given that there was an absence of COX deficiency (0%) detected in the colonic smooth 
muscle of animal 2885 (m.5024 C>T 26%), this could only be completed in animals 
2884 and 2887. Due to the small size of the colonic smooth muscle fibers, successful 
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amplification of DNA fragments for mtDNA genome analysis was only achieved when 
>25 single muscle fibers were laser micro-dissected and pooled together for each 
sample.  
Sequencing of the m.5024 region in COX positive (n=5) and COX deficient (n=5) 
smooth muscle fibers from animals 2884 and 2887, confirmed the presence of the 
m.5024 C>T mutation in colonic smooth muscle fibers, revealing very high 
heteroplasmy (Figure 5-26). Furthermore the m.5024 C>T mutation appeared to 
segregate with the COX deficiency, with COX deficient smooth muscle fibers 
presenting with very high heteroplasmy (>75%) /homoplasmy of the m.5024 C>T 
mutation and COX positive fibers presenting with moderate heteroplasmy (<75%) 
(Figure 5-26).  
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Figure 5-26: Example sequencing electropherograms demonstrating the presence of the m.5024C>T mutation 
in colonic smooth muscle fibers of aged mt5024C>T tRNAAla mutant mice. 
(a)+(b) Electropherograms from control mice 9831 and 10045 respectively, illustrating the presence of the WT C 
base at position m.5024. (c) Sequencing of this region in a COX deficient smooth muscle fiber sample from mouse 
2884, 70 weeks old (m.5024C>T66%) revealed the m.5024C>T mutation at 100% homoplasmy and (d) in a COX 
positive smooth muscle fiber sample m.5024C>T ~50% heteroplasmy. (e) Sequencing of this region in a COX 
deficient smooth muscle fiber sample from mouse 2887, 70 weeks old (m.5024C>T51%) revealed the m.5024C>T 
mutation at 100% homoplasmy and (f) in a COX positive smooth muscle fiber sample revealed m.5024C>T, ~15% 
heteroplasmy. The stars indicate the m.5024 position and the C>T base change in the mouse mtDNA sequence. 
Pyrosequencing of COX positive (n=14) and COX deficient smooth muscle fibers 
(n=14) from animals 2884 and 2887 was subsequently completed to accurately quantify 
the m.5024 C>T heteroplasmy, determine whether the mutation segregated with COX 
deficiency and identify the biochemical threshold in smooth muscle fibers. This 
revealed that the highest levels of the m.5024 C>T mutation segregated with the COX 
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deficiency in both 70 week old tRNA
Ala
 mice (p= <0.0001, one way ANOVA) (Figure 
5-27a). COX deficient fibers presented with significantly higher heteroplasmy (84.31 ± 
1.055) than COX positive fibers (54.85 ± 1.550) (p= <0.0001, unpaired t test), 
identifying a potential threshold of ~84% (Figure 5-27b). Note that the variation in 
heteroplasmy in COX positive versus COX deficient smooth muscle fibers is very tight, 
demonstrating a clear and precise segregation of the mutation with COX deficiency. A 
two way ANOVA revealed that m.5024C>T heteroplasmy in colonic smooth muscle 
fibers was significantly affected by COX activity (p= <0.0001), accounting for ~81% 
variance in heteroplasmy (Figure 5-27c). Variability between the two mice also had a 
significant effect on m.5024 C>T heteroplasmy (p= <0.0001), however this only 
accounted for ~6% variance (Figure 5-27c). This variability was unsurprising given that 
only two mice were used; however the m.5024C>T heteroplasmy was indeed higher in 
the COX deficient and COX positive colonic smooth muscle fibers of animal 2884 with 
the higher tail heteroplasmy (m.5024C>T 66%) than animal 2887 (m.5024C>T 51%) 
(Figure 5-27a). Segregation of the m.5024C>T mutation with the COX deficiency in the 
colonic smooth muscle fibers further demonstrates pathogenicity of the mutation, 
showing that it is causal in the muscle phenotypes observed in these mice, which is 
representative of disease caused by mt-tRNA mutations (Swalwell, Deschauer et al. 
2006; McFarland, Swalwell et al. 2008). Given that the apparent threshold for COX 
deficiency in the colonic crypts was ~70%, the data from the colonic smooth muscle 
fibers also provides evidence that different cell types in the mutant tRNA
Ala
 mice have 
different biochemical thresholds. 
 
. 
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Figure 5-27: Segregation of the m.5024C>T mutation with COX deficiency in colonic smooth muscle fibers of 
70 week old mutant tRNAAla mice. 
(a) The m.5024C>T heteroplasmy is significantly higher in COX deficient colonic smooth muscle fibers than COX 
positive fibers from tRNAAla mutant mice 2884 (m.5024C>T 66%) and 2887 (m.5024C>T51%) (p= <0.0001, one 
way ANOVA test). (b) M.5024C>T heteroplasmy in all COX positive colonic smooth muscle fibers (54.85 ± 1.550) 
is significantly lower than COX deficient fibers (84.31 ± 1.055) (p= <0.0001, unpaired t test). (c) The effect of COX 
activity and mouse variability on the m.5024C>T heteroplasmy in colonic smooth muscle fibers. The m.5024C>T 
heteroplasmy was significantly affected by COX activity (p= <0.0001) and variability between the two mice 
(p=<0.0001) two way ANOVA test. 
5.6 Discussion 
Establishing mouse models of mitochondrial DNA disease that harbour pathogenic 
heteroplasmic mtDNA point mutations is extremely desirable to enable further research 
into: disease mechanisms and pathogenicity; disease progression; transmission and the 
development of potential treatments. In this study I show that young mice harbouring a 
m.5024C>T mutation in mt-tRNA
Ala
 routinely display evidence of respiratory chain 
deficiency in the colonic epithelium, with which the mutation segregated, establishing 
that the m.5024 C>T mutation was pathogenic. This also suggests that dual COX/SDH 
histochemistry in the colon is a good early experimental screening tool for identifying in 
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vivo mitochondrial dysfunction and pathogenic mtDNA point mutations in the breeding 
of mouse lineages. Furthermore I show that aged m.5024C>T tRNA
Ala
 mutant mice 
show signs of progressive disease, displaying muscle phenotypes and respiratory chain 
deficiency, with different cell types showing different biochemical thresholds, which are 
typical features of mitochondrial disease caused by an mt-tRNA mutation (Jacobs 
2003). Finally I also demonstrate a selective loss and elimination of the m.5024C>T 
mutation from the colonic epithelium of aged tRNA
Ala
 mutant mice, establishing a 
difference in m.5024C>T heteroplasmy between post-mitotic and mitotic tissues. This 
data therefore suggests that mice harbouring the m.5024C>T mutation would be a 
valuable model of mitochondrial disease caused by an mt-tRNA point mutation and 
could be extremely useful for studying disease progression, presentation, transmission 
and the development of treatments.   
COX deficiency routinely presented in colonic crypts of young tRNA
Ala
 mutant mice, 
where the m.5024C>T mutation segregated with the COX deficiency and revealed an 
apparent threshold level of ~70%. Different point mutations have different critical 
threshold levels for precipitating a biochemical defect. Mt-tRNA point mutations are 
commonly quite recessive and have a high critical threshold level before a biochemical 
defect is observed as seen with: the A8344G mutation in tRNA
Lys
 in MERRF patients 
(>80%) (Boulet L 1992), the m.5591G>A mutation (~99%) and the m.5650G>A 
mutation (~95%) in tRNA
Ala
 in patients with isolated mitochondrial myopathies 
(Swalwell, Deschauer et al. 2006; McFarland, Swalwell et al. 2008). One potential 
reason for the lower threshold of the m.5024C>T mutation in the colonic crypts of 
tRNA
Ala
 mutant mice could be the hypothesised low mtDNA copy number in colonic 
crypt stem cells. As such there would be a decreased number of WT mtDNA molecules 
capable of maintaining normal mitochondrial function, resulting in much earlier 
segregation of the mutation and presentation of COX deficiency. Alternatively, or in 
combination with, another reason could be that the m.5024C>T mutation is more 
pathogenic. Highly recessive mt-tRNA mutations, presenting at very high heteroplasmy 
increases the transmissibility of a mutation to offspring, as seen with the m.5650G>A 
mutation in the three successive female generations (McFarland, Swalwell et al. 2008). 
If the m.5024C>T mutation is indeed more pathogenic this may explain why there is 
high variability in the transmission of the mutation to offspring, and why a threshold of 
77% m.5024 C>T heteroplasmy is consistently observed, even still to date. Embryo 
reabsorption of the allele or early death of pups before or immediately after they are 
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born, due to the m.5024C>T mutation being more pathogenic could explain this 
apparent threshold seen in offspring.  
It is widely accepted that mt-tRNA point mutations in the stem region of tRNAs are 
highly likely to be pathogenic (McFarland, Elson et al. 2004). The m.5024C>T 
mutation is predicted to cause a significant deformation in the acceptor stem of the 
tRNA
Ala
 and as such may render this mutation more pathogenic and contribute to the 
lower threshold level observed. The acceptor stem of a tRNA is critical for binding to 
the aminoacyl tRNA synthetase necessary for aminoacylation and binding to the 
specific amino acid (alanine) prior to protein translation (Park and Schimmel 1988). The 
m.5024C>T mutation occurs next to a U:U pairing in the acceptor stem of the mouse 
tRNA
Ala
 (Figure 5-3). U:U lacks a Watson-Crick base pair, which alone is very 
destabilizing to the tRNA acceptor stem. Thus the presence of the C>T mutation next to 
the U:U pairing, is expected to be highly destabilizing to the acceptor stem and is likely 
to cause a break down in the tertiary structure, leading to degradation of tRNA
Ala
. 
Indeed reduced steady state levels of tRNA
Ala
 are observed on northern blots from both 
young (Figure 5-4b) and aged mutant tRNA
Ala
 mice with high m.5024C>T tail 
heteroplasmy, where there is an absence of any down regulation of other tRNAs, 
supporting that the m.5024 C>T mutation causes degradation of tRNA
Ala
. This would be 
expected to have significant effect upon mitochondrial protein translation, which has 
indeed been detected by western blots from mutant tRNA
Ala
 mice with high (67/68%) 
tail heteroplasmy (Figure 5-4c). Such a significant deformation in the tRNA
Ala
 and 
impact upon protein translation in mice with 67% m.5024 C>T heteroplasmy therefore 
indicates high pathogenicity of the mutation, which would contribute to the low 
threshold for COX deficiency in the colonic crypts and threshold of 77% for producing 
offspring. 
COX deficiency in the heart and skeletal muscle was not a characteristic feature in 
young (<22 weeks) mutant tRNA
Ala
 mice, detected at only moderate levels in 2 out of 8 
mice for both. COX deficiency is a common feature of muscle biopsies of patients with 
mtDNA disease, and indeed those with mt-tRNA
Ala
 mutations (Sciacco M 1994; 
Swalwell, Deschauer et al. 2006; McFarland, Swalwell et al. 2008) and as such the 
initial findings in young animals could question the validity of the tRNA
Ala
 mutant 
mouse as a model of disease. Despite the lack of respiratory chain deficiency, young 
mutant tRNA
Ala
 mice with high heteroplasmy, did show evidence of decreased body 
mass, indicating a muscle phenotype, as well as evidence of cardiomyopathy 
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characterised by an increased heart to body mass ratio and elevated levels of atrial 
natriuretic factor (ANF), a sensitive indicator of cardiac pathogenesis (Vikstrom, 
Bohlmeyer et al. 1998) (James Stewart, unpublished results). Given that the heart and 
skeletal muscle are post-mitotic tissues, in which clonal expansion is not as rapid as the 
colon (Taylor and Turnbull 2005; Fellous, McDonald et al. 2009), the absence of 
routine respiratory chain deficiency may simply be due to the fact that more time is 
needed for the mutation to reach the critical threshold level to precipitate a biochemical 
defect. Indeed this would appear to be the case, with the discovery that 70 week old 
tRNA
Ala
 mutant mice displayed evidence of COX deficiency in the heart, thigh and calf. 
Furthermore, pyrosequencing of COX deficient and COX positive colonic smooth 
muscle fibers revealed a higher m.5024C>T threshold level (~84%) for COX 
deficiency. As such it would appear that muscle tissues have a higher threshold level for 
an impairment of the respiratory chain to ensue, and therefore take longer to become 
afflicted.  
Even though evidence of COX deficiency was documented in the heart and skeletal 
muscle of 70 week old mutant tRNA
Ala
 mice, this was only moderate in both tissues, 
and could be argued as too low for a model of mtDNA disease. This may be attributable 
to species specific differences as mtDNA defects tend to be tolerated fairly well in both 
mouse heart and muscle, as evidenced by normal respiratory chain function in the heart 
and plastic properties of muscle, in tissue specific TFAM knockout mice (Wredenberg, 
Wibom et al. 2002; Freyer, Park et al. 2010). Furthermore mouse muscle relies much 
more on glycolysis than OXPHOS for energy production (Ibrahim, Zweber et al. 1981) 
and so may not be as severely affected by respiratory chain dysfunction as human 
muscle. Alternatively, however it may simply be that respiratory chain deficient muscle 
fibers with high levels of the m.5024C>T mutation undergo apoptosis, as studies in rats 
have previously shown that respiratory chain deficiency in muscle fibers was associated 
with muscle atrophy (Herbst, Pak et al. 2007). Indeed some of the 70 week old mutant 
tRNA
Ala
 mice with high tail heteroplasmy did display signs of muscle wasting when 
they were sacrificed (James Stewart, personal communication).The magnitude of COX 
deficiency that was detected in the heart and skeletal muscle as well as the colonic 
smooth muscle fibers of 70 week old tRNA
Ala
 mutant mice did not correlate with the 
m.5024 C>T heteroplasmy recorded in tail clippings. This may simply be due to the 
limited number of tissues this was completed on and the inherent variability that would 
occur between mice, especially given that the incidence only varied by a few percent. 
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Alternatively, this may be due to the fact that the incidence of COX deficiency in 
tissues does not always correlate with the clinical presentation and disease severity in 
mtDNA disease patients (Betts, Jaros et al. 2006; McFarland, Swalwell et al. 2008). 
This leads on to the primary limitation of this study, being that COX/SDH 
histochemistry was the only screen used to identify mitochondrial dysfunction in tissues 
of the mutant tRNA
Ala
 mice. Histological abnormalities in muscle, such as enlarged 
mitochondria and the presence of ragged red fibers are also typical of patients with 
mitochondrial disease caused by mt-tRNA mutations and are used in diagnosis (Hirano 
1994; Finnilä, Tuisku et al. 2001; Taylor and Turnbull 2005). Furthermore combined 
respiratory chain defects, including a loss of complex I activity, is also common in 
patients with mt-tRNA mutations  (Bonilla, Sciacco et al. 1992; Ciafaloni, Ricci et al. 
1992; Swalwell, Deschauer et al. 2006; McFarland, Swalwell et al. 2008). As such 
evidence of mitochondrial dysfunction and tissue phenotypes cannot simply be judged 
by COX deficiency in tissues of tRNA
Ala
 mutant mice.  
An interesting observation in this study was that the m.5024C>T mutation segregated 
promptly in colonic crypts of young mutant tRNA
Ala
 mice, but was selectively lost from 
the colonic epithelium of aged animals, which actually displayed segregation of the 
mutation in the colonic smooth muscle. Not only does this demonstrate varied 
segregation of the mutation in different cell types within the same tissue but it also 
indicates a selective loss of the pathogenic mutation in mitotic, actively dividing cells. 
This was further supported by the fact that post mitotic tissues of aged animals 
maintained constant heteroplasmy. This data suggests that colonic crypts are not as 
permissive as originally thought and that respiratory chain deficient colonic crypt stem 
cells are not able to survive with high levels of a markedly pathogenic mtDNA point 
mutation after a certain length of time. It could therefore be hypothesised that COX 
deficiency decreases the half-life of a crypt, such that a stem cell harbouring high levels 
of a markedly pathogenic m.5024C>T mutation may become arrested in a senescent 
state or undergo apoptosis. As such these stem cells would no longer fulfil their purpose 
and repopulate the crypt, giving an absence of progeny cells with high levels of the 
mutation. Only those stem cells with low levels/ an absence of the mutation would be 
able to replicate and repopulate the crypt. In this case the actively dividing nature and 
the low mtDNA copy number of intestinal stem cells (Barker, Van Es et al. 2007) 
coupled with the marked pathogenicity of the m.5024C>T mutation could make colonic 
crypt stem cells highly vulnerable to the mutation and unable to fulfil their purpose. 
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This would therefore account for the loss of the mutation from the colonic epithelium 
and the high incidence of partial COX deficient crypts in aged animals.  Contrastingly 
post mitotic tissues contain 1000s of copies of the mtDNA genome (Lightowlers, 
Chinnery et al. 1997) and so more mutant mtDNA genomes can be tolerated before a 
biochemical defect and mitochondrial dysfunction ensues, as demonstrated with the 
higher threshold level in the COX deficient colonic smooth muscle fibers of aged 
mutant tRNA
Ala
 mice. The high threshold coupled with random replication of 1000s of 
copies of the mtDNA genome could maintain heteroplasmy at a constant level in post 
mitotic tissues.  
The selective loss of a mt-tRNA point mutation in actively dividing stem cells in human 
disease is not uncommon. Patients with MELAS (m.3243A>G in tRNA
Leu
 
(UUR)
) 
typically display higher heteroplasmy in post-mitotic tissues than mitotic, actively 
dividing tissues (Ciafaloni, Ricci et al. 1992) and more importantly they frequently 
show a selective loss of the m.3243A>G mutation in blood over time (Chinnery, 
Zwijnenburg et al. 1999; Rahman, Poulton et al. 2001). Furthermore analysis of COX 
activity in colon biopsies of a few patients with MELAS has revealed an absence of 
COX deficiency in the colonic crypts but the colonic smooth muscle was almost entirely 
COX deficient (unpublished data from this lab). However, the selective elimination of 
mt-tRNA point mutations in actively dividing stem cells is not a characteristic feature of 
all patients with mt-tRNA point mutations, where heteroplasmy can remain constant 
across all tissues, as seen in MERRF patients with the tRNA
Lys
 mutation (Lombès, Diaz 
et al. 1992). Given that the MERRF mt-tRNA
Lys
 mutation is relatively benign in terms 
of pathogenicity and the resulting biochemical defect, it is likely that the selective loss 
of a mutation in mitotic tissues is influenced by the pathogenicity of the mutation and 
the degree of mitochondrial dysfunction that ensues. Thus for mt-tRNA mutations this 
may depend on the deformation of the tRNA and the subsequent defect in protein 
translation. Indeed this could account for the loss of the m.5024C>T mutation, which is 
predicted to be highly pathogenic, given the predicted significant deformation in the 
acceptor stem (see earlier). Alternatively, given that the OriL is critical for mtDNA 
replication (Wanrooij, Miralles Fusté et al. 2012), if a mutation caused problems at the 
OriL, this could also contribute to the selective loss during mtDNA replication, 
occurring at a much faster rate in actively dividing tissues. Interestingly studies in 
humans have shown that those mt-tRNA point mutations that display an overriding 
phenotype in dividing cells and are selectively lost, are least likely to be inherited 
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(Elson, Swalwell et al. 2009). As such the selective loss of the pathogenic m.5024 C>T 
mutation that we see in actively dividing colonic crypts of tRNA
Ala
 mutant mice could 
hold implications for the transmission of this mutation, explaining  the threshold level 
observed in offspring.  
The overriding, long term aim of this study was to determine whether the m.5024 C>T 
mutant tRNA
Ala
 mice could serve as a model of mtDNA disease and be used to uncover 
disease mechanisms associated with heteroplasmic point mutations. This mouse 
demonstrates routine evidence of respiratory chain deficiency, with which the m.5024 
C>T mutation segregates, demonstrating pathogenicity of the mutation. Aged animals 
also become more afflicted, displaying phenotypic evidence of mitochondrial 
respiratory chain dysfunction in the heart, skeletal muscle and colonic smooth muscle, 
which is representative of disease caused by mt-tRNA point mutations (Taniike, 
Fukushima et al. 1992; Taylor, Giordano et al. 2003; Swalwell, Deschauer et al. 2006; 
McFarland, Swalwell et al. 2008). Moreover aged mutant tRNA
Ala
 mice with high 
heteroplasmy also show routine evidence of cardiomyopathy (enlarged hearts), as well 
as elevated levels of fibroblast growth factor (FGF-21), a serum marker of muscle 
mitochondrial respiratory chain deficiencies (Suomalainen 2013) with a few high level 
animals showing evidence of muscle difficulties and hind limb myopathy (James 
Stewart, unpublished results). Moreover these mice also display characteristic features 
of patients harbouring mt-tRNA point mutations, including different threshold levels for 
different cell types, mitotic segregation of the mutation and the selective loss in actively 
dividing cells (Chinnery, Zwijnenburg et al. 1999; Rahman, Poulton et al. 2001). The 
data presented here therefore suggests that the m.5024C>T tRNA
Ala
 mutant mouse is 
the first mouse model to harbour a pathogenic heteroplasmic mtDNA point mutation, 
that displays mitochondrial respiratory chain dysfunction, differential segregation of the 
mutation and tissue phenotypes that are representative of mitochondrial disease caused 
by an mt-tRNA point mutation.  
5.6.1 Future work 
Given that aged mutant tRNA
Ala
 mice routinely demonstrate evidence of 
cardiomyopathy, it would be useful to complete pyrosequencing of COX deficient and 
COX positive cardiac muscle fibers to directly associate pathogenicity of the mutation 
with the phenotype. Given that the colonic crypts and smooth muscle fibers displayed 
different threshold levels for COX deficiency, this would also uncover the threshold 
necessary for COX deficiency in the heart, and whether this is even higher, as is often 
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the case in humans (Bates, Bourke et al. 2012). Preliminary experiments suggest that 
pyrosequencing would require substantial optimisation, given the overlapping nature of 
cardiac muscle fibers, to ensure that only COX deficient fibers and no COX positive 
fibers are present in a sample, and vice versa. Reducing section thickness and collecting 
more fibers will be necessary in order to optimise this technique successfully for heart 
tissue.  
Future work would undoubtedly involve looking for other evidence of mitochondrial 
dysfunction in muscle and heart samples from the m.5024 C>T tRNA
Ala
 mutant mice. A 
Gomori Trichrome stain to look for the presence of ragged red fibers and mitochondrial 
hyperproliferation could be used in skeletal muscle as well as using 
immunohistochemistry/ immunofluorescence to look for complex I deficiency in the 
muscle and heart. Complex I defects often precede a loss of complex IV activity in 
patients with mt-tRNA point mutations (Bonilla, Sciacco et al. 1992; Ciafaloni, Ricci et 
al. 1992), and so the incidence of complex I deficiency may be higher than the observed 
COX deficiency in these tissues. Complex I screening will be especially interesting in 
the heart, given that biochemical analysis of mutant tRNA
Ala
 mice also shows a down 
regulation in complex I activity (James Stewart, personal communication). Screening 
for complex I defects may also be useful in the brain of these mice, given that 
neurological features and complex I defects in the brain are also common in mtDNA 
disease (Tanji, Kunimatsu et al. 2001).  
Whilst the loss of the m.5024 C>T mutation in the colonic crypts suggests a loss of the 
mutation in actively dividing stem cell tissues, it would be useful to confirm this in the 
blood. Mutation load quantification, by either pyrosequencing or RFLP, from blood 
samples taken from animals 22 weeks old and then again, at multiple stages throughout 
lifespan (40 weeks and then >65 weeks) would determine whether the m.5024 C>T 
mutation is generally lost from mitotic tissues of these mice.  
Future work will also involve using these mice to uncover disease mechanisms, by 
ageing them further to determine how the disease phenotypes progress and how 
severely afflicted the mice become, as well as examining transmission of pathogenic 
mt-tRNA point mutations further. Quantification of m.5024 C>T heteroplasmy from 
oocytes and embryos from mothers could be performed to help determine whether the 
breeding threshold occurs during the germline, due to the genetic bottleneck or whether 
there is embryo reabsorption of the allele/ early embryo loss in those with very high 
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m.5024 C>T heteroplasmy. Furthermore rescue experiments with leucyl tRNA 
synthetase, could be used to see if steady state levels of tRNA
Ala
 are maintained, due to 
stabilization of the tRNA and prevention of degradation, in an attempt mitigate 
mitochondrial dysfunction and develop strategies to manage/ treat disease.  
5.7 Conclusions 
In this study I have shown that COX/SDH histochemistry in the colon correlated a 
genotype to a phenotype in young m.5024 C>T tRNA
Ala
 mutant mice before the onset 
of high heteroplasmy and disease like phenotypes in aged mice. This therefore provides 
evidence that this is a useful early experimental screening tool for the detection of 
pathogenic mtDNA point mutations in the breeding of mouse lineages. Furthermore the 
m.5024 C>T tRNA
Ala
 mutant mice appear to be a reasonably good model of a 
pathogenic heteroplasmic mt-tRNA point mutation in disease; demonstrating evidence 
of mitochondrial dysfunction and tissue phenotypes which become progressively worse 
over time and from which we are already uncovering certain disease mechanisms 
regarding mitotic segregation and transmission of the allele. This therefore suggests that 
this mouse model will be a valuable tool for understanding factors that govern disease 
progression caused by mt-tRNA point mutations, disease presentation and the 
development of potential treatments.
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Chapter 6. Final Discussion 
The overarching aim of this thesis was to further our understanding of the clonal 
expansion of mtDNA point mutations and resulting respiratory chain deficiency that 
occurs during ageing and the mechanisms associated with disease heterogeneity, using 
mice that harbour mtDNA point mutations. Establishing good mouse models is 
fundamental to enable more detailed phenotyping of the effects of mtDNA point 
mutations upon cellular functions and processes to uncover how they contribute to the 
ageing process and to understand the mechanisms that drive the progression and 
transmission of mtDNA disease.  
The study in the PolgA
+/mut
 mouse colon provided evidence for a conserved mechanism 
for the clonal expansion of somatic mtDNA point mutations by random genetic drift, 
without any selective constraints, resulting in age-related respiratory chain deficiency in 
colonic epithelial tissue of both PolgA
+/mut
 mice and ageing humans. Establishing the 
PolgA
+/mut
 mouse as a good model of age-related mitochondrial dysfunction therefore 
enabled the RNA sequencing study to begin to uncover the potential functional 
consequences of somatic mtDNA point mutations upon cellular processes. This study 
provided novel preliminary data suggesting that age-related COX deficiency in colonic 
crypts could be associated with alterations in: the cell cycle and proliferation; DNA 
maintenance and repair; cell adhesion and tight junction formation; the adaptive 
immune response and energy metabolism. Furthermore this study revealed a number of 
interesting potential associations between age-related respiratory chain deficiency and a 
predisposition to cancer in the colonic crypts and the pathogenesis of inflammatory 
bowel disease. 
Regarding the study in the m.5024C>T tRNA
Ala
 mice I demonstrated that COX/SDH 
histochemistry in colonic epithelial tissue is a useful early experimental screening tool 
for the detection of pathogenic mtDNA point mutations in the breeding of mouse 
lineages. Moreover I presented evidence that the m.5024C>T tRNA
Ala
 mouse appears to 
be a good model of a pathogenic mt-tRNA point mutation in mtDNA disease as: the 
m.5024C>T mutation was shown to be pathogenic; mice displayed phenotypic evidence 
of respiratory chain deficiency; aged mice displayed evidence of disease progression; 
different cell types showed different biochemical thresholds and mitotic segregation was 
observed, with a preferential loss of the mutation in actively dividing cells. To my 
knowledge this is the first study to present evidence for a good mouse model of a 
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pathogenic heteroplasmic mtDNA point mutation in disease and will therefore be 
invaluable for understanding factors that govern mtDNA disease progression, 
presentation, transmission and the development of potential treatments. 
6.1 Segregation of mtDNA point mutations: why is there a selective loss?  
Interestingly the data in this thesis highlighted a difference in the accumulation of 
mtDNA point mutations in colonic crypts over time.  Deleterious mutations were able to 
clonally expand and cause an increase in COX deficiency in the ageing PolgA
+/mut
 
mouse colonic epithelium, yet the m.5024C>T mutation was selectively eliminated 
from colonic crypts in mutant tRNA
Ala
 mice over time. This therefore begs the question 
why some mtDNA point mutations are lost from the stem cell pool and others are not?  
Whilst the m.5024C>T mutation is predicted to be highly deleterious and cause a 
significant deformation in the tRNA, the elimination of this mutation cannot simply be 
attributable to pathogenicity. Equally pathogenic, non-synonymous mtDNA point 
mutations and STOP codons have also been detected in mt-tRNA genes and protein 
encoding genes in the ageing colonic epithelium of both the PolgA
+/mut
 mouse (chapter 3 
and (Baines, Stewart et al. 2014)) and ageing human colon (Greaves, Elson et al. 2012). 
An alternative argument could be the origin and occurrence of the mtDNA point 
mutation within the stem cells and the subsequent time taken for clonal expansion. In 
the m.5024C>T tRNA
Ala
 mouse the mutation was already present at high levels in the 
germline, whereas somatic mtDNA point mutations are only believed to occur during 
early development and have to clonally expand throughout adulthood (Coller, Khrapko 
et al. 2001; Elson, Samuels et al. 2001; Greaves 2014). This could mean that the 
m.5024C>T mutation was lost, simply because it accumulated to higher levels quicker 
in the colonic crypts. However, this would not explain why somatic mtDNA point 
mutations are still detected at high heteroplasmy (>75%) and in the homoplasmic state 
in COX deficient colonic crypts in both the PolgA
+/mut
 mouse (chapter 3 and (Baines, 
Stewart et al. 2014)) and human colon (Greaves, Elson et al. 2012). 
The incidence of clonally expanding mtDNA point mutations in the ageing colonic 
epithelium, in combination with the pathogenicity of the mutation, could be an 
alternative and more plausible hypothesis to explain segregation and the loss of certain 
pathogenic point mutations from stem cell populations. In the ageing human colon it 
takes ~20 years for the first somatic mtDNA point mutations to clonally expand and 
cause COX deficiency (Taylor, Barron et al. 2003). Over time there is an exponential 
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increase in COX deficiency in the colonic epithelium, with different COX deficient 
crypts displaying different clonally expanded somatic mtDNA point mutations (Taylor, 
Barron et al. 2003; Greaves, Elson et al. 2012; Baines, Stewart et al. 2014). Indeed, an 
increase in the frequency of clonally expanded somatic mtDNA point mutations has 
recently been reported in the ageing human colonic epithelium (Greaves 2014). It could 
therefore be possible that all markedly pathogenic clonally expanded mtDNA point 
mutations are lost from colonic crypts after a certain amount of time, as stem cells 
carrying such mutations become arrested/ undergo apoptosis and are unable to 
repopulate the crypt. If this were the case clonally expanded somatic mtDNA mutations 
and an increase in COX deficiency would simply be observed in the colon of ageing 
humans and PolgA
+/mut 
mice, due to an increase in clonally expanded mtDNA point 
mutations that occur with age (Greaves 2014). This hypothesis could explain why I saw 
a loss of the m.5024C>T mutation in mutant tRNA
Ala
 mice where I was just examining 
the expansion of the one notably pathogenic mutation (Figure 6-1a); unlike in the 
PolgA
+/mut
 mouse and ageing human colon where the overall incidence of clonally 
expanded somatic mtDNA point mutations is examined, which will constantly increase 
with age and include a number of pathogenic mutations (Figure 6-1b) (Greaves, Elson 
et al. 2012; Baines, Stewart et al. 2014; Greaves 2014). As such this hypothesis suggests 
that the selective loss of a mtDNA point mutation would be governed by both the 
pathogenicity of the mutation and the incidence of clonal expansions.  
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Figure 6-1: The accumulation of mtDNA point mutations in colonic crypts is affected by the incidence of clonal 
expansions. 
(a) In the m.5024C>T tRNAAla mice colonic epithelium, the half-life of a COX deficient crypt is decreased and so a 
stem cell becomes arrested or undergoes apoptosis after harbouring high levels of the m.5024C>T mutation for a 
certain length of time. Colonic crypts are only repopulated by stem cells with low levels of the mutation that have 
survived and so the mutation is lost from the colonic epithelium over time. (b) In the ageing colonic epithelium high 
level, clonally expanded mtDNA point mutations are still lost from the stem cell pool by causing growth arrest/ 
apoptosis, however the increased frequency of clonal expansions means that clonally expanded somatic mtDNA 
mutations are increasingly detected in colonic crypts, overriding the loss. Blue lines represent the clonal expansion of 
an mtDNA point mutation and red lines represent loss of the mutation from the stem cell pool. 
6.2 The colon: a model replicative tissue 
The data in this thesis confirms that mtDNA point mutations undergo high rates of 
clonal expansion in the colon (Taylor, Barron et al. 2003; Fellous, McDonald et al. 
2009), and convincingly shows that mitochondrial dysfunction presents much earlier in 
the colon than in other tissues. This is most likely due to the hypothesised low mtDNA 
copy number in colonic crypt stem cells (Barker, Van Es et al. 2007). Interestingly, 
however, data from these studies indicates for the first time that the colonic crypts may 
not be as permissive stem cell environment as originally thought. Data from the mutant 
tRNA
Ala
 mice suggests that respiratory chain deficient colonic crypt stem cells cannot 
survive and repopulate crypts for extended periods of time, but eventually become 
arrested. This therefore questions the use of mtDNA point mutations as benign stem cell 
markers used in cell lineage tracing and understanding stem cell dynamics (Fellous, 
McDonald et al. 2009). Nevertheless the data presented does support the use of the 
colonic epithelium as a model replicative tissue for studying stem cell populations. The 
defined architecture of the crypts and the fact that all cells are derived from the stem 
cells in the crypt base was crucial in understanding the prevalence of partially COX 
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deficient crypts in the colon of aged mutant tRNA
Ala
 mice to form the above hypothesis 
in an attempt to explain the selective loss and segregation of mtDNA point mutations.   
6.3 Use of mouse models 
Species specific differences and the breeding of mice in a controlled environment, with 
a lack of exposure to environmental stresses will always be a disadvantage of using 
mouse models to study the mechanisms involved in ageing and disease. This was the 
reason for such extensive phenotypic and genotypic characterisation of the respiratory 
chain deficiency and mtDNA point mutations, at the cellular level, in the two mouse 
models used in this thesis, so that extensive comparisons could be made to human 
processes. Mouse models are invaluable for studying the ageing process and disease 
progression, quite simply due to the ability to collect tissues at multiple stages 
throughout their lifespan, allowing processes to be monitored over time in a relatively 
large number of samples. Moreover multiple tissues can be collected from the same 
mouse, which is often not possible for humans. The implications of this were paramount 
in the study on mutant tRNA
Ala
 mice, and the discovery that the m.5024C>T mutation 
was selectively eliminated from the colonic epithelium, but maintained at constant 
levels in post-mitotic tissues of aged animals. Mitotic segregation is a hallmark of 
human mtDNA disease, and contributes to disease heterogeneity (Taylor and Turnbull 
2005) and as such this mouse will be valuable for monitoring the effects of this on 
disease progression and prognosis. Finally, the extensive homology between the human  
and mouse mtDNA genomes (Bibb, Van Etten et al. 1981), renders them an ideal 
mammalian model in which to study the effects of mtDNA defects in ageing and 
disease.  
6.4 Implications for ageing and disease 
The studies in this thesis confirmed that COX/SDH histochemistry is useful for 
identifying the presence of mtDNA defects in cells in both disease and ageing, which 
was fundamental in characterising the PolgA
+/mut
 mouse and the m.5024C>T tRNA
Ala
 
mouse as good models of mitochondrial dysfunction in ageing and disease. Indeed, the 
PolgA
+/mut
 mouse is already proving valuable for uncovering the potential functional 
consequences of age-related respiratory chain deficiency upon cellular processes and 
normal tissue homeostasis in colonic crypts, with potential implications for the 
development of age-related disease, namely cancer. However, much further research 
still needs to be done to determine how mtDNA point mutations cause alterations in 
these cellular processes. Mechanisms have been suggested in this thesis concerning: 
196 
 
alterations in ROS production and signalling; defective energy production affecting 
energy requiring cellular processes; and disturbed Ca
2+
 homoeostasis and signalling. 
However, experiments targeted to answering this question still need to be developed and 
will be fundamental to categorically establish a role for somatic mtDNA point 
mutations in the ageing of replicative tissues. 
Research using the m.5024C>T tRNA
Ala
 mouse is also proving valuable for studying 
certain disease mechanisms that influence the heterogeneity of mtDNA disease, 
progression and transmission including: mitotic segregation of the mutation and a 
selective loss from actively dividing cells; different biochemical thresholds in different 
cell types and a non-random transmission of the mutation.  Further characterisation of 
the extent of mitochondrial dysfunction in these mice, such as complex I deficiency and 
muscle histology, will be crucial to categorically determine the mtDNA disorder this 
mouse is most representative of.  Indeed the use of these mice to study mtDNA disease 
extends much further beyond disease presentation and progression, with the potential to 
use this mouse to test novel treatments prior to their use in humans. For example there 
are future plans to treat these mice with restriction endonuclease enzymes targeted to 
the mitochondria (mitoTALENS) to see if the mtDNA mutation can be cleaved from the 
mtDNA genome. Furthermore there is the potential to use a modified tRNA synthetase, 
such as leucyl tRNA synthetase, to see if this would stabilise and rescue levels of 
tRNA
Ala
, thus preventing the mitochondrial dysfunction in these mice. Moreover these 
mice could be bred on different nuclear backgrounds, to determine how the interaction 
between the nuclear and mtDNA genomes plays a role in mtDNA disease heterogeneity 
in patients that harbour the same mtDNA point mutation (Jacobs 2003). Undoubtedly 
the potential that these mice hold for mtDNA disease research is extensive and the 
detailed molecular characterisation performed in this thesis will prove fundamental for 
the continued monitoring of disease progression/presentation and determining the 
efficacy of treatments in rescuing these phenotypes.  
6.5 Concluding remarks 
In conclusion the data presented in this thesis has characterised the PolgA
+/mut
 mouse 
and the m.5024C>T tRNA
Ala
 mutant mice as good representative models of the 
mitochondrial dysfunction we see in human ageing and disease. Already the 
characterisation of these mice and functional analyses are providing valuable insights 
for understanding the role of mtDNA point mutations in the ageing process and the 
mechanisms involved in disease progression and transmission. Using mouse models to 
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understand these mechanisms is crucial if we ever aim to recue tissue phenotypes and 
improve survival to benefit human health and well-being. 
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Chapter 7. Appendices 
7.1 Appendix A: Mice used in this study 
 
Details of PolgA
+/mut
 mice used for detection of 
clonally expanded somatic mtDNA point 
mutations in single colonic crypts 
Mouse number Age Tissue 
Hz1346 18 weeks Colon 
Hz1140 30 weeks  Colon 
Hz539 40 weeks  Colon 
Hz576 40 weeks  Colon 
Hz21 48 weeks  Colon 
Hz27 48 weeks  Colon 
Hz160 59 weeks  Colon 
Hz1059 81 weeks  Colon 
Hz1136 81 weeks  Colon 
Hz1137 81 weeks  Colon 
 
Details of PolgA
mut/mut
 used for COX deficiency calculations for 
modelling 
Mouse number Genotype Age Tissue 
LPA194 PolgA
mut/mut 
3 months Colon 
LPA195 PolgA
mut/mut
 3 months Colon 
Polg215 PolgA
mut/mut
 3 months Colon 
Polg220 PolgA
mut/mut
 3 months Colon 
Polg221 PolgA
mut/mut
 3 months Colon 
Polg126 PolgA
mut/mut
 6 months Colon 
Polg129 PolgA
mut/mut
 6 months Colon 
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Polg150 PolgA
mut/mut
 6 months Colon 
Polg194 PolgA
mut/mut
 6 months Colon 
Polg196 PolgA
mut/mut
 6 months Colon 
Polg73 PolgA
mut/mut
 9 months Colon 
Polg88 PolgA
mut/mut
 9 months Colon 
Polg115 PolgA
mut/mut
 9 months Colon 
Polg118 PolgA
mut/mut
 9 months Colon 
Polg158 PolgA
mut/mut
 9 months Colon 
Polg161 PolgA
mut/mut
 9 months Colon 
Polg199 PolgA
mut/mut
 9 months Colon 
Polg137 PolgA
mut/mut
 11.5 months Colon 
Polg163 PolgA
mut/mut
 11 months Colon 
Polg63 PolgA
mut/mut
 12 months Colon 
Polg74 PolgA
mut/mut
 12 months Colon 
Polg78 PolgA
mut/mut
 12 months Colon 
Polg85 PolgA
mut/mut
 12 months Colon 
 
M.5024  tRNA
Ala
 mutant and control mice 
Mouse number Age Tail 
m.5024C>T 
heteroplasmy 
Mutant/Control Tissues 
111 83 weeks 29% Mutant Colon 
112 83 weeks  24% Mutant Colon 
471 72 weeks  45% Mutant Colon 
472 72 weeks  18% Mutant Colon 
483 71 weeks  39% Mutant Colon 
1180 49 weeks  11% Mutant Colon 
1181 14 weeks  54% Mutant Colon 
1183 48 weeks  55% Mutant Colon 
1184 48 weeks  59% Mutant Colon 
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1622 22 weeks  74% Mutant Colon 
1623 21 weeks  75% Mutant Colon 
1624 21 weeks 64% Mutant Colon 
1625 21 weeks 69% Mutant Colon 
1626 21 weeks  72% Mutant Colon 
1734 20 weeks 60% Mutant 
Colon, Muscle, 
Heart 
1764 20 weeks 66% Mutant 
Colon, Muscle, 
Heart 
2265 20 weeks 60% Mutant 
Colon, Muscle, 
Heart 
2266 20 weeks 53% Mutant 
Colon, Muscle, 
Heart 
2267 20 weeks 77% Mutant 
Colon, Muscle, 
Heart 
2268 20 weeks 66% Mutant 
Colon, Muscle, 
Heart 
2269 20 weeks 74% Mutant 
Colon, Muscle, 
Heart 
2307 
12 weeks 
(culled) 
51% Mutant 
Colon, Muscle, 
Heart 
1299 10 weeks 50% Mutant Colon 
1305 10 weeks 12% Mutant Colon 
2191 22 weeks 10% Control 
Colon, Muscle, 
Heart 
2192 22 weeks 20% Control Muscle, Heart 
2489 21 weeks 7% Control 
Colon, Muscle, 
Heart 
2430 22 weeks 24% Control 
Colon, Muscle, 
Heart 
2431 22 weeks 7% Control Muscle, Heart 
2432 22 weeks 13% Control 
Colon, Muscle, 
Heart 
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2241 65.9 weeks 68% Mutant Colon 
2242 65.9 weeks 65% Mutant Colon 
2261 64.9 weeks 64% Mutant Colon 
2199 68 weeks 61% Mutant Colon 
2200 68 weeks 58% Mutant Colon 
2262 64.9 weeks 52% Mutant Colon 
2264 64.9 weeks 60% Mutant Colon 
9831 65.7 weeks WT Control Colon 
10045 62.7 weeks WT Control Colon 
2884 70 weeks 66% 
Mutant 
Colon, Muscle, 
Heart 
2885 70 weeks 26% 
Mutant 
Colon, Muscle, 
Heart 
2887 70 weeks 51% 
Mutant 
Colon, Muscle, 
Heart 
17066 69 weeks WT 
Control 
Colon, Muscle, 
Heart 
17369 68 weeks WT 
Control 
Colon, Muscle, 
Heart 
TN139 
 
0% 
Positive 
control Colon 
 
Details of PolgA
+/mut
 mice used for RNA sequencing  
Mouse number Genotype Age Tissue 
Polg23 PolgA
+/mut
 12 months Colon 
Polg25 PolgA
+/mut
 12 months Colon 
Polg42 PolgA
+/mut
 12 months Colon 
Polg44 PolgA
+/mut
 12 months Colon 
Polg45 PolgA
+/mut
 12 months Colon 
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7.2 Appendix B: Primer sequences and positions for molecular biology 
techniques 
 
Polg POP PCR Primers 
Primers Primer Position Size (incl primer) 
POLG58Forward  
POLG59Reverse 
                          1114-1134 
                          1407-1386 
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Polg POP PCR Primers 
Primer Sequence 
POLG58Forward 
POLG59Reverse 
5’-GCCTCGCTTTCTCCGTGACT-3’    
5’-GGATGTGGCCCAGGCTGTAACTCA-3’ 
 
Primers used for amplification of the entire mitochondrial genome 
Primers Primer Position Size (incl primer) 
1 1081-1101 2314-2294 1234 
2 2666-2685 3840-3821 1175 
3 4241-4260 5516-5498 1276 
4 5904-5926 7135-7116 1232 
5 7638-7658 8832-8811 1195 
6 9377-9396 10162-10143 786 
7 10628-10647 11868-11848 1241 
8 12404-12424 13685-13665 1282 
9 14190-14209      15334-15314 1145 
10 15774-15794 676-657 1198 
11 54-74 1217-1198 1164 
12 1629-1648 2757-2738 1129 
13 3132-3151 4372-4353 1241 
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Primers used for amplification of the entire mitochondrial genome 
14 5181-5200 6250-6231 1070 
15 6432-6452 7787-7769 1356 
16 8192-8214 9487-9464 1296 
17 9822-9844 10735-10716 914 
18 11131-11150 12493-12473 1363 
19 12996-13015 14317-14298 1322 
20 14682-14701 15898-15879 1217 
21 556-575        1745-1725 1190 
22 2116-2135 3330-3311 1215 
23 3757-3776 5177-5157 1421 
24 5406-5424 6558-6539 1153 
25 7026-7045 8293-8217 1268 
26 8745-8765 9824-9799 1080 
27 10060-10079 11269-11250 1210 
28 11773-11793 13142-13123 1370 
29 13609-13629 14818-14799 1210 
30 15141-15161 132-113 1287 
 
Primers used for amplification of the entire mitochondrial genome 
Primer Sequence 
1 Forward 
1 Reverse 
TGTAAAACGACGGCCAGTATGAACACTCTGAACTAATCC 
CAGGAAACAGCTATGACCACTTTGACTTGTAAGTCTAGG 
2 Forward 
2 Reverse 
TGTAAAACGACGGCCAGTAGAGAAGGTTATTAGGGTGG 
CAGGAAACAGCTATGACCGGATAAGGTGTTTAGGTAGC 
3 Forward 
3 Reverse 
TGTAAAACGACGGCCAGTCCATTCCACTTCTGATTACC 
CAGGAAACAGCTATGACCAAAAGCATGGGCAGTTACG 
4 Forward 
4 Reverse 
TGTAAAACGACGGCCAGTCTGCTCCTATTATCACTACC 
CAGGAAACAGCTATGACCGATATAGAGGACTAAGGAGC 
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Primers used for amplification of the entire mitochondrial genome 
5 Forward 
5 Reverse 
TGTAAAACGACGGCCAGTTGTCCTAGAAATGGTTCCAC 
CAGGAAACAGCTATGACCGTACAATAGGAGTGTGGTGGCC  
6 Forward 
6 Reverse 
TGTAAAACGACGGCCAGTTTGATGAGGATCTTACTCCC 
CAGGAAACAGCTATGACCGTAGGTTGAGATTTTGGACG 
7 Forward 
7 Reverse 
TGTAAAACGACGGCCAGTAATCGGTTCTATTCCACTGC 
CAGGAAACAGCTATGACCAGAATTTGATTGATGTGGTGG 
8 Forward 
8 Reverse 
TGTAAAACGACGGCCAGTAGGAAAATCAGCACAATTTGG 
CAGGAAACAGCTATGACCATGATGTTGGAGTTATGTTGG 
9 Forward 
9 Reverse 
TGTAAAACGACGGCCAGTCACTCATTCATTGACCTACC 
CAGGAAACAGCTATGACCTCATTTCAGGTTTACAAGACC 
10 Forward 
10 Reverse 
TGTAAAACGACGGCCAGTGAAACTTTATCAGACATCTGG 
CAGGAAACAGCTATGACCGCTGAATTAGCAAGAGATGG 
11 Forward 
11 Reverse 
TGTAAAACGACGGCCAGTTGTATCCCATAAACACAAAGG 
CAGGAAACAGCTATGACCTGCGGTACTAGTTCTATAGC 
12 Forward 
12 Reverse 
TGTAAAACGACGGCCAGTAGAAAGCGTTCAAGCTCAAC 
CAGGAAACAGCTATGACCAGAACACTATTAGGGAGAGG 
13 Forward 
13 Reverse 
TGTAAAACGACGGCCAGTTCACTATTCGGAGCTTTACG 
CAGGAAACAGCTATGACCGATAGTAGAGTTGAGTAGCG  
14 Forward 
14 Reverse 
TGTAAAACGACGGCCAGTAATGGCGGTAGAAGTCTTAG 
CAGGAAACAGCTATGACCGCTGATGTAAAGTAAGCTCG 
15 Forward 
15 Reverse 
TGTAAAACGACGGCCAGTGATACATACTATGTAGTAGCC 
CAGGAAACAGCTATGACCTTGATGTATCTAGTTGTGG 
16 Forward 
16 Reverse 
TGTAAAACGACGGCCAGTCACATACATTTACACCTACTACC 
CAGGAAACAGCTATGACCTTAATGAAGATAACAGTGTACAGG 
17 Forward 
17 Reverse 
TGTAAAACGACGGCCAGTAAAAAAATTAATGATTTCGACTC 
CAGGAAACAGCTATGACCCATGAAGCGTCTAAGGTGTG  
18 Forward 
18 Reverse 
TGTAAAACGACGGCCAGTCATCATCACTCCTATTCTGC 
CAGGAAACAGCTATGACCGTACTTGAGTGTAGTAGTGCT 
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Primers used for amplification of the entire mitochondrial genome 
19 Forward 
19 Reverse 
TGTAAAACGACGGCCAGTACAGCTATGTACAGCATACG 
CAGGAAACAGCTATGACCTCTGATGTGTAGTGTATGGC 
20 Forward 
20 Reverse 
TGTAAAACGACGGCCAGTGCTTTCCACTTCATCTTACC 
CAGGAAACAGCTATGACCCACAGTTATGTTGGTCATGG 
21 Forward 
21 Reverse 
TGTAAAACGACGGCCAGTAGAGAACTACTAGCCATAGC 
CAGGAAACAGCTATGACCTACTCATACTAACAGTGTTGC 
22 Forward 
22 Reverse 
TGTAAAACGACGGCCAGTTTGACCTTTCAGTGAAGAGG 
CAGGAAACAGCTATGACCTTGTTTCTGCTAGGGTTGAG 
23 Forward 
23 Reverse 
TGTAAAACGACGGCCAGTCAAGCCCTCTTATTTCTAGG 
CAGGAAACAGCTATGACCTTTTTTCGGCGGTAGAAGTAG 
24 Forward 
24 Reverse 
TGTAAAACGACGGCCAGTGGAATAGTGGGTACTGCAC 
CAGGAAACAGCTATGACCTTGCTCATGTGTCATCTAGG 
25 Forward 
25 Reverse 
TGTAAAACGACGGCCAGTTCCAACTTGGTCTACAAGAC 
CAGGAAACAGCTATGACCGTTTTTAGTTTGTGTCGGAAGCC 
26 Forward 
26 Reverse 
TGTAAAACGACGGCCAGTCTACTCACCAATATCCTCAC 
CAGGAAACAGCTATGACCTTTTAAACTAATTG 
27 Forward 
27 Reverse 
TGTAAAACGACGGCCAGTACCATCTTAGTTTTCGCAGC 
CAGGAAACAGCTATGACCGCTAGATTAGCTAGACTTGC 
28 Forward 
28 Reverse 
TGTAAAACGACGGCCAGTTCTTCATTCTTCTACTATCCC 
CAGGAAACAGCTATGACCGACAAATCCTGCAAAGATGC 
29 Forward 
29 Reverse 
TGTAAAACGACGGCCAGTTACTACCATCATTCAAGTAGC 
CAGGAAACAGCTATGACCGTATAGTAGGGGTGAAATGG 
30 Forward 
30 Reverse 
TGTAAAACGACGGCCAGTCTTATCTTAACCTGAATTGGG 
CAGGAAACAGCTATGACCTCTATGGAGGTTTGCATGTG 
 
M.5024 First round PCR Primers 
Primers Primer Position Size (incl primer) 
2Forward                                2666-2685  4470 
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M.5024 First round PCR Primers 
4Reverse                                7135-7116 
 
 
 
M.5024 First round PCR Primers 
Primer Sequence 
2 Forward 
4 Reverse 
TGTAAAACGACGGCCAGTAGAGAAGGTTATTAGGGTGG 
CAGGAAACAGCTATGACCGATATAGAGGACTAAGGAGC 
 
M.5024 Second round PCR Primers 
Primers Primer Position Size (incl primer) 
3Forward 
3Reverse 
                               4241-4260 
                               5516-5498 
 1276 
 
M.5024 Second round PCR Primers 
Primer Sequence 
3 Forward 
3 Reverse 
TGTAAAACGACGGCCAGTCCATTCCACTTCTGATTACC 
CAGGAAACAGCTATGACCAAAAGCATGGGCAGTTACG 
 
Pyrosequencing PCR primers  
Primers Primer Position Size (incl primer) 
5024 Forward 
biotinylated 
5024 Reverse 
                          4891-4913 
 
                          5114-8091 
 224 
 
Pyrosequencing PCR primers  
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Pyrosequencing PCR primers  
Primer Sequence 
5024 Forward 
biotinylated 
5024 Reverse 
Biosg/TTCCACCCTAGCTATCATAAGC 
 
CGTAGGTTTAATTCCTGCCAATCT 
 
Long-range PCR (1
st 
und)  
Primer  Primer position                             Size (incl primer) 
L272 
H16283 
  272-301 16 042 
                      16283-16312 
 
Long-range PCR (1
st
 round)  
Primer Sequence 
L272 
H16283 
GACTAAGTTATACCTCTTAGGGTTGGTAAA 
CTGAATAGAGTATGATTAGAGTTTTGGTTC 
 
Long-range PCR (2
nd
 round)  
Primer  Primer position                             Size (incl primer) 
L1275 
H15833 
  1275-1304 14 530 
                      15833-15804 
 
Long-range PCR (2
nd
 round)  
Primer Sequence 
L1275 
H15833 
TTTTGCATAATGAACTAACTAGAAAACTTC 
GTATGGGCGATAACGCATTTGATGGCCCTG 
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7.3 Appendix C-Somatic mtDNA point mutations detected in the PolgA+/mut mouse colonic crypts. 
Crypts and mutations highlighted in blue were those detected in COX deficient colonic crypts from two 48 week old PolgA+/mut mice (Holly Baines, MRes Project) 
Crypt 
COX 
Histochemistry Mutation 
WT 
base 
Mutant 
base 
Heteroplasmy 
level Gene 
Codon 
change 
Amino acid 
change 
Substitution 
type 
1 
Deficient m.4892 T>C T C 100% MT-ND2 TTC Phe-Phe syn 
Deficient m.6779 T>C T C 25% MT-CO1 CCA Ser-Pro ns 
2 
Deficient m.4892 T>C T C 100% MT-ND2 TTC Phe-Phe syn 
Deficient m.5831 T>C T C 50% MT-CO1 ACT Ile-Thr ns 
Deficient m.7413 C>T C T 50% MT-CO2 TGA Arg-Trp ns 
Deficient m.9740 T>C T C 100% MT-ND3 CCA Leu-Pro ns 
Deficient m.10392 A>G A G 25% MT-ND4 CTG Leu-Leu syn 
Deficient m.13817 G>T G T 25% MT-ND6 AAA Asn-Lys ns 
Deficient m.13852 C>T C T 50% MT-ND6 ACT Ala-Thr ns 
3 Deficient m.6098 T>A T A 75% MT-CO1 GAA Val-Glu ns 
4 
Deficient m.986 G>A G A 50% MT-16SrRNA - -   
Deficient m.2283 G>T G T 50% MT-16SrRNA - -   
Deficient m.6024 G>A G A 75% MT-CO1 CAA Gln-Gln syn 
5 
Deficient m.1214 C>G C G 75% MT-16SrRNA -     
Deficient m.5695 G>A G A 100% MT-CO1 AGA Gly-Gly syn 
Deficient m.6835 C>T C T 75% MT-CO1 TAC His-Tyr ns 
Deficient m.6919  C>T C T 100% MT-tRNA
Ser
 -     
Deficient m.7641 G>A G A 100% MT-CO2 ATC Val-Ile ns 
6 
Deficient m.506 C>T C T 75% MT-12SrRNA - -   
Deficient m.812 C>G C G 75% MT-12SrRNA - -   
Deficient m.2424 C>T C T 50% MT-16SrRNA - -   
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Deficient m.2446 C>T C T 75% MT-16ArRNA - -   
Deficient m.4946 A>G A G 75% MT-ND2 GCC Thr-Ala ns 
Deficient m.11539 C>T C T 25% MT-ND4 ATA Thr-Met ns 
Deficient m.15243 C>T C T 50% MT-CYB TCA Pro-Ser ns 
7 
Deficient m.3429 G>A G A 75% MT-ND1 AAG Glu-Lys ns 
Deficient m.5713 A>G A G 25% MT-CO1 TGC Tyr-Cys ns 
Deficient m.5894 T>A T A 75% MT-CO1 CTA Leu_leu syn 
Deficient m.6444 G>C G C 50% MT-CO1 CTA Val-Leu ns 
Deficient m.14400 G>A G A 25% MT-CYB AGA Gly-Null ns 
Deficient m.16254 G>A G A 50% ctrl region - - - 
8 
Deficient m.847 T>A T A 50% MT-12SrRNA - -   
Deficient m.2537 G>A G A 50% MT-16SrRNA - -   
Deficient m.4143 A>T A T 25% MT-ND2 ATC Asn-Ile ns 
Deficient m.5959 C>T C T 50% MT-CO1 ATA Thr-Met ns 
Deficient m.8126 C>T C T 50% MT-ATP6 ATA Thr-Met ns 
Deficient m.8744 C>T C T 75% MT-CO3 GGT Gly-Gly syn 
9 
Deficient m.1181 A>G A G 25% MT-16SrRNA -     
Deficient m.6305 C>T C T 25% MT-CO1 ACT Thr-Thr syn 
Deficient m.11402 T>A T A 50% MT-ND4 ATA Ile-Met ns 
Deficient m.12015 G>A G A 25% MT-ND5 ATA Val-Met ns 
10 
Deficient m.221 C>T C T 75% MT-12SrRNA       
Deficient m.2649 C>T C T 50% MT-16SrRNA       
Deficient m.2807 C>T C T 75% MT-ND1 TTT Phe-Phe syn 
Deficient m.2970 G>A G A 75% MT-ND1 ACA Ala-Thr ns 
Deficient m.6402 T>C T C 75% MT-CO1 CCC Ser-Pro ns 
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Deficient m.7533 C>T C T 50% MT-CO2 GTC Ala-Val ns 
Deficient m.10360 T>C T C 25% MT-ND4 TCA Leu-Ser ns 
Deficient m.15357 C>T C T 75% Mt-tRNA P       
11 
Deficient m.4925 C>T C T 25% MT-ND2 TCC Pro-Ser ns 
Deficient m.5714 C>T C T 25% MT-CO1 TAT Tyr-Tyr syn 
Deficient m.5977 C>T C T 25% MT-CO1 ATA Thr-Met ns 
12 
Deficient m.212 G>A G A 25% MT-12SrRNA       
Deficient m.366 C>T C T 75% MT-12SrRNA       
Deficient m.2745 C>T C T 100% MT-tRNA L1       
Deficient m.3053 G>A G A 75% MT-ND1 GGA Gly-Gly syn 
Deficient m.4830 C>T C T 25% MT-ND2 CTA Pro-Leu ns 
Deficient m.6640 G>A G A 75% MT-CO1 CAA Arg-Gln ns 
Deficient m.6886 C>T C T 75% MT-tRNA S1       
Deficient m.8489 C>T C T 75% MT-ATP6 ATA Thr-Met ns 
Deficient m.9268 G>A G A 75% MT-CO3 CAA Gln-STOP ns 
Deficient m.10165 C>T C T 25% MT-ND4 L TAA Ala-Val ns 
Deficient m.11062 C>T C T 50% MT-ND4 GTA Ala-Val ns 
Deficient m.11643 C>T C T 75% MT- tRNA S2       
Deficient m.12862 G>A G A 75% MT-ND5 GAA Val-Glu ns 
Deficient m.12946 G>A G A 75% MT-ND5 TAC Cys-Tyr ns 
Deficient m.13268 A>G A G 25% MT-ND5 ATG Met-Met syn 
Deficient m.14471 T>C T C 75% MT-CYB TTC Phe-Phe syn 
13 
Deficient m.4966 C>T C T 75% MT-tRNA W       
Deficient m.5440 G>A G A 75% MT-CO1 CAA Arg-Gln ns 
Deficient m.10387 C>T C T 25% MT-ND4 CTA Pro-Leu ns 
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Deficient m.10420 A>G A G 50% MT-ND4 AGA Lys-Null ns 
Deficient m.14309 C>T C T 50% MT-CYB TAT Tyr-Tyr syn 
Deficient m.14326 C>T C T 50% MT-CYB ATA Thr-Met ns 
Deficient m.15632 C>T C T 25% Ctrl region       
14 
Deficient m.239 C>T C T 25% MT-12SrRNA       
Deficient m. 2461 G>T G T 50% MT-16SrRNA       
Deficient m.3278 G>A G A 25% MT-ND1 CTA Leu-Leu syn 
Deficient m. 3649 T>A T A 50% MT-ND1 TAA Leu-STOP ns 
Deficient m.5580 C>T C T 50% MT-CO1 TTA Leu-Leu syn 
Deficient m.7486 C>T C T 25% MT-CO2 GAT Asp-Asp syn 
Deficient m.12241 C>T C T 25% MT-ND5 GTA Ala-Val ns 
Deficient m.12986 C>T C T 25% MT-ND5 GCT Ala-Ala syn 
Deficient m.12997 C>T C T 25% MT-ND5 ATA Thr-Met ns 
Deficient m.14617 C>T C T 75% MT-CYB ATA Thr-Met ns 
15 
Deficient m.9077 c>T C T 25% MT-CO3 AAT Asn-Asn syn 
Deficient m.14537 C>T C T 25% MT-CYB TAT Tyr-Tyr syn 
Deficient m.15529 A>T A T 25% 
Ctrl Region / 
ETAS2       
16 
Deficient m.491 G>T G T 50% MT-12SrRNA       
Deficient m.501 C>T C T 25% MT-12SrRNA       
Deficient m.1001 A>T A T 25% MT-12SrRNA       
Deficient m.2411 C>T C T 25% MT-16SrRNA       
Deficient m.6186 G>A G A 25% MT-CO1 ATA Val-Met ns 
Deficient m.6418 A>T A T 75% MT-CO1 GTC Asp-Val ns 
Deficient m.7772 C>T C T 50% MT-ATP8 TAA Gln-STOP ns 
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Deficient m.8109 C>T C T 50% MT-ATP6 CAT His-His syn 
17 
Deficient m.5032 C>T C T 75% MT-tRNA A       
Deficient m.9430 T>C T C 75% MT-tRNA G       
Deficient m.9666 G>A G A 75% MT-ND3 ACT Ala-Thr ns 
Deficient m.11317 C>T C T 75% MT-ND4 TTA ser-Leu ns 
Deficient m.12218 C>T C T 75% MT-ND5 TAT Tyr-Tyr syn 
Deficient m.13403 C>T C T 75% MT-ND5 GAT Asp-Asp syn 
Deficient m.15005 A>T A T 25% MT-CYB AAT Lys-Asn ns 
Deficient m.15298 G>A G A 75% MT-tRNA T       
18 
Deficient m.5718 C>T C T 50% MT-CO1 TCT Pro-ser ns 
Deficient m.11508 A>T A T 50% MT-ND4 TCT Thr-Ser ns 
Deficient m.13783 C>T C T 75% MT-ND6 GTA Val-Val syn 
19 Deficient m.5976 A>T A T 25% MT-CO1 TCA Thr-Ser ns 
20 
Deficient m.2083 G>A G A 75% MT-16SrRNA       
Deficient m.2386 A>T A T 50% MT-16SrRNA       
Deficient m.4879 C>T C T 25% MT-ND2 CCT Pro-Pro syn 
Deficient m.5096 G>A G A 75% MT-tRNA N       
Deficient m.5647 C>T C T 75% MT-CO1 CTA Pro-Leu ns 
Deficient m.6241 T>C T C 50% MT-CO1 TCT Phe-Ser ns 
Deficient m.6850 C>T C T 50% MT-CO1 CTA Pro-Leu ns 
Deficient m.8864 C>G C G 75% MT-CO3 TTG Phe-Leu ns 
Deficient m.9985 G>A G A 75% MT-ND4L ATA Val-Met ns 
Deficient m.11710 C>T C T 75% MT- tRNA l2       
Deficient m.13789 C>T C T 50% MT-ND6 TTA Leu-Leu syn 
Deficient m.13967 C>T C T 75% MT-ND6 AAT Ser-Asn ns 
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21 
Deficient m.14808 C>T C T 100% MT-CYB TCC Pro-Ser ns 
Deficient m.14818 C>T C T 25% MT-CYB ATA Thr-Met ns 
Deficient m.14925 C>T C T 100% MT-CYB TCA Pro-Ser ns 
Deficient m.14938 C>T C T 25% MT-CYB CTA Pro-Leu ns 
22 
Deficient m.5536 T>A T A 75% MT-CO1 GAA Val-Glu ns 
Deficient m.6964 C>T C T 75% MT-tRNA D -   - 
Deficient m.7164 C>T C T 75% MT-CO2 ATA Thr-met ns 
Deficient m.9520 C>T C T 75% MT-ND3 GTA Ala-Val ns 
Deficient m.16166 A>T A T 75% ctrl region -   - 
Deficient m.16286 A>G A G 75% ctrl region -   - 
23 
Deficient m.2679 A>T A T 100% MT-tRNA L1 -   - 
Deficient m.4890 T>A T A 50% MT-ND1 TAT Phe-Tyr ns 
Deficient m.5686 C>T C T 25% MT-CO1 GTA Ala-Val ns 
Deficient m.6342 C>T C T 75% MT-CO1 TTA Leu-Leu syn 
Deficient m.11012 A>T A T 100% MT-ND4 TTT Leu-Phe ns 
Deficient m.11429 C>T C T 25% MT-ND4 AAT Asn-Asn syn 
Deficient m.12080 C>T C T 100% MT-ND5 AAT Asn-Asn syn 
Deficient m.12143 C>T C T 100% MT-ND5 GCT Ala-Ala syn 
24 
Deficient m.2078 A>T A T 100% MT-16SrRNA       
Deficient m.4885 A>T A T 75% MT-ND2 CTT Leu-Leu syn 
Deficient m.6472 C>T C T 75% MT-CO1 TTA ser-Leu ns 
Deficient m.9203 G>A G A 75% MT-CO3 ATA Met-Met syn 
Deficient m.11951 C>T C T 100% MT-ND5 ACT Thr-Thr syn 
Deficient m.14905 A>G A G 75% MT-CYB GGC Asp-Gln ns 
Deficient m.15921 T>A T A 100% Ctrl Region       
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25 
Deficient m.1776 T>A T A 75% MT-16SrRNA -   - 
Deficient m.5521 T>C T C 50% MT-CO1 ACA Met-Thr ns 
Deficient m.5931 C>A C A 75% MT-CO1 ATA leu-Met ns 
Deficient m.6484 T>A T A 75% MT-CO1 GAG Val-Glu ns 
Deficient m.8627 A>G A G 50% MT-CO3 GCG Ala-Ala syn 
Deficient m.8631 C>T C T 50% MT-CO3 TAC His-Tyr ns 
Deficient m.8650 C>T C T 50% MT-CO3 CTA Pro-Leu ns 
Deficient m.9505 A>G A G 50% MT-ND3 AGG Thr-Null ns 
Deficient m.11172 C>T C T 75% MT-ND4 TGG Arg-Trp ns 
Deficient m.11698 G>A G A 25% MT-tRNA L2 -   - 
Deficient m.12218 C>T C T 50% MT-ND5 TAT Tyr-Tyr syn 
Deficient m.12706 C>T C T 25% MT-ND5 CTA Pro-Leu ns 
Deficient m.14462 A>T A T 50% MT-CYB TCT Ser-Ser syn 
26 
Deficient m.192 A>G A G 50% MT-12SrRNA -   - 
Deficient m.424 G>T G T 25% MT-12SrRNA -   - 
Deficient m.3497 C>T C T 50% MT-ND1 ATT Ile-Ile syn 
Deficient m.3553 C>T C T 50% MT-ND1 TTA Ser-Leu ns 
Deficient m.3609 C>T C T 25% MT-ND1 TAT His-Tyr ns 
Deficient m.5697 A>G A G 75% MT-CO1 GCA Thr-Ala ns 
Deficient m.6047 C>T C T 75% MT-CO1 CAT His-His syn 
Deficient m.6386 A>G A G 75% MT-CO1 CTG Leu-Leu syn 
Deficient m.6444 G>A G A 75% MT-CO1 ATA Val-Met ns 
Deficient 
m. 15323 
A>G A G 25% MT-tRNA T -   - 
27 Deficient m.13033 C>T C T 25% MT-ND5 ATA Thr-Met ns 
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Deficient m.14024 C>T C T 25% MT-ND6 AAA Cys-Lys ns 
28 
Deficient m.4879 C>T C T 25% MT-ND2 CCT Pro-Pro syn 
Deficient m.5096 G>A G A 50% MT-tRNA N       
Deficient m.13457 C>T C T 25% MT-ND5 AAT Asn-Asn syn 
29 
Deficient m.568 G>A G A 100% MT-12SrRNA       
Deficient m.635 C>T C T 75% MT-12SrRNA       
Deficient m.655 C>T C T 75% MT-12SrRNA       
Deficient m.2357 G>A G A 75% MT-16SrRNA       
Deficient m.2712 A>T A T 75% MT-tRNA L1       
Deficient m.2898 G>A G A 75% MT-ND1 ACA Ala-Thr ns 
Deficient m.5357 C>T C T 100% MT-CO1 ACT Thr-Thr syn 
Deficient m.6147 G>A G A 75% MT-CO1 ATA Val-Met ns 
Deficient m.6486 T>A T A 75% MT-CO1 ATT Phe-Ile ns 
Deficient m.10449 T>C T C 75% MT-ND4 CAC Tyr-His ns 
Deficient m.11236 C>T C T 75% MT-ND4 ATA Thr-Met ns 
Deficient m.12829 C>T C T 25% MT-ND5 ATA Thr-Met ns 
Deficient m.13971 C>T C T 75% MT-ND6 TAA Val-Leu ns 
1 
Positive m.3716 C > G C G 50% MT-tRNA I 
disrupts 
DHU stem   - 
Positive m.7961 C > T C T 50% MT-ATP8/6 TAA 
Pro-Leu/Gln-
STOP ns/ns 
Positive m.13224 G>A G A 50% MT-ND5 ATA Val-Met ns 
Positive m.15116 G>A G A 25% MT-CYB TTA Leu-Leu syn 
2 Positive m.2291 T>C T C 50% MT-16SrRNA     - 
3 Positive m.5957 A>G A G 25% MT-CO1 CTG Leu-Leu syn 
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Positive m.12723 C>T C T 25% MT-ND5 TAC His-Tyr ns 
Positive m.12783 C>T C T 75% MT-ND5 TAT His-Tyr ns 
4 
Positive m.3084T>C T C 25% MT-ND1 CCA Ser-Pro ns 
Positive m.8578 G>A  G A 75% MT-ATP6 ATA Val-Met ns 
Positive m.11970 A>G A G 75% MT-ND5 GAA Lys-Glu ns 
Positive m.12783 C>T C T 50% MT-ND5 TAT His-Tyr ns 
Positive m. 13200 A>T A T 50% MT-ND5 TAA Lys-STOP ns 
Positive m.15164 C>T C T 50% MT-CYB GGT Gly-Gly syn 
5 
Positive m.381 A>T A T 75% MT-16SrRNA     - 
Positive m.6265 C>T C T 50% MT-CO1 GTA Ala-Val ns 
Positive m.7860 C>T C T 25% MT-ATP8 ATA Thr-Met ns 
Positive m.8079 A>T A T 50% MT-ATP6 AAT Lys-Asn ns 
Positive m.8126 C>T C T 50% MT-ATP6 ATA Thr-Met ns 
Positive m.10717 A>T A T 50% MT-ND4 CTC His-Leu ns 
Positive m.12105 A>T A T 75% MT-ND5 TCA Thr-Ser ns 
Positive m.12353 C>T C T 75% MT-ND5 TCT Ser-Ser syn 
Positive m.12592 C>T C T 75% MT-ND5 ATC Thr-Ile ns 
Positive m. 14658 A>T A T 75% MT-CYB TAA Lys-STOP ns 
6 
Positive m.3541 T>C T C 50% MT-ND1 CCA Leu-Pro ns 
Positive m.5966 C>T C T 25% MT-CO1 CGT Arg-Arg syn 
Positive m.8048 G>A G A 25% MT-ATP6 CAT Arg-His ns 
Positive m.8489 C>T C T 50% MT-ATP6 ATA Thr-Met ns 
Positive m.11001 C>T  C T 25% MT-ND4 TAA Gln-STOP ns 
Positive m.11113 T>C T C 50% MT-ND4 ACA Met-Thr ns 
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Positive m.11180 C>T C T 25% MT-ND4 CAT His-His syn 
Positive m.13403 C>T C T 75% MT-ND5 GAT Asp-Asp syn 
7 
Positive m.3908 G>A G A 50% MT-tRNA M 
A:G 
Mismatch to 
A:A in AA 
stem   - 
Positive m.8518 C>A C A 75% MT-ATP6 ATA Leu-Met ns 
Positive n.12088 G>T G T 25% MT-ND5 CTA Arg-Leu ns 
Positive m.12211 G>A G A 25% MT-ND5 TAA Trp-STOP ns 
8 Positive m.13033 C>T C T 25% MT-ND5 ATA Trp-Met ns 
9 
Positive m.5499 G>A G A 50% MT-CO1 ATA Val-Met ns 
Positive m.8065 C>T C T 25% MT-ATP6 TAC His-Tyr ns 
Positive m.13435 C>T C T 25% MT-ND5 TTC Ser-Phe ns 
10 
Positive m.2525 C>T C T 25% MT-16SrRNA     - 
Positive m.3226 C>T C T 75% MT-ND1 TTC Ser-Phe ns 
Positive m.5668 C>T C T 75% MT-CO1 GTA Ala-Val ns 
Positive m.6960 A>G A G 50% MT- tRNA D DHU Loop   - 
Positive m.7881 C>T C T 25% MT-ATP8 CTA Pro-Leu ns 
Positive m.8955 C>T C T 25% MT-CO3 TCT pro-Ser ns 
Positive m.9780 C>T C T 75% MT-ND3 TAA Gln-STOP ns 
Positive m. 10549 C>T C T 25% MT-ND4 CTA Pro-Leu ns 
Positive m.10939 C>T C T 75% MT-ND4 GTA Ala-Val ns 
Positive m.11066 A>T A T 25% MT-ND4 TCT Ser-Ser syn 
Positive m.12942 A>T A T 75% MT-ND5 TCC Thr-Ser ns 
11 Positive m.10466 C>T C T 50% MT-ND4 ATT Ile-Ile syn 
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Positive m.14447 C>T C T 75% MT-CYB GGT Gly-Gly syn 
Positive m.15191 C>T C T 75% MT-CYB ATT Ile-Ile syn 
Positive m.15202 T>C T C 75% MT-CYB CCA Leu-Pro ns 
12 Positive none none none none none none none none 
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7.4 Appendix D: Incidence of COX deficiency in different tissues of mutant 
and control tRNA
Ala
 mice 
Mouse code Age   m.5024C>T Tail 
heteroplasmy 
COX –ve colonic 
crypts 
Partial 
colonic crypts 
COX +ve 
colonic crypts 
111 83 weeks 29% 1% 21% 78% 
112 83 weeks  24% 1% 15% 84% 
471 72 weeks  45% 4% 10% 86% 
472 72 weeks  18% 1% 10% 89% 
483 71 weeks  39% 1% 17% 82% 
1180 49 weeks  11% - 14% 86% 
1181 14 weeks  54% - 6% 94% 
1183 48 weeks  55% - 16% 84% 
1184 48 weeks  59% 1% 11% 88% 
1622 22 weeks  74% 1% 12% 87% 
1623 21 weeks  75% 2% 16% 82% 
1624 21 weeks 64% - 17% 83% 
1625 21 weeks 69% - 27% 73% 
1626 21 weeks  72% - 15% 85% 
1734 20 weeks 60% - 19% 81% 
1764 20 weeks 66% - 21% 79% 
2265 20 weeks 60% 0% 6% 94% 
2266 20 weeks 53% 0% 6% 94% 
2267 20 weeks 77% 5% 20% 75% 
2268 20 weeks 66% 0% 11% 89% 
2269 20 weeks 74% 0% 13% 87% 
2307 12 weeks 
(culled) 
51% 0% 7% 93% 
1299 10 weeks 50% - 11% 89% 
1305 10 weeks 12% - 2% 98% 
2191 22 weeks 10% 0% 0% 100% 
2489 21 weeks 7% 0% 0% 100% 
2430 22 weeks 24% 0% 0% 100% 
2432 22 weeks 13% 0% 0% 100% 
 221 
 
Mouse code Age   M.5024C>T tail 
heteroplasmy 
COX –ve 
colonic crypts 
Partial 
colonic crypts 
COX +ve 
colonic crypts 
COX-ve 
colon smooth 
muscle 
COX +ve 
colon smooth 
muscle 
2241 65.9 weeks 68% 0% 9% 91% 1% 99% 
2242 65.9 weeks 65% 0% 4% 96% 4% 96% 
2261 64.9 weeks 64% 0% 8% 92% 1% 99% 
2262 64.9 weeks 52% 0% 8% 92% - - 
2264 64.9 weeks 60% 0% 7% 93% - - 
2199 68 weeks 61% 0% 17% 83% - - 
2200 68 weeks 58% 0% 24% 76% 4% 96% 
2884 70 weeks 66% 2% 23% 75% 2% 98% 
2885 70 weeks 26% 3% 47% 50% 0% 100% 
2887 70 weeks 51% 2% 28% 70% 2% 98% 
 
Mouse code Age   M.5024C>T Tail 
heteroplasmy 
COX –ve 
SKM fibers 
Intermediate 
SKM fibers 
Transitional 
SKM fibers 
COX +ve 
SKM fibers 
COX -ve 
Heart fibers  
COX -ve 
Heart fibers 
2884 70 
weeks 
66% Thigh 0% 
Calf 1% 
Thigh 1% 
Calf 3% 
Thigh 1% 
Calf  1% 
Thigh 98% 
Calf 95% 
9% 91% 
2885 70 
weeks 
26% Thigh 0%  
Calf 0% 
Thigh 3% 
Calf 2% 
Thigh 2% 
Calf 3% 
Thigh 95% 
Calf 95% 
5% 95% 
2887 70 
weeks 
51% Thigh 0%  
Calf 0% 
Thigh 2% 
Calf 2% 
Thigh 3% 
Calf 3% 
Thigh 95% 
Calf 95% 
3% 97% 
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